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The bone marrow microenvironment serves as the primary site for post-natal hematopoiesis 
allowing for HSC development and maturation. More specifically, B lineage cells rely on key signals 
from both the physical and soluble components of the marrow for their survival and maturation. In 
addition to normal hematopoiesis the bone marrow has been shown to be a sanctuary for leukemic 
cells, as well as other tumors, that can interact with cues from the microenvironment allowing for 
their protection during chemotherapy. The studies described in this dissertation focus on two 
supportive components of the bone marrow microenvironment, osteoblasts and bone marrow 
stromal cells (BMSC), in the settings of post high dose chemotherapy and survival of leukemic cells 
during chemotherapy, respectively. 
Abstract
 
In the first study we investigated the effects of high dose chemotherapy on human 
osteoblasts (HOB). Previous studies from our laboratory have shown that high dose chemotherapy 
causes increases in the amount of active TGF-β released from BMSC and subsequently leads to 
diminished ability to support pro-B cells. Here we describe the novel observation that HOB treated 
with chemotherapy have increased levels of active TGF-β as well as a diminished capacity to 
interact with, and support, human embryonic stem cells and pro-B cells.  Additionally, we 
determined that HOB treatment with chemotherapy or rTGF-β  led to increased levels of active 
TGF-β,   as well as decreased CXCL12 mRNA and protein leading to a decreased adherence of 
pro-B cells to HOB.  Chemotherapy or rTGF-β  treatment also lead to the diminished ability of HOB 
to support pluripotent OCT-4 positive stem cell colonies and  microarray analysis of HOB treated 
with Melphlan, rTGF-β  or Conditioned Media from BMSC treated with Melphlan led to dramatic 
changes in the gene expression profiles of the HOB. This study elucidates the importance of 
osteoblasts in the marrow following ablative therapy and indicates how different components of the 
marrow are altered by chemotherapy. 
Our laboratory and others have previously shown that BMSC are able to protect tumor cells from 
chemotherapy however the mechanisms by which the bone marrow microenvironment regulates tumor 
cell survival are diverse. This study describes the novel observation that in addition to Philadelphia 
chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) cell lines, primary patient cells also 
express Vascular Endothelial Cadherin (VE-cadherin) which is regulated by Abl kinase and has been 
associated with aggressive phenotype and poor prognosis in other models. Targeted knockdown of VE-
cadherin rendered ALL cells more susceptible to chemotherapy, even in the presence of BMSC derived 
survival cues. Pre-treatment of Ph+ ALL cells with ADH100191, a VE-cadherin antagonist, resulted in 
increased apoptosis during in vitro chemotherapy exposure. Consistent with a role for VE-cadherin in 
modulation of leukemia cell viability, lentiviral-mediated expression of VE-cadherin in Ph- ALL cells 
resulted in increased resistance to treatment-induced apoptosis. Collectively, these data contribute to 
our understanding of the alterations that occur to the different supportive components of the bone 
marrow microenvironment during chemotherapy and the mechanisms that alter their ability to support 
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Imatinib Mesylate     (Imatinib, Gleevec, STI571) 
Insulin-like growth factor-1     (IGF-1)  
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Interleukin       (IL) 
 
Leukemia inhibitory factor     (LIF) 
 
Macrophage colony stimulating factor   (M-CSF) 
Macrophage inflammatory protein-1•    (MIP-1• ) 
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oxygen dependent domain     (ODD)  
 
Pax/Aryl hydrocarbon receptor/Sim    (PAS)  
Platelet endothelial cell adhesion molecule-1            (PECAM1, CD31) 
Philadelphia chromosome     (Bcr/ABl , Ph+, t(9;22)) 
POU class 5 homeobox 1 family    (POU5F1) 
proline-rich tyrosine kinase 2    (Pyk-2) 
Protein phosphatase-2A     (PP2A) 
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Severe combined immunodeficiency   (SCID) 
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Signaling lymphocyte activation molecules  (SLAM) 
Stem cell factor      (SCF) 
 
Terminal deoxynucleotidyl transferase)   (Tdt) 
Transforming growth factor-•     (TGF-• ) 
Tumor initiating cells      (TIC) 
Tumor necrosis factor-•      (TNF-• )  
 
Vascular Cell Adhesion Molecule   (V-CAM) 
Vascular Endothelial Cadherin    (VE-cadherin, also known as  
CD144) 
Very Late Antigen-4     (VLA-4) 
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Architecture of the Bone Marrow 




1. Architecture of the bone marrow microenvironment/ hematopoietic 
niche, hematopoiesis and normal B cell development 
I. Physical Structure of the Niche 
 The stem cell niche can be characterized as a specialized environment which can vary 
in content and location based on the tissue and stem cell type that it supports. Early work of 
Curry and Trenton in 1966 first coined the phrase  “hematopoietic inductive microenvironment” 
(HIM) and the first description of a stem cell niche was hypothesized by Shofield in 1978 who 
suggested that stem cells were in association with other cells that influence their behavior 1;2.  
More recently, the Scadden lab has proposed that the niche is a group of cells that allow a stem 
cell to maintain its identity 3;4.  Our focus has been the bone marrow microenvironment which is 
anatomical space that houses the unique niche for hematopoietic stem cells (HSC) and is the 
primary site of post-natal hematopoiesis.  
 The primary function of the niche is to facilitate the anchorage, growth and expansion of 
stem cells. Early studies characterizing the progression and renewal of stem cells were 
completed in Drosophila and C. elegans models 5-7. Further studies to characterize the 
expansion of stem cells in a mammalian model have shown that stem cell survival and self 
renewal is accomplished by supporting cells providing both physical and soluble cues to stem 
cells that hone towards, and bind to, the physical architecture of the stem cell niche 8;9;10. Until 
recently, the composition and location of the stem cell niche components remained somewhat 
elusive. Shackney, followed by others, suggested a model of gradient hematopoiesis in the 
bone marrow with more primitive cells located near the endosteum, with differentiation and 
maturation increasing as the cells moved toward the vascularized bone marrow cavity to be 
mobilized to the periphery 11;12 (Figure 1).  
 Current studies have segregated the HSC niche into two main support systems, the 
osteoblastic or endosteal niche and the vascular niche 11;13;14. The supportive components of 
2
these stem cell niches are mesenchymal stem cells that differentiate into supportive lineages 
including osteoblasts (both spindle-shaped N-cadherin positive (SNO) and negative), fibroblastic 
cells (also known as bone marrow stromal cells, BMSC and mesenchymal stem cells, MSC), 
endothelial cells, chondrocytes, adipocytes, and myocytes  15-19 .  Recent studies from the 
Taichman lab suggest an interesting role for HSC in the regulation of differentiation of 
supportive cells suggesting that HSC directly participate in niche activities 20;21. Our studies have 
focused on two of the main components of each niche, osteoblasts and bone marrow stromal 
cells.  
 The endostosteum, found lining the bone surface, consists mostly of osteoblasts and 
serves as the primary site in which quiescent HSC reside 22-25. Osteoblasts are mononucleate 
cells that are responsible for the production of bone and are further separated into spindle-
shaped N-cadherin positive, or SNO cells, or N-cadherin negative16;26. Prior to the knowledge of 
the specific architecture of the niche, Gong and Lord showed in 1975 that more primitive 
hematopoietic progenitor cells were in close proximity to the endosteal surface, while more 
differentiated cells were seen in the center of the bone marrow space24;25. Literature summarized 
by the work of  multiple groups 14;19;26-28 then revealed the first true glimpses of the structure, in 
vivo location, function and signaling of the cells in the niche, showing the N-cadherin positive 
osteoblasts that line the endosteal surface play a role in the regulation of HSC. Additionally, 
these studies showed that the number of osteoblasts, as well as HSC adhesion to them, directly 
regulate both the number and quiescence of the HSCs found in the niche 26;14  . 
 There is a discrepancy in the literature regarding the importance of N-cadherin 
regulating HSC in the niche. Zhang et al.  showed that N-cadherin expression on osteoblasts is 
critical to the regulation of the number of HSC in the niche 26. Subsequent papers by Kiel et al.,  
from the Morrision lab, deleted N-cadherin from HSC using Mx-1-Cre(+)N-cadherin(fl/-) mice 
and showed that N-cadherin deficiency did not affect bone marrow cellularity or lineage 
composition, the numbers of colony-forming progenitors, the frequency of HSC, the ability of 
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HSC to sustain hematopoiesis over time, or their ability to reconstitute irradiated mice in primary 
or secondary transplants29;30. These observations confirm that the osteoblasts may be 
important, but that N-cadherin expression is not critical for HSC development in the endosteal 
niche. Studies using the ability to inducibly ablate osteoblasts in transgenic mice expressing the 
herpes virus thymidine kinase gene, under the control of the osteoblast specific collagen α1 
promoter, were performed by Visnjic et al. and showed that the loss of osteoblasts led to 
substantial decrease in the number of progenitor cells (lymphoid, myeloid and erythroid) in the 
bone marrow 31;32. Additionally, these studies showed a decrease in the total number of HSC 
and decreased bone marrow cellularity, all of which could be restored by the reconstitution of 
the osteoblasts 31;32. In parallel, the Taichman lab has shown that the in vitro survival of 
hematopoietic progenitor cells on osteoblasts is dependent upon the engagement of VLA-4 
(Very Late Antigen) and VLA-5, and that HSC are able to regulate the osteoblast secretion of 
certain factors necessary for stem cell survival and differentiation suggesting an active 
reciprocal relationship between HSC and the supportive cells of the niche 21;33-35. 
 The second major physical component of the bone marrow niche includes stromal cells 
which are adherent, clonogenic, non-phagocytic cells that express a variety of molecules 
necessary for immune function36;37. In 1968, Friedenstein, Owen, and colleagues were the first 
to determine that bone marrow stromal cells, or fibroblastic colony forming units (CFU-F) as 
they called them, were able to be derived and propagated from the bone marrow of post-natal 
animals  38-43.  
 The bone marrow contains adventitial (outer) reticular marrow cells which line the sinus 
wall and fibroblastic reticular marrow cells (referred to as bone marrow stromal cells, BMSC) 
that are found scattered in the mid bone region, and form a three-dimensional cellular network 
integrating the underlying sinusoidal network and play a major role in regulation of 
hematopoiesis, specifically B cell development. These fibroblastic BMSC have classically been 
described as not expressing hematopoietic or co-stimulatory molecules but are able to express 
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extracellular matrix proteins including collagen I, III, IV, V, VI, fibronectin, vitronectin, laminin, 
thrombospondin, hemonectin, and 
tenascin 44-46. They have the surface markers CD105 (SH2), CD73 (SH3/4), CD44, CD90(Thy-
1), CD71, and Stro-1 as well as adhesion molecules CD166 (activated leukocyte cell adhesion 
molecule [ALCAM]), intercellular adhesion molecule (ICAM)-1, CD29, Stro-1 and VCAM-1 
(Vascular Cell Adhesion Molecule-1, CD106) which are important for hematopoiesis 47-49. 
Additionally, they produce soluble factors, including CXCL12 (chemokine (CXC motif) ligand 12, 
also known as SDF-1 (Stromal Cell Derived Factor-1) and Interleukin-7, that are important for 
the differentiation and maturation of HSC 50-52.  
  Interestingly, bone marrow stromal cells (BMSC) expression of physical and soluble 
factors allows them to both positively and negatively influence hematopoiesis, and multiple 
studies have suggested that they play an important role in both the osteoblastic and vascular 
niches 53. Expression of cytokines which positively influence hematopoiesis include granulocyte-
macrophage colony stimulating factor (GM-CSF), interleukin-1 (IL-1), IL-3, IL-5, IL-6, IL-7, IL-11, 
IL-12, leukemia inhibitory factor (LIF), fibroblast growth factor (FGF), stem cell factor (SCF), Flt-
3 ligand (FMS-like tyrosine kinase 3), c-kit, macrophage colony stimulating factor (M-CSF), 
insulin-like growth factor-1 (IGF-1) and tumor necrosis factor-α (TNF-α) 54-60 . In contrast, 
interferon-γ (INF-γ), transforming growth factor-β (TGF-β), and macrophage inflammatory 
protein-1α (MIP-1α) act as negative regulators of hematopoiesis61-64.   Importantly, BMSC lack 
phenotypic markers of osteoblasts, such as osteopontin and osteocalcin, showing they are 
distinct from osteoblasts consistent with their documentation of performing unique functions65. 
Stromal cells were initially shown to support hematopoietic cells by Dexter, Whitelock, and Witte 
and have been shown to be crucial in the early stages of B cell development, or B 
lymphopoiesis. Additionally, stromal cells have the ability to protect of B-lineage leukemias, as 
well as other malignancies, from chemotherapy 66-71.   
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 While not a focus of work presented in the current studies, it is important to touch on the 
endothelial, or vascular, niche. The endothelial niche is an environment which provides signals 
for HSC proliferation, differentiation into progenitors, and subsequently mature blood cells, as 
well as mobilization into the blood stream72;73. Bone marrow endothelial cells (BMEC) interact 
with HSC through constitutive expression of chemokines such as CXCL12 and through the 
expression of adhesion markers VCAM-1, PECAM1 (platelet endothelial cell adhesion 
molecule-1), E-selectin (endothelial-selectin)  as well as others11;18;74. HSC vacillate between the 
osteoblastic and vascular niche, potentially by utilizing BMSC, during normal homeostatic 
conditions. This migration is increased during times of stress when the need for blood cells is 
increased. Endothelial cells have been shown to be a crucial component of the niche, as upon 
ablation of endothelial cells in vivo by utilizing anti-VE-cadherin antibody, hematopoietic failure 
ensued and the addition of endothelial cells has been shown to increased hematopoietic 
reconstitution 75-77.   
 A close relationship between endothelial cells and HSC is not surprising as both 
lineages are derived from a common precursor, though there is discrepancy in the literature 
whether the common lineage is a hemangioblast, haemogenic endothelium or both 78;79. 
Hemangioblasts are mesodermal progenitors with both endothelial and haematopoietic potential 
while haemogenic endothelium is phenotypically differentiated endothelial cells with 
haematopoietic potential 80. The hemangioblast theory initially arose from studies in the late 
1990’s identifying that during embryonic stem cell differentiation a clonal precursor, the blast 
colony-forming cell (BL-CFC), was able to give rise to blast colonies with both endothelial and 
haematopoietic components81;82. Further research has provided evidence for the presence of 
this bipotential precursor, or BL-CFC in vivo, however, the mechanism by which hematopoietic 
cells are generated from the hemangioblast, and the role of the haemogenic endothelium, is still 
being investigated.   
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 Recently, to address this discrepancy, the Lacaud laboratory, and other groups, followed 
individual blasts cell development by time-lapse photography and demonstrated that the 
hematopoietic cells are generated from the hemangioblast, using the haemogenic endothelium 
as an intermediate step. They utilized the endothelial markers Tie2/Tek13, as well as the 
hematopoietic commitment markers CD41/IIb integrin and c-kit to investigate the sequential, 
developmental steps, as well as identify transitional populations, and also determined that the 
transcription factors Scl/Tal110 and Runx1/AML1 are necessary for the establishment of the 
haemogenic endothelium and the generation of hematopoietic cells, respectively79;80;83;84. 
 Another factor further solidifying the relationship between endothelial cell and HSC 
interactions are expression of cell surface receptors of the SLAM (signaling lymphocyte 
activation molecules) family. These molecules, expressed on the surface of HSC, consist of 
CD150, CD244 and CD48 and are commonly associated with the population of HSC that 
interacts directly with the endothelial cells and are self-renewing HSC  that can be mobilized 
rapidly, if needed, and replaced by cells recruited from the endosteal niche 72.  
 
II. Characteristics of a hematopoietic stem cell (HSC).  
 
 In the early 1900’s Alexander Maximow gave the first description of a hematopoietic 
stem cell stating that, "In the mammalian organism exists one cell type, the lymphocyte in the 
widest sense of the word, which may look different according to the site of residence as well as 
to the local conditions and which can produce different products of cellular differentiation85.” The 
1960’s brought about the next phase in the investigation of the HSC with the work of Goodman 
and Hodgson who coined the term HSC86. Additionally, groups such as Till and McCulloch, 
Bradley and Metcalf , Pluznik and Sachs, and Castro-Malaspina and Moore clearly delineated 
the importance of the bone marrow in regulation of hematopoiesis 87-93. Critical techniques were 
also developed in order to analyze HSC in vitro with spleen colony forming assays, and the 
growth of niche cells in vitro, respectively94;95.  
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 More current studies of HSC characterize them as pluripotent, self-renewing, non-cycling 
cells with a surface marker phenotype of CD34+, Lineage-, SCA1+, KIT+96;97.  HSC give rise to all 
cells of the immune system including lymphoid (T, B, and Natural Killer (NK) cells) and myeloid 
lineage cells (monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, 
megakaryocytes/platelets, and dendritic cells) while maintaining their ability to self renew 98;99 
(Figure 2, 100) . Many adhesion and soluble factors are necessary for the maintenance of the 
stem cell phenotype. The important adhesion molecules of the niche include N-cadherin/-
catenin, VCAM/integrin and osteopontin/1 integrin 5;101. Though the exact functions of these 
adhesion molecules are largely unknown, studies blocking the function of integrins have shown 
their importance in the adhesion and homing of HSC to the niche. Soluble factors that have 
been shown to be important in the maintenance of HSC include CXCL12, which plays a role in 
homing, transendothelial migration, proliferation and survival, and G-CSF (Granulocyte colony-
stimulating factor) which induces HSC and progenitor mobilization. The most primitive HSC are 
quiescent and found in the endosteal niche interacting with osteoblasts and subsequently 
interacting with BMSC and BMEC as they differentiate into progenitors and mature into 
competent immune cells that will migrate into the peripheral blood.   
 Innovative mouse studies from Akashi and Weissman proved the existence of specific 
and restricted common lymphoid (CLP) and myeloid progenitor (CMP) stem cells that arose 
from the HSC population and specifically gave rise to B, T and NK cells (CLP) and 
Monocyte/Granulocyte, Megakaryocyte/Erythrocyte progenitor lineages (CMP), respectively102-
106.  These studies were the first to prove the existence of these intermediate progenitor stem 
cells and further classified them as Lin-, IL-7R+, Thy-1-, Sca-1lo, c-Kitlo  (CLP) and Lin-, IL-7R-, 
Thy-1-, Sca-1-, c-Kit+, FcRlo (CMP). Further discussions of stem cell progenitor development 
will focus on the CLP, more specifically, its B-lineage progeny.  
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III. Normal B cell development.  
 
 B (bursa or bone marrow derived) lymphocytes, both normal and malignant, were 
discovered and characterized throughout the mid 1960’s and early 1970’s by Max Cooper and 
Robert Good utilizing both patients with immune deficiencies as well as experimental animal 
models107-110. B lymphocytes consist of a population of bone marrow derived cells that express 
clonally diverse cell surface immunoglobulin receptors recognizing specific antigenic epitopes 
107. Early B cell development requires stromal cell physical contact and soluble factors in order 
to complete differentiation steps which involve rearrangement of immunoglobulin variable region 
gene segments to produce a mature, and functional, B lineage cell.  B lymphopoiesis occurs 
initially in primary lymphoid tissue (fetal liver and then fetal/adult bone marrow), with functional 
maturation occurring in secondary lymphoid organs (lymph nodes and spleen) with the final 
endpoint being functional plasma cells that are terminally differentiated 107;111-114.  
 B lymphopoiesis occurs as HSC differentiate to a committed lymphoid progenitor stem 
cell (CLP) which then become pro-B, pre-B cells as their immunoglobulin variable region gene 
segments are rearranged (Figure 3, 100). This rearrangement occurs in both the heavy () and 
light () chain variable regions by a tightly regulated process that utilizes the Tdt, or terminal 
deoxynucleotidyl transferase, and recombinase-activating enzymes (Rag1 and Rag2) leading to 
the expression of IgM, on the surface of the immature B cell. Immature B cells additionally 
express CD19, CD20, CD40, MHC class II and CD45R, and cells that exit the marrow acquire 
surface IgD, as well as CD21 and CD22, and have functionally important changes in the density 
of other receptors107;115;116.  
 The crucial factors driving B lymphocyte development, in vivo, include Interluekin-7 (IL-
7), CXCL12/CXCR4, Flt-3L/FLT3, SCF, RANKL, and VCAM-1 and will be discussed below. IL-7 
provides both survival/proliferation signals, promotes V to DJ heavy chain rearrangement by 
altering the accessibility of DNA substrates to the recombinase, and was the first cytokine 
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shown to be essential for B cell development 117-119. IL-7 is secreted from the bone marrow 
stromal cells and binds to the IL-7R on the pre-B cell. Ligand binding stimulates maturation 
resulting in down-regulation of adhesion molecules on the pre-B cell so that it can proliferate 
and is no longer stromal, but still IL-7, dependent.  The receptor for IL-7 is comprised of two 
chains: IL-7Rα and the cytokine-receptor common γ-chain (γc), and IL-7- and IL-7Rα-deficient 
mice have severe defects in the development of B and T cells 120. IL-7 has been shown to play a 
vital role in the pro-B cell stage of development which has been confirmed by studies in IL-7- or 
IL-7Rα- deficient mice showing that their bone marrow is composed of normal numbers of pre-
pro-B cells but has severe deficits of pro-B cells, pre-B cells and the more differentiated B cells 
with other studies suggesting the importance of IL-7 at the CLP stage of development 107;117-121 .   
 CXCL12 and its receptor CXCR4 have been shown to be important in the retention of B 
lineage cells in primary lymphoid tissues and colonization in the bone marrow of B-lineage cells 
as well as HSC122;123. Murine studies of CXCL12 deficient embryos or WT mice reconstituted 
with CXCR4 deficient fetal cells, show severely reduced numbers of very early B- precursors in 
the fetal liver as well as decreases in the pre-pro-B cells of the adult marrow, respectively, 
suggesting that CXCL12–CXCR4 axis is absolutely crucial for the earliest stages of B-cell 
development in the fetus and adult 124;125. CXCR4/CXCL12 signaling has also been shown to be 
important in the homing of end stage B cells to the bone marrow, however, the specific 
mechanisms by which CXCL12 functions in the regulation of B-cell development still remain 
unknown. Another receptor for CXCL12, CXCR7 has been identified and been shown to 
heterodimerize with CXCR4 to enhance CXCL12 signaling, and aid in transendothelial  
migration of B lineage ALL cells; however, a specific role for CXCR7 in B cell development has 
not yet been identified as conditionally deficient  CXCR7-/- mice have normal B cell 
development 126;127.   
 FLT-3L/FLT3 is a ligand for the FLT-3 receptor which has sequence and structural 
homology to the class-III-receptor tyrosine kinases including the macrophage colony-stimulating 
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factor (M-CSF) receptor (c-fms), the SCF receptor (KIT), and the α- and β-platelet-derived 
growth factor (PDGF) receptors 128. Flt3 deficient mice have reductions in the number of pre-pro 
and pro-B cells with generally normal numbers of pre-B cells, immature B cells and mature B 
cells 129. In contrast, FLT3L deficient mice have substantial reductions in the number of pre-pro-
B-cells, marginally diminished numbers of pro-B cells and pre-B cells, and normal numbers of 
more differentiated B cells 130. These data indicate that, similar to CXCL12,  FLT3L is pivotal for 
the development of pre-pro-B cells but the phenotypic difference between FLT3 and FLT3L 
deficient mice suggests the potential for another receptor for FLT3L. 
 SCF binds to the KIT class-III-receptor tyrosine kinase and has been shown to play a 
role in the development of many cells types including hematopoietic cells 131. SCF or c-kit 
deficient mice have been shown to have normal B cell development with significantly reduced 
numbers of CLP in mice younger than 4 weeks of age, and at 195 days (approximately 28 
weeks), the numbers of pre-pro-B cells were normal but the numbers of pro-B and pre-B cells 
were severely reduced suggesting that in younger mice SCF/C-kit may be redundant but that it 
plays a critical role in adult B cell development and maintenance 132-134. During B cell 
development, c-kit on the surface of the pro-B cell interacts with SCF on the surface of the 
stromal cell which activates the tyrosine kinase activity inducing pro-B to pre-B division and 
differentiation.  
 RANKL (receptor activator of nuclear factor-κ B ligand) binds to the RANK receptor, and 
its expression on B cells has been shown to be important for B cell development. Reconstitution 
of immunodeficient recombination-activating gene 1 (Rag1–/–) mice with Rankl–/– fetal liver 
cells led to reduced numbers of pre-B cells and B220+IgM+ immature B cells, where 
reconstitution of Rankl–/– mice with wild-type bone-marrow cells led to normal B-cell 
development 135. 
 VCAM-1 provides physical interaction between pro and pre-B cells and allows for 
retention in the bone marrow. Additionally, interactions between VCAM-1 on the stromal cells 
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and VLA-4 on the B cells hold them in close proximity to each other so that the B cells can 
interact with soluble factors being produced by the BMSC. Although some early studies 
suggested that VCAM-1 may not be essential to B lymphopoiesis, 136 more recent studies have 
shown the importance of VCAM in both normal and neoplastic B cell survival137-141.  
IV. Damage to the microenvironment alters support of stem and progenitor cells.   
 
 As mentioned previously, in a healthy bone marrow microenvironment, the supportive 
cells of the niche, osteoblasts and bone marrow stromal cells, act as crucial mediators in both 
the survival of primitive stem cells as well as the maturation of these cells into functional cells of 
the immune system. As such, it is important to address the functional consequences and deficits 
that occur when supportive cells of the bone marrow microenvironment are damaged by myelo-
suppressive or ablative chemotherapy or radiation as a common complication in the setting of 
bone marrow transplantation.  
 Early studies from the Fried lab showed that both chemotherapy and irradiation led to 
lasting deficits in stromal cell function and subsequently to a decrease in the number of 
fibroblastic colony forming units (CFU-F)142-144. Patient retrospective studies from the late 1990’s 
show that even at 12 years, post-transplant patients' CFU-F frequencies were reduced by 60%-
90% compared to controls145;146. More recent studies show that Acute Lymphoblastic Leukemia 
(ALL) patients who received ablative therapy prior to bone marrow transplantion were found to 
have diminished hematopoietic support that was attributed to an increase in transforming growth 
factor beta (TGF-)147.  In contrast, studies from Isaikinia et al. investigated the ability of 
mesenchymal stem cells (MSC) from both normal donors and patients exposed to 
chemotherapy and/or radiation (Non-Hodgkin’s, Hodgkin’s Lymphoma or Ewings sarcoma) to 
support CD34+ cells148. They saw no difference in expansion or differentiation of hematopoietic 
cells at 7, 14, or 21 days. 
 Further studies are clearly needed to better understand the mechanisms that underlie 
the damage that occurs with different chemotherapy regimens and how functional changes alter 
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long term hematopoietic recovery. Previous publications of in vitro studies, from our laboratory, 
as well as others, established that chemotherapy increases the amount of active TGF- in bone 
marrow stromal cells and data shown in chapter 1 elucidates the functional consequences of 
chemotherapy mediated increases in TGF- in osteoblasts on their capacity to support human 
stem and hematopoietic progenitor cells149-151.   
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Critical Components of a Functional Stem Cell Niche are 













       Sustained long-term hematopoietic reconstitution, following bone marrow or stem cell 
transplantation, requires a microenvironment niche capable of supporting stem cells with the 
capacity to differentiate and expand to provide hematopoietic recovery, with osteoblasts 
comprising one important component of this niche. We determined that treatment of human 
osteoblasts (HOB) with chemotherapy resulted in an increase in phospho-Smad2, consistent 
with increased TGF-  activity coincident with reduced HOB capacity to support immature B 
lineage cell chemotaxis and adherence.  The supportive deficit was not limited to committed 
progenitor cells, as human embryonic stem cells (hESC) co-cultured with chemotherapy or 
rTGF- pre-treated HOB had diminished Oct-4 expression when compared to hESC co-cultured 
with untreated HOB. These functional deficits were downstream of significant changes in HOB 
gene expression profiles following chemotherapy.  In addition, HOB gene expression patterns 
were impacted by either recombinant TGF-, or conditioned media from Melphalan treated bone 
marrow stromal cells, suggesting response to direct genotoxic stress as well as to factors 
potentially elaborated by neighboring cells that would be found in the marrow. Chemotherapy 
induced damage of HOB  suggests vulnerability of the stem cell niche to therapeutic agents 
frequently utilized in pre-transplant regimens and suggests that dose escalated chemotherapy 
may contribute to post-transplantation hematopoietic deficits by damage structural components 
of the stem cell niche.    
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Introduction: 
       The stem cell niche hypothesis was first presented in 1978 by Schofield who suggested 
that stem cells were associated with accessory cells that influence their behavior 1.  Studies 
from several labs have expanded our appreciation of the unique anatomical niches within the 
marrow microenvironment and have characterized areas of optimal stem cell support 2-4. The 
niche structure and cellular components have been more recently elucidated to consist of  
osteoblasts  (HOB), bone marrow stromal or mesenchymal stem cells (BMSC, MSC), and 
endothelial cells 5-7. Recent work has demonstrated the importance of the interaction of 
osteoblasts and stem cells in the niche, suggesting that hematopoietic stem cells (HSC) can 
regulate MSC differentiation into osteoblasts and that they, in turn, play an important role in the 
support of B lymphocytes and differentiation of HSC 8;9. Additionally, it has been shown that 
resting HSC are maintained in a quiescent state as a result of their close proximity to 
osteoblasts and that the number of HSCs change as a result of the number and type of 
osteoblasts present 10;11.  Studies describing BMSC have shown that damage by chemotherapy 
and radiotherapy can affect the ability of the BMSC to self-repair and leads to decreased 
numbers of functional immune system cells in the blood, with deficits persisting years after 
transplant 12-14.  The effects of chemotherapy on osteoblasts, and subsequently HSC support, 
have not been as well characterized as those on BMSC, and warrant further investigation.  
       The stem cell niche is characterized, in part, by expression of specific cytokines, 
including TGF-β and CXCL12, to facilitate signaling between the niche components and HSC.  
Studies by our laboratory, and others, demonstrate that chemotherapy increases the levels of 
active TGF- resulting in decreased ability of BMSC to support HSC 15;16. It has also been 
shown that TGF-β has potential crosstalk with CXCL12 and can stimulate the differentiation of  
progenitor cells to erythroid and myeloid cells resulting in a deficit of the primitive stem cell pool 
17;18.  The importance of CXCL12 is demonstrated by its requirement for homing of progenitor 
cells to the bone marrow following transplantation 19;20.  We have previously demonstrated that 
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diminished levels of CXCL12 in the supernatants of VP-16 treated BMSC results in loss of an 
optimal chemokine gradient to which CXCR4+ pro-B cells respond and  CXCL12 was 
subsequently shown to also be important in regulation of stem cell phenotype by Guo et al.  21;22.  
Sugiyama et al showed that mice deficient in the CXCL12 receptor, CXCR4, had a reduction in 
HSC, in both vascular and endosteal niches, and increased sensitivity to myelotoxic stress 
compared to their wild-type counterparts 23.  Other studies of CXCR4 in the HSC niche have 
shown that CXCR4 is essential to maintain the quiescence, and retention, of stem cells in their 
specific niches 24.   In the current study we investigate chemotherapy-mediated damage of 
osteoblasts with emphasis on CXCL12 and TGF-β levels following chemotherapy.   HOB cells 
were evaluated for their ability to support maintenance of undifferentiated human embryonic 
stem cells as a model of one critical element of the stem cell niche.  
       In addition to soluble factors that define the stem cell niche, adhesion molecules are also 
known to be critical to physically tether immature cells in areas of concentrated cytokines and to 
initiate intracellular signaling following integrin engagement 25. VCAM-1 has been shown to be 
one adhesion molecule that stem cells rely upon to anchor to the marrow stroma which plays a 
crucial role in lymphopoiesis 26;27. Animal studies have shown that VCAM-1 neutralizing 
antibodies, or VCAM-1 conditional knockout, block engraftment of HSC in mice 28;29.   
       In the current study, global changes in HOB gene expression in response to Melphalan, 
a clinically relevant pre-transplant agent, were investigated to determine the general 
vulnerability of this particular component of the stem cell niche to genotoxic stress.  In addition,  
TGF-, CXCL12 and VCAM-1 were investigated as representative osteoblast proteins involved 
in three critical functions of the endosteal niche; support of pluripotency, homing and stem cell 
retention 30-32.   Our results indicate diverse changes in gene expression profiles following HOB 
exposure to Melphalan, conditioned media from BMSC  treated with Melphalan, and following 
exposure to rTGF- as one of the factors elaborated by chemotherapy damaged stroma 15. HOB 
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treated with chemotherapy had increased levels of active TGF-, consistent with the earlier 
documented effect on BMSC 15.  Melphalan, VP-16, or rTGF- pre-treated HOB demonstrated 
reduced ability to support OCT-4 positive embryonic stem cell colonies. Additionally, HOB 
treatment with chemotherapy or rTGF- resulted in decreased levels of CXCL12, and reduced 
chemotactic support and adhesion of CXCR4+ pro-B cells. In contrast to our earlier reports of 
decreased expression of VCAM-1 by BMSC exposed to VP-16, treatment of HOB with VP-16, 
Melphalan, or rTGF- did not lead to significant reductions in VCAM-1, suggesting that signaling 
through this adhesion molecule is maintained.  These data suggest that while stem cells may be 
spared direct cytotoxic insult by chemotherapeutic agents, the niche in which they reside may 
be more vulnerable to damage than previously appreciated.   
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Materials and Methods: 
Cell Lines and Reagents 
      Human osteoblasts (HOB) were purchased from Promocell (Heidelberg, Germany) and 
maintained in osteoblast growth media. The CXCR4+/VLA-4+  pre-pro-B leukemic cell line JM-1 
was purchased from the ATCC (CRL-10423, Manassas, VA). The BMSC and IL-7 dependent 
murine pro-B cell line C1.92 was kindly provided by Dr. Kenneth Landreth and has been 
described in detail 33. Melphalan (Sigma-Aldrich, St. Louis, MO) was reconstituted at a stock 
concentration of 2.5mg/ml or 50mg/ml immediately prior to use. VP-16 (Etoposide, Bristol Myers 
Squibb, New York, NY) was stored at a concentration of 33.98mM and diluted immediately prior 
to use. Human rTGF- (R&D, Minneapolis, MN) was used at a concentration of 10ng/ml. In all 
experiments that include rTGF-, it was added to the culture every 6 hours based on its short 
half-life.  Human embryonic stem cells (H9, WiCell, Madison WI) were maintained on irradiated 
mouse embryo fibroblasts (MEF) and grown in DMEM-F12 media (Mediatech, Manassas, VA) 
supplemented with Knockout Serum Replacement (Gibco/Invitrogen, Carlsbad, CA) 2 mM L-
glutamine (Mediatech), 0.05 µM 2-mercaptoethanol (Sigma-Aldrich), non-essential amino acids  
and B-FGF solution. H9 cells were moved to HOB feeder layers where indicated.  
      Adhesion assay 
       HOB were pre-treated with 50g/ml Melphalan, 50µM VP-16, or 10ng/ml rTGF- for 24 
hours. C1.92 pro-B cells were stained with Cell Tracker Green (Invitrogen) according to the 
manufacturer’s instructions.  The HOB adherent layer was thoroughly rinsed following treatment 
and 1x105 fluorescently labeled C1.92 pro-B cells were added in co-culture for 24 hours. 
Subsequently, the media containing non-adherent C1.92 was aspirated and the cultures were 
gently rinsed.  Remaining HOB and adherent C1.92 were trypsinized and C1.92 cells were 
enumerated using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ) with events counted 
for 30 seconds on high flow rate. Data were analyzed using WinMDI software. 
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Chemotaxis assays 
HOB were plated in the bottom chamber of a transwell at 100% confluence and were left 
either untreated or treated with 50µg/ml Melphalan, 50µM VP-16, or 10ng/ml rTGF-  for 24 
hours. After 24 hours, 350 µL of supernatant was placed in the bottom of a transwell and 150 µL 
of JM-1 cells (1x106 cells/mL) were added to the top chamber, and incubated at 37°C for 4 
hours. JM-1 cells migrated through the 5µm pores to the bottom chamber towards media 
supplemented with 100 ng/mL CXCL12 (positive control), towards media alone (negative 
control), or towards media conditioned by the chemotherapy treated or non-treated HOB. 
Migrated JM-1 cells were collected using a FACSCalibur flow cytometer (BD) with events 
counted for 30 seconds on high flow rate with data analyzed using WinMDI software. 
     ELISA  
     CXCL12 and TGF- ELISAs were purchased from R&D. To complete the CXCL12 
ELISA, HOB were plated at 100% confluence in a 96 well plate and left untreated or treated with 
50µg/ml Melphalan, 50µM VP-16, or 10ng/ml rTGF- in complete media for 24 hours. The 
media was then removed, cells were rinsed and fresh serum-free media was added to each 
well. After 24 and 48 hours of incubation supernatants were collected and analyzed for CXCL12 
following the manufacturer’s instructions. The TGF- ELISA was completed using HOB plated at 
100% confluence in a 96 well plate in serum free media and left untreated or treated with 
10ng/ml rTGF- every 6 hours for a total of 24 hours. The media was removed, cells were 
rinsed, and fresh serum-free media was added to each well. After 24 and 48 hours supernatants 
were collected and analyzed for TGF- secretion following the manufacturer’s instructions. 
      Fluorescent Microscopy  
       HOB cells were cultured on coverslips and left untreated or treated with 50µg/ml 
Melphalan, 50µM VP-16, or 10ng/ml rTGF- for 24 hours, washed thoroughly with media and 
H9 stem cells added. Stem cell colony expansion and differentiation were monitored for 2 days 
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before pictures were taken, counts based on colony morphology were completed, and cells 
were subsequently stained for Oct-4. To complete intracellular staining, cells were fixed in 4% 
formaldehyde for 15 minutes at room temperature (RT) and permeabilized with 0.5% Triton-X-
100 at RT for 15 minutes.  After blocking for 30 minutes in 5% BSA/1X PBS, cells were 
incubated with mouse -human primary antibody (1µg), specific for human Oct-4 or the 
matched isotype control, in 5% BSA/1X PBS for 1 hour at RT. Coverslips were washed three 
times with 1X PBS and incubated with Alexafluor 488 labeled secondary -mouse antibody (1 
µg) at RT for 1 hour.  Coverslips were mounted on glass microscope slides with ProLong Gold 
plus DAPI (Invitrogen, Carlsbad, CA).  Confocal images were acquired using a Zeiss LSM510 
confocal system connected to a Zeiss AxioImager microscope (Thornwood, NY). Photographs 
of human embryonic stem cells and C1.92 pro-B cells were taken using a Nikon Coolpix 990 
camera. To complete phospho-smad2 staining, HOB cells were plated on coverslips and left 
untreated or treated for 4 hours with 100µg/ml Melphalan, 100µM VP-16, or with conditioned 
media from BMSC that were maintained in control media   untreated or treated with 100µg/ml 
Melphalan or 100µM VP-16 for 24 hours. Staining and imaging was completed as described 
above using a murine primary antibody (1.5µg/coverslip), specific for human phospho-smad2 
(Cell Signaling Technology Inc., Danvers, MA) or matched isotype control.  
Microarray 
       HOB cells were left untreated, or treated with 50µg/ml Melphalan, 10ng/ml rTGF- or 
conditioned media from BMSC (treated with 50µg/ml Melphalan for 24 hours) for 6 hours. Total 
RNA was isolated from HOB using the RNEasy RNA isolation kit (Qiagen,Valencia, CA) with 
quality assessed by electrophoretic analysis on an Agilent Model 2100 Bioanalyzer. RNA 
samples had integrity numbers greater than 8.0 (8.4-10).  RNA (250 ng) was used as the 
template for synthesis of internally labeled cRNAs using the Agilent QuickAmp Labeling kit and 
cyanine 3-CTP and cyanine 5-CTP (Perkin Elmer, Waltham, MA) and a modified QuickAmp 
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protocol 34. A total of 825 ng of cyanine 3- and cyanine5-labeled cRNAs was combined and 
hybridized onto Agilent Whole Human Genome 4 x 44 K microarrays at 65oC for 17 hours and 
washed according to the manufacturer’s protocol. Slides were scanned on an Agilent DNA 
Microarray Scanner. HOB treated with rTGF- and conditioned media were competitively 
hybridized against untreated HOB in a balanced block design with six replicates. Melphalan 
treated HOB and untreated HOB were hybridized against Stratagene Universal Reference RNA 
(Agilent Technologies, Santa Clara, CA) in a universal reference design with four replicates. 
Intersections of groups and corresponding statistically significant fold changes (details 
described in the supplemental section) for each experiment were imported into Ingenuity 
Pathway Analysis (IPA) software v 2.6 (Ingenuity Systems ®, Redwood City, CA, 
www.ingenuity.com). We performed a core analysis in IPA, using default settings, to search for 
networks associated with these lists of genes. Complete microarray data may be accessed at 
the NCBI Gene Expression Omnibus (GEO) database (GSE17860). 
 Real Time Reverse Transcriptase PCR  
       Total cellular RNA was isolated from HOB using the RNAeasy RNA isolation kit 
(Qiagen). Real time RT-PCR was performed using 50ng RNA per reaction using the QuantiTech 
SYBR Green RT-PCR kit supplied by Qiagen. Primers specific for human CXCL12 were 
obtained from SuperArray (Frederick, MD) with 0.25µl used per reaction. Primers specific for 
TGF- and the housekeeping gene (HPRT-1) were purchased from Real Time Primers, LLC 
(Elkins Park, PA).  Samples were analyzed in triplicate using the Applied Biosystems 7500 
Real-time PCR system (Foster City, CA). Amplification parameters included 50C for 30 
minutes, 95C for 15 minutes, 94C for 15 seconds (x 45 cycles), 58C for 30 seconds, and 
72C for 45 seconds.  Changes in gene expression were determined using the Comparative Ct 
method and analysis of relative gene expression data using real-time quantitative PCR and the 
2(-Delta Delta C(T)) Method.  
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Statistics 
       Data were analyzed using the Students–t test or ANOVA where appropriate with 
statistical significance of p≤.05 denoted by an asterisk (*). Microarray data analysis is described 
in the supplemental section. 
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Results: 
Direct Melphalan exposure or factors from chemotherapy damaged BMSC affect HOB.  
       Observations from our laboratory, and others, have demonstrated that BMSC treated 
with chemotherapy have higher levels of active TGF- and a diminished capacity to support pro-
B cells and normal hematopoiesis 15-17;35.  Additionally, retrospective studies of patients that 
received allogeneic bone marrow transplants showed that they have serious and irreversible 
stromal damage as measured by CFU-F frequencies that did not recover to the levels of normal 
control patients even after 12 years, suggesting that the damage done to the supportive cells of 
the bone marrow is irreversible 36. 
       To determine if direct chemotherapy damage to HOB cells results in increased active 
TGF-, HOB were treated with Melphalan or VP-16 and the expression of total and active TGF-
 was assessed. Data shown in Figures 1A and B show that direct exposure to chemotherapy 
(left panels) does not alter the expression of TGF- mRNA or protein respectively.  However, 
direct treatment with rTGF- (right panels) does increase both TGF- mRNA and protein 
expression.  In contrast to total TGF- mRNA and protein expression, chemotherapy exposure 
does result in increases in the levels of active TGF- capable of cell signaling reflected as 
increased phosphorylation of Smad2 protein (Figure 1C).  Additionally, to mimic the indirect 
effects of soluble cues elaborated by damaged stroma on HOB, BMSC were treated with 
Melphalan or VP-16, rinsed, and allowed to condition media that was then placed on HOB that 
had not been exposed to chemotherapy. HOB exposed to conditioned media from damaged 
BMSC have higher levels of phosphorylated Smad2 than their counterparts exposed to 
conditioned media from untreated stroma.  
       
 
43
Chemotherapy or rTGF- treatment diminishes the ability of osteoblasts to support 
human stem cells and diminishes the physical interaction of HOB and pro-B cells 
       One of the critical functions of osteoblasts in the endosteal niche is to support stem cells, 
and post-transplantation, osteoblasts are crucial to efficient and sustained hematopoietic 
reconstitution 37;38. Therefore, we investigated how chemotherapy or rTGF- modulates the 
ability of osteoblasts to support human stem cells. Figure 2 shows that in the absence of 
treatment, osteoblasts are able to support undifferentiated stem cell colonies characterized by 
morphology of dense round colonies with definitive, regular, cell borders. In contrast, after HOB 
pre-treatment with Melphalan, VP-16 or rTGF-, there is an increase in the number of 
differentiated stem cell colonies with irregular borders and a decrease in the number of  
undifferentiated colonies (Figure 2A) supported by the pre-treated feeder layers. OCT-4 staining 
was completed on stem cell colonies as a measure of pluripotency potential, with a decrease in 
the ability to support OCT-4 positive colonies observed in HOB that had been pre-treated with 
chemotherapy or rTGF- (Figure 2B).   
       Alterations in osteoblast function after aggressive treatment could impact transplant 
engraftment and hematopoietic reconstitution 11;30;39. For technical ease we utilized CXCR-
4+/VLA-4+   C1.92 and JM-1 pro-B cells to investigate the effects of chemotherapy on the ability 
of HOB to support immature hematopoietic progenitor cells. HOB  were  pre-treated with 
Melphalan, VP-16 or rTGF- and C1.92 adhesion to HOB was analyzed as described. Data 
shown in  Figure 2C indicates that following HOB pre-treatment with chemotherapy or rTGF-, 
C1.92 pro-B cells did  not adhere to the pre-treated HOB as efficiently as their untreated control 
counterparts. To determine if alterations in adhesion molecule expression were associated with 
decreased adhesion between C1.92 and HOB, VCAM-1, CD44 and Hyaluronan expression 
were evaluated on the HOB in the presence and absence of chemotherapy. No modulation of 
these proteins was detected on the HOB during chemotherapy exposure suggesting that, 
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changes in expression of classical adhesion proteins does not appear to be responsible for 
decreased pro-B cell adhesion to Melphalan treated HOB (data not shown).  
     Chemotherapy or rTGF- diminishes HOB expression of CXCL12 coincident with reduced 
support of pro-B cell chemotaxis 
       Inhibition of CXCL12 in the bone marrow has been shown to have a negative impact on 
chemotaxis leading to deficits in HSC homing and engraftment 19;40;41.  To further investigate the 
impact of chemotherapy and rTGF- treatment on expression of osteoblast derived CXCL12, 
real time RT-PCR and ELISA were completed as described. Pre-treatment of HOB with 
chemotherapy or rTGF- decreased the amount of CXCL12 mRNA and protein detected by real 
time RT-PCR and ELISA, respectively (Figure 3A and B) 42. Additionally, as a functional readout 
of a potential CXCL12 deficit in our model, chemotaxis of JM-1 cells toward HOB that were 
untreated or pre-treated with chemotherapy or rTGF- was completed. Figure 3C summarizes 
data suggesting that chemotaxis of progenitor cells toward adherent layers of HOB was 
impaired by Melphalan or rTGF- treatment.   
Direct and indirect chemotherapy induced damage result in global changes to osteoblast 
gene expression 
       To elucidate the global changes that occur in osteoblasts with direct and indirect insult 
from chemotherapy, HOB were exposed to either rTGF-β to mimic increased active TGF-β 
released by neighboring, damaged stroma or Melphalan to investigate direct insult of 
osteoblasts by chemotherapy.  In addition, HOB were exposed to conditioned media from 
BMSC that had been pre-treated with Melphalan (drug removed prior to collection of conditioned 
media)  to recapitulate signaling that may occur in response not only to active TGF-β elaborated 
by BMSC, but also in response to the collective soluble factors elaborated by BMSC in 
response to chemotherapy induced stress.  Microarray analysis of gene expression was 
performed as described. The genes for which expression changed in each group individually, 
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and common gene targets that overlap between treatment groups, are indicated in the Venn 
diagram (Figure 4A).  HOB exposure to recombinant TGF-β resulted in the most pronounced 
effect on gene expression for the treatment groups compared, the highest number of genes 
influenced across the treatment groups evaluated, with Melphalan exposure also resulting in a 
robust effect. Twenty-five common genes significantly changed when the intersection of all 
treatment groups was considered.  The Venn and network diagrams show the modulations of 
genes due to treatment, and potential relationships between some of the responsive genes. 
BCL2A1, which has been shown to be regulated by NFB and up-regulated during stress to 
prevent apoptosis, emerges as one point of convergence in the pathway analysis shown 
(Figures 4-7). The genes that were commonly up-regulated (indicated in red) or down-regulated 
(in green) between treatment groups are shown and numerically were: 4 up-regulated, 2 down-
regulated (Figure 4, Intersection of all 3 treatments), 16 up-regulated, 3 down-regulated (Figure 
5, CMM:Melphalan), 26 up-regulated, 11 down-regulated (Figure 6, TGF:CMM), and 97 up-
regulated, 188 down-regulated (Figure 7, TGF:Melphalan).  This summary can be compared 
with those genes that were influenced, but in opposing directions, between groups 
(Supplemental Figure 1).  
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Discussion: 
           Ablative therapy followed by stem cell reinfusion is used to treat hematopoietic, and brain 
tumors as well as childhood sarcomas, and immune deficiencies 43-45.  As the primary site of 
postnatal hematopoiesis, the functional integrity of the bone marrow microenvironment is critical 
for hematopoietic recovery subsequent to stem cell transplantation.  Earlier reports have 
suggested that BMSC are vulnerable to functional damage imposed by aggressive 
chemotherapeutic agents 46;47.  These studies have focused largely on the ability of stromal cells 
to generate fibroblastic colonies (CFU-F) or to support survival or expansion of committed 
progenitor cells when isolated from patients following treatment of subsequent to in vivo drug 
exposures 48.     
Murine models of ablative treatment and stem cell transplant have shown long-term 
deficits in hematopoietic recovery and in vitro models have paralleled these documenting the 
inability of transplanted cells to migrate efficiently to the necessary anatomical niches for 
engraftment 49.  Observations of long-term hematopoietic deficits in bone marrow of 
transplantation patients suggest that the functionality of the developmental niches required for 
appropriate support of stem cells may have been compromised by aggressive pre-transplant 
therapies. One study observed that at 1 year post transplant 61% of patients have subnormal 
values in one or more hematopoietic lineages 50.  Further, Nieboer et al. showed that at 5 years 
post transplant 15% of the patient population analyzed had low values in one or more 
hematopoietic cell lineages 51.  Investigation of the mechanisms that underlie damage of the 
hematopoietic and stem cell niche is further encouraged by retrospective studies of patients that 
received allogeneic bone marrow transplants in which patient HSC did not recover to the levels 
of control patients, even after 12 years, as measured by CFU-F frequencies, suggesting that the 
damage of the structural, hematopoietic supportive cells of the bone marrow can be sustained 
36.  
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 In the current study we characterized the impact of direct and indirect damage on 
osteoblasts and their subsequent ability to support progenitor and stem cells. Following 
transplantation and during development, HSC home to the endosteal niche which acts as a 
critical regulator of stem cell quiescence, proliferation, and conservation of the stem cell pool. 
Direct contact between osteoblasts and HSC is required for HSC survival 52-54 with a dynamic 
relationship demonstrated by the ability of HSC to  regulate the cytokines expressed by 
osteoblasts in order to enhance their own survival. Studies by Calvi et al., and others, have 
shown that number of osteoblasts present in the niche directly modulates the numbers of HSC 
that can be supported by the niche 10;11;30.   
           In light of the delicate balance between osteoblasts and HSCs, it is not surprising that 
either direct, or indirect damage via factors elaborated by other populations of cells within the 
niche, to osteoblasts results in a deficit in the HSC pool. Our data has shown that both direct 
exposure to chemotherapy as well as exposure to conditioned media from chemotherapy 
damaged BMSC increases the activity of osteoblast derived TGF-, one of the known negative 
regulators of HSCs (Figure 1C) 15-17. Consistent with the literature suggesting that TGF- activity 
leads to decreased expression of HSC surface cytokine receptors and a deficit in the stem cell 
pool, 55;56 Figures 2 and 3 summarize data that show the decreased ability of chemotherapy 
damaged osteoblasts to interact with, and support, both human embryonic stem cells as well as 
more differentiated pro-B cells. Direct treatment of HOB with active TGF- results in a 
comparable reduction in pro-B cell adhesion and chemotaxis as well as diminished ability to 
support Oct-4 positive stem cells. Collectively, these data suggest that chemotherapy induced 
increases in active TGF-, from damaged BMSC and HOB, could contribute to deficits in the 
stem cell pool  
           Another consideration when evaluating the dynamic balance of the niche is the role of 
adhesion molecules physically tethering progenitor cells to supportive cells of bone marrow, 
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which provides signals for their maturation and survival 57.  Earlier reports have described the 
role of the VCAM-1/VLA-4 interaction in hematopoiesis. Ryan et al demonstrated that adhesion 
of B cell precursors to BMSC was dependent on this interaction and Dittel et al elucidated how 
cytokines could alter the surface expression of VCAM-1 26;27. Studies in murine models showed 
that a VCAM-1 knockout was embryonic lethal, while a conditional deletion led to decreases in 
immature B cells found in the bone marrow with a subsequent impairment in immune response 
28. 
In addition to the VCAM-1/ VLA-4 interaction, the CD44/ hyaluronan (HA) interaction has 
also been recognized for its role in hematopoiesis and homing of primitive cells to the bone 
marrow 58;59.   Avigdor et al demonstrated the important roles of CXCL12 with respect to the 
migration and anchorage of progenitors to the bone marrow through CD44/ HA 60.  It was based 
on these observations that we investigated the effects of chemotherapy on VCAM-1, CD44, and 
HA in our model of osteoblast damage.  Figure 2C shows that pro-B cells co-cultured with 
chemotherapy or rTGF-β pre-treated osteoblasts are unable to adhere to the osteoblasts 
efficiently.  However, investigation of the adhesion molecules VCAM-1, CD44 and Hyaluronan 
indicated no altered expression with either chemotherapy or rTGF-β exposure.  These 
observations suggest that the deficit in hematopoietic support, in our model, is the result of 
changes in a soluble factor acting in either an autocrine or paracrine manner to diminish optimal 
cell:cell interaction. Paracrine effects could be modulated, in part, through alteration of integrin 
activity, which would not have been detected in our assay. These observations also suggest 
very specific effects of chemotherapy on stromal and osteoblast components of the niche, 
emphasizing the need to understand each population individually to understand the total 
response of the niche to therapy.  
 In light of the data suggesting that decreased expression of specific adhesion molecules 
was not obviously responsible for the inability of damaged osteoblasts to support stem and 
progenitor cells, we examined the effect of chemotherapy damage on osteoblast derived 
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CXCL12.  Data in Figure 3 shows that both chemotherapy and rTGF-β decrease CXCL12 
mRNA and protein in osteoblasts 42. The decrease in CXCL12 correlated with a decrease in 
chemotaxis of CXCR4+ cells towards osteoblasts pre-treated with either Melphalan or rTGF-β. 
However, in contrast to previous experiments in which we reported chemotactic deficits in VP-
16 treated BMSC 21,  no  significant reduction in chemotactic support of CXCR4+ cells was 
noted in the VP-16 treated HOB groups, even though they exhibited the decrease in CXCL12. 
These data suggest potential drug specific effects in which Melphalan may target CXCL12 
expression as well as other critical chemotactic factors in HOB while VP-16 does not as globally 
affect chemotaxis regulators, allowing some maintenance of chemotactic support.  One such 
factor for future investigation would include stem cell factor, SCF, which has been shown to 
synergize with CXCL12 in homing of stem cells and retention in their developmental niche 61;62.   
Collectively, these data suggest that generation of active TGF-β in the endosteal niche 
can negatively affect production of CXCL12, thus impairing progenitor cells from homing to the 
bone marrow, engrafting, and reconstituting the patient’s immune system.  This observation of 
vulnerability of gene expression to genotoxic stress in HOB prompted us to attempt to 
understand the magnitude of direct and indirect chemotherapy-induced damage to osteoblasts 
by microarray analysis. After only 6 hours of treatment the diverse changes observed in HOB 
gene expression alone allow for a better understanding of the significance of the potential 
damage to the niche and the subsequent impact on hematopoietic reconstitution that relies on 
balanced expression of several proteins.  Previous reports suggest that NF-B can be activated 
by both TGF- and TNF- leading to the transcription of BCL2A1, to suppress chemotherapy 
induced apoptosis 63;64. Interestingly, all 3 HOB treatments (rTGF-, Melphalan and conditioned 
media from Melphalan pre-treated BMSC) evaluated in the microarray analysis had the 
convergence point of increased BCL2A1 mRNA, suggested by the network analysis to be 
regulated by NF-B (Figures 4-7).  As with all gene expression pathway analysis, in the 
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absence of targeted genetic manipulation or biochemical analysis, the interactions remain 
hypothetical.  The most pronounced value of these data in the current study is to provide a 
sense of the responsiveness of osteoblasts to genotoxic stress as well as to factors from other 
structural components in the stem cells niche. Points of convergence, such as BCL2A1 as just a 
single example, may then provide the focus for a more mechanistic understanding of cell 
signaling downstream of stress in the bone marrow microenvironment. 
             Central to our investigation was an interest in the influence of active TGF-β released 
from chemotherapy treated HOB as well as TGF-β that may be released from neighboring 
BMSC in a damaged microenvironment as just two potential sources of this growth factor. 
Understanding the role of TGF-β in the bone marrow microenvironment is extremely important 
when attempting to modulate therapeutic intervention to reconstitute the niche post-transplant. 
Studies by Batard et al have described the importance of low levels of TGF-β in the bone 
marrow microenvironment for maintenance of the stem cell pool through up-regulation of the 
CD34 antigen, a marker of primitive HSC 55.  Consistent with the need for rigorous control of 
total TGF-β levels, a number of studies have shown the benefit of TGF-β neutralization in cases 
where TGF-β levels are increased in response to therapy 65;66.  Lagneaux et al showed that 
stromal cells isolated from B-CLL patients had increased TGF-β production correlated with 
decreased colony-stimulating activity which was corrected by  neutralizing TGF-β activity 17.   
Using a murine model of breast cancer, Biswas et al showed that radiation or doxorubicin 
treatment increased levels of TGF- which correlated with increased circulating tumor cells and 
increased metastasis 67. These effects were  abrogated by anti-TGF-β antibodies providing 
rationale for utilization of TGF-β inhibitors, such as GC1008 in clinical trials in the setting of 
renal cell carcinoma and malignant melanoma 68.  Based on our observations, application of 
TGF-β neutralizing antibodies may have utility in restoration of the stem cell pool as well, 
through influence on both stem cells and the niche in which they develop.   
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Our observations indicate that HOB, a critical regulator of stem cell development, are 
susceptible to genotoxic stress documented by both functional deficits and broad alteration of 
gene expression profiles.  Further investigation will identify targets that may prove useful in 
augmenting hematopoietic recovery through “balancing” the stem cell niche following therapy-
induced damage. Long-term hematopoietic deficits may, in fact, derive in part from the 
immediate changes in the stem cell niche that are imposed by aggressive therapeutic regimens.  
This aspect of marrow function may highlight an area in which better understanding could 




Figure 1: Direct and indirect damage increase HOB levels of active TGF- β.  A) HOB were 
 treated with 50g/ml Melphalan, 50M VP-16, or 10ng/ml rTGF- for 24 hours and real time 
 RT-PCR for TGF- β was performed. B) HOB were treated with 50g/ml Melphalan, 50M VP-16 (left 
panel), or 10ng/ml rTGF- (right panel) for 24 hours. The HOB layer was rinsed and new media was 
added and allowed to condition for 24 hours before being evaluated by ELISA to quantitate the amount 
of secreted TGF-. C) HOB were treated directly for 4 hours with chemotherapy (100M VP-16, 
100g/ml Melphalan) or with media from BMSC that had been left untreated (BMSC CM control) or pre-
treated with 50g/ml Melphalan (BMSC CM Melphalan) or 50M VP-16 (BMSC CM VP-16) for 24 
hours. HOB cells were then fixed and stained for detection of phospho-Smad2 (green) and DAPI (blue).  
 
Figure 2: Chemotherapy or rTGF-β exposure diminished the ability of HOB to support 
 Oct-4 positive human embryonic stem cells and diminish HOB interaction with pro-B 
cells   HOB were pre-treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24 
hours. HOB were rinsed thoroughly and embryonic stem cells were co-cultured in complete 
media as recommended by WiCell. After 2 days of co-culture, stem cell colonies were counted 
and designated as undifferentiated or differentiated based on classic morphology of well defined 
borders (A) and were stained for Oct-4 as an indicator of potential for pluripotency (B).  HOB 
were treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24 hours. Adherent 
layers of HOB were rinsed thoroughly and co-cultured with 1x105 fluorescently labeled pro-B 
cells. After 24 hours the media was aspirated and non-adherent pro-B cells were gently rinsed. 
Remaining HOB and pro-B cells adherent to the HOB layer were then trypsinized and events 
within the easily distinguishable lymphoid gate, based on fluorescence and forward/side scatter, 
were counted on high flow rate for 30 seconds to enumerate number of pro-B cells attached to 
the HOB (C).  
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      Figure 3: Chemotherapy or rTGF- diminishes HOB expression of CXCL12 and support of 
pro-B cell chemotaxis. A) HOB were treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or 
50M VP-16 for 24 hours. RNA was isolated and Real Time RT-PCR was performed for 
CXCL12. B) HOB were treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24 
hours. Growth factor or chemotherapy was removed and fresh media was added, allowed to 
condition for 24 or 48 hours, and then evaluated in a CXCL12 specific ELISA. C) HOB were 
treated with rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24 hours. 350ul of the supernatant 
was then removed and placed into the bottom chamber of a transwell.  1x105  JM-1 progenitor 
cells were placed in the top chamber and allowed to migrate for 4 hours. After 4 hours the cells 
migrated were read on high flow rate for 30 seconds on a flow cytometer.  
 
Figure 4: Intersection of global gene changes during direct and indirect chemotherapy.    HOB 
cells were treated for 6 hours with 10ng/ml rTGF-β, 50 g/ml Melphalan, or conditioned media from 
BMSC  (CMM) pre-treated with 50 g/ml Melphalan for 24 hours.  BMSC exposed to Melphalan were 
rinsed and fresh media was place on adherent layers to condition and to remove drug prior to 
stimulating HOB.  After the 6 hour treatment, HOB RNA was isolated and microarray analysis was 
completed to evaluate global changes in gene expression. A) The Venn diagram summarizes the 
number of HOB genes that changed within each group as well as the changes between the groups.  B) 
A gene summary was made of  the genes that commonly were up-regulated (4, red) or down-regulated 
(2, green) for the intersection of all 3 treatments (rTGF-:CMM:Melphalan).  C) A network diagram was 
generated that highlight potential paths that converged upon the commonly increased gene, BCL2A1, 
for the intersection of all 3 groups. All genes listed were generated using a 2.5% FDR and 1.5 fold 
significant cut off.  
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Figure 5: Soluble factors in BMSC exposed to chemotherapy induce HOB gene expression 
changes in common with those subsequent to Melphalan exposure.  HOB cells were treated for 6 
hours with 50 g/ml Melphalan, or conditioned media from BMSC pre-treated with 50 g/ml Melphalan 
for 24 hours.  BMSC exposed to Melphalan were rinsed and fresh media was place on adherent layers 
to condition and to remove drug prior to stimulating HOB.  After the 6 hour treatment, HOB RNA was 
isolated and microarray analysis was completed to evaluate global changes in gene expression.  A) 
Gene changes for the intersections of the CMM:Melphalan groups were analyzed based on the genes 
that commonly increased (16, red) or decreased (3, green). B)  A network diagram was generated that 
highlight potential paths that converged upon the commonly increased gene, BCL2A1, for the 
intersection of CMM:Melphalan groups. All genes listed were generated using a 2.5% FDR and 1.5 fold 
significant cut off.  
 
Figure 6: Soluble factors in BMSC exposed to chemotherapy induce HOB gene expression 
changes in common with those subsequent to rTGF- exposure.  HOB cells were treated for 6 
hours with 10ng/ml rTGF-β, or conditioned media from BMSC pre-treated with 50 g/ml Melphalan for 
24 hours.  BMSC exposed to Melphalan were rinsed and fresh media was place on adherent layers to 
condition and to remove drug prior to stimulating HOB.  After the 6 hour treatment, HOB RNA was 
isolated and microarray analysis was completed to evaluate global changes in gene expression.  A) 
Gene changes for the intersections of the TGF-:CMM groups were analyzed based on the genes that 
commonly increased (26, red) or decreased (11, green). B)  A network diagram was generated that 
highlight potential paths that converged upon the commonly increased gene, BCL2A1, for the 
intersection of  TGF-:CMM groups. All genes listed were generated using a 2.5% FDR and 1.5 fold 
significant cut off.  
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Figure 7: rTGF- exposure  induces HOB gene expression changes in common with those 
subsequent to Melphalan exposure.  HOB cells were treated for 6 hours with 10ng/ml rTGF-β, or with 
50 g/ml Melphalan for 24 hours.  After the 6 hour treatment, HOB RNA was isolated and microarray 
analysis was completed to evaluate global changes in gene expression.  A) Gene changes for the 
intersections of the TGF-:Melphalan groups were analyzed based on the genes that commonly 
increased (97, red) or decreased (188, green). B)  A network diagram was generated that highlight 
potential paths that converged upon the commonly increased gene, BCL2A1, for the intersection of  
TGF-:Melphalan groups. All genes listed were generated using a 2.5% FDR and 1.5 fold significant 
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3. Acute Lymphoblastic Leukemia 
 
I. Acute Lymphoblastic Leukemia 
 
As previously mentioned, normal B lymphopoiesis occurs in the bone marrow and gives 
rise to mature B cells that express immunoglobulin and are responsible for humoral immunity. In 
some cases, normal B cells acquire stage specific mutation(s) and undergo developmental 
arrest, while continuing to proliferate and expand, without being functional modulators of 
immunity. This leads to an accumulation of blasts, or immature B cells, in the bone marrow and 
subsequently in the periphery, that are indistinguishable from their normal counterparts and are 
representative of the disease clinically classified as Acute Lymphoblastic Leukemia.  
 Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, with 
the peak incidence being ages 2-5, and approximately 5,700 new cases will be diagnosed this 
year in the United States1;2.  Although a direct cause of leukemia is not known, exposure to 
chemicals such as benzene, high levels of radiation or chemotherapeutic agents increases the 
chance of leukemia, as do certain viruses, and inherited diseases such as Down's syndrome, 
but it is believed that these represent less than 5-10% of diagnosed leukemias. Literature 
suggesting high birth weight being associated with leukemia is becoming more prevalent, but 
much more research is needed to attempt to determine the causation of the disease3.  The start 
of the disease is unknown, and it has been suggested that some leukemias may start in utero 
while others state that the first mutation in the multistep pathway may start in a hematopoietic 
stem cell (HSC) with multi-lineage developmental capacity or a progenitor cell committed to 
specific lineage4. 
Additionally, the presence of chromosomal abnormalities is relevant to the disease but is 
ruled out as the sole causation since screening of neonatal cord blood has shown that potential 
leukemic clones with the TEL-AML fusion gene (aka ETV6-RUNX1) has been found in 1% of 
newborn babies which is a frequency 100 times higher than the incidence of ALL with this fusion 
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gene in childhood5. The Philadelphia chromosome (Bcr/ABl , Ph+) has also been detected in 
circulating cells of healthy people who never develop leukemia further substantiating that the 
single translocations are not enough to cause the full disease6-11. At diagnosis, risk assessment 
is based on age, white blood cell count, and the presence of chromosomal abnormalities12. 
Diagnosis is further classified by surface expression of T or B-lineage markers, and prognostic 
significance is based on these classifications as well as initial response to therapy. Further 
discussion will focus specifically on B-lineage ALL.  
 B-lineage Acute Lymphoblastic Leukemia is responsible for 75-80% of ALL and is a 
malignant disease characterized by an accumulation of blasts, or immature cells, that undergo 
clonal expansion resulting in suppression of normal hematopoiesis and potential infiltration of 
extramedullary sites13. Clinically it is seen as fever, effects of anemia such as severe fatigue 
and malaise, an absence of functioning granulocytes (proneness to infection and inflammation), 
and thrombocytopenia (hemorrhagic diathesis) 12. The 5 year overall survival rates for B-lineage 
ALL are 60-70 percent overall; 90.9 percent for children under 514-16. However, these numbers 
are altered by expression of negative cytogenetic markers. Chromosomal abnormalities 
detected at diagnosis are used for both risk assessment as well as deciding on treatment 
regimens 12;17;18. Common translocations found in B-Lineage ALL are high hyperploidy (51-65 
chromosomes) and TEL/AML1 fusion; t(12;21) which are typically associated with younger 
patients (1-10yrs old, 22-50% of ALL children, 2-10% of ALL adults) with low leukocyte counts 
and are correlated with a favorable prognosis18.  Other common alterations and translocations 
include: hypodiploidy (fewer than 44-45 chromosomes), intra-chromosomal amplification of the 
AML1 gene on chromosome 21 (Iamp21), and rearrangements of the Mixed Lineage Leukemia 
gene (MLL, 11q23), E2A-PBX1 t(1:19). These alterations are all associated with a poor 
prognosis and high risk of relapse.  MLL (4;11, most common and significantly poor prognosis in 
children under 1 with overall survival ~50%) and the Bcr/Abl t(9;22)  (poor prognosis in children 
and adults)17;18. 
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The Philadelphia chromosome (Ph+, t(9;22)(q34;911)  is a reciprocal translocation of the 
long arms of chromosomes 9 and 22 .  It was discovered in 1960 by Peter C. Nowell in Chronic 
Myelogenous Leukemia (CML),19;20 but it was not until the early 1970’s that improved 
cytogenetics techniques allowed the origin of the translocation, chromosomes 9 and 22, to be 
known21. The Ph+ increases in frequency with age, from 3-5 percent in children to 20 percent in 
adults to more than 50 percent in patients older than 50 years 22 18.  Interestingly, in patients with 
ALL who have t(9;22), the Philadelphia chromosome,  children one to nine years of age have a 
better prognosis than adolescents with the same disease, who in turn fare better than adults 22.  
 Treatment for ALL typically consists of 3 phases: remission induction, consolidation or 
intensification and maintenance therapy12;17;22;23. The goal of remission induction is to eradicate 
99% of the leukemia burden and to restore normal hematopoiesis and performance status. 
Patients with 1% or greater leukemic blasts at the end of 4–6 weeks of remission induction 
therapy fare nearly as poorly as those who do not achieve clinical remission by the accepted 
morphological standard (≥5% leukaemic cells), where people who achieve molecular or 
immunological remission (<0・01% leukemic cells) have an excellent outcome 17;24-27. Children 
that have high risk or very high risk ALL, as well as most adults, tend to receive four or more 
chemotherapeutic drugs during this aggressive therapy.  
Remission induction usually lasts approximately a month and typically includes 
HyperCVAD. Hyper refers to hyperfractionated nature of the chemotherapy, which is given in 
smaller doses, more frequently, to minimize side-effects and CVAD is an acronym for the 
chemotherapeutic agents utilized: Cyclophosphamide, Vincristine,  Daunorubicin (Adriamycin, 
Ara-C, or Doxorubicin) and Dexamethasone (Prednisone) 25;28.  Additionally, based on the 
patient's prognostic factors, some regimens may also include L-asparaginase, etoposide, and/or 
high doses of methotrexate or cytarabine (Ara-C) as part of the induction phase. During 
remission induction, prophylactic treatment is also given to keep the leukemia from spreading to 
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the CNS (Central Nervous System). This treatment may include intrathecal chemotherapy 
(injected directly into the spinal fluid), high dose methotexate IV, high dose Ara-C or cranial 
irradiation. The number of rounds of therapy depends on age and tolerability of therapy, but 
generally consists of 8 cycles of treatment 12;29.   For Ph+ ALL disease, patients also receive 
Imatinib or Dasatinib as part of therapy and throughout maintenance. 
 Consolidation therapy occurs when a patient is considered to be in remission (both 
cytogeneic and hematopoietic recovery) and is a short course (a few months) of the same 
chemotherapy as remission induction, CNS treatment.  Patients with a high risk phenotype 
(Ph+), or that had a poor initial response to treatment, may have allogeneic bone marrow 
transplants after the induction of remission.  Transplant is decided in the first remission based 
on several factors: 1. age at diagnosis, 2- chromosome abnormalities at diagnosis (ie Ph+, 
11q23 abnormalities, etc a ‘poor risk), - 3- WBC at diagnosis, 4- availability of a donor (do they 
have a matched sibling available) 17;29. If patients are going to transplant in first remission, they 
generally complete 4 cycles of therapy, then go to transplant. If patients are staying on 
treatment, they generally proceed through therapy.  If they relapse, they get further therapy to 
try to get into remission, then go through transplant (in second remission) 17;29.  After the initial 8 
cycles, patients then receive maintenance therapy with methotrexate, vincristine, prednisone, 
and 6-MP, on a monthly schedule for 2 more years.   
These treatments, though aggressive in nature, often do not result in eradication of 
disease. Minimal residual disease (MRD) and subsequent relapse typically occur in the bone 
marrow and monitoring of patient disease status has been revolutionized by the Campana 
laboratory, and others24;30;31.  MRD could previously be detected only by morphological 
microscopic analysis and did not allow for efficient detection of relapse or monitoring of 
response to treatment.  Approximately 30 years ago, Janossy and colleagues were one of the 
first groups to attempt to identify residual tumor cells using more than morphology, and they 
observed that T-lineage ALL cells co-expressed both TdT and T-cell marker, which normal 
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blood and bone marrow cells did not 32;33. The most widely used techniques for detection of 
MRD are PCR and flow cytometry which allow for the detection of chromosomal translocations 
and immunoglobulin gene rearrangements and are able to observe a single tumor cell in the 
background of thousands to millions of normal cells 34;35. Currently, the ability to utilize 
immunologic markers allows for the detection of  the unique tumor phenotypes that cause MRD 
in both T and B lineage ALL.    
II. Tumor stem cell phenotype 
Tumor cells with diverse phenotypes have been shown to both interact with, and alter, 
their microenvironment with leukemia cells also having the potential to change the ability of 
normal HSC to proliferate and function in shared niches36;37. Although many microenvironments 
have been shown to be protective to multiple types of tumors, numerous studies from the Dalton 
and Campana laboratories laid the seminal ground work for the hypothesis of the bone marrow 
microenvironment being protective to hematopoietic tumors, as well as a key site of metastasis 
for solid tumors25;38. Therefore, the bone marrow microenvironment has unique biological 
relevance and its interaction with tumors with a stem- like phenotype is the focus of the following 
section.  
On the surface, leukemic cells express identical proteins to their normal immature 
hematopoietic cell counterparts. This stems from the fact that a B-lineage, acute lymphoblastic 
leukemia (ALL) cell is, for all intents and purposes, a normal B cell that is arrested in a pre-pro 
progenitor stage and is unable to differentiate to become a mature, functional B cell but has 
extreme proliferative capacity. Blunted differentiation leads to the rapid accumulation of 
immature B-lineage cells, or leukemic blasts in the acute phase. The hallmark difficulties in 
treatment then become not only eradicating the proliferative leukemic blasts, but also their 
ability to be protected by the microenvironment by utilizing normal B cell/stromal 
microenvironment interactions resulting in residual tumor that can contribute to relapse of 
disease. As mentioned previously, normal B cells interact with the microenvironment through 
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physical interactions (Integrins, VLA-4/VCAM-1 interactions) as well as through soluble cues 
(CXCL12, SCF, IL-7, TGF-B).  Although it is hypothesized that leukemic cells have a stage of 
stromal cell dependence,39 40 blast cells are commonly found in the blood and periphery at 
advanced stages of disease, suggesting that part of the evolution of this malignancy is a loss of 
stromal cell dependence that would normally control expansion of pre-pro-B cells. Our 
laboratory, as well as others, have focused on the factors that influence survival of B-lineage 
ALL during chemotherapy with respect to the protection given by the bone marrow 
microenvironment41-45.   
The data presented in Chapters 2 and 3 summarizes our investigation of specific 
aspects of Philadelphia chromosome positive ALL cells that may help them survive 
chemotherapy exposure more efficiently than their Ph- counterparts. In addition to having the 
Bcr/Abl translocation leading to high Abl kinase activity, these cells also express vascular 
endothelial cadherin (VE-cadherin) and high levels of -catenin, a pro-survival protein. These 
cells additionally have a stem-like phenotype, expressing markers expressed in pluripotent stem 
cells including Oct-4, HIF-2, CD133, TRA-1-61, and TRA-1-80.  Stem cell properties are 
sustained by co-culture with BMSC contact during chemotherapy leading to the survival of these 
Ph+ cells during treatment.  
 The existence of a cancer stem cell was first suggested in the 1960’s 46;47and has been 
thoroughly investigated by the Weinberg, Dick, Lapidot and Weissman labs, as well as 
others41;48-55. Tumor initiating cells (TIC) or tumor stem cells have been found in both 
hematopoietic tumors, with the foundational work being done in AML (Acute Myeloid 
Leukemia)51;56, and in solid tumors including breast cancer, ovarian cancer, pancreatic cancer, 
colon cancer, prostate cancer,  hepatocellular carcinoma,  melanoma,  lung cancer, 
glioblastoma, other brain tumors, and neuroblastoma43;48;57-67. The initial classification of a 
cancer stem cell was that it could be isolated from the tumor of one animal, transferred to an 
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immuno-compromised recipient animal and subsequently establish disease. This has been 
expanded upon to include a panel of markers that are in common with embryonic and adult 
hematopoietic stem cells and that slightly differ between tumor types. These makers typically 
consist of CD133, CD34, CD44 as well as Oct-4, BMI-1, and other markers of pluripotentcy, 
although in different cancers there is a slightly different stem cell profile 68-71. For example, 
breast cancer stem cells are CD44+ and CD24- 72. Leukemic stem cells tend to be lineage -, 
cKithigh, Sca-1-, CD34+, CD38-, (AC) CD133+. John Dick’s lab found that in Acute Myeloid 
Leukemia (AML) a CD34+ CD38- (leukemic stem cell, LSC) fraction was always able to give 
rise to leukemia when transplanted into immunodeficient mice and that targeting of CD44 led to 
a diminished ability of these cells to interact with supportive niches and evade treatment- 
induced apoptosis 51;73. In addition to their unique phenotype, cancer stem cells from multiple 
tumor types are able to interact with the bone marrow microenvironment and utilize cues 
derived from it to evade treatment leading to both minimal residual disease as well as relapse 
74;75.   
Although controversy remains regarding the relevance of cancer stem cell markers in 
murine models as well as the potential for species incompatibility, leading to cancer stem cells 
that are unable to engraft, it is consistent that these markers give insight on the progress of the 
disease and allow for in vivo therapeutic manipulation76;77.  
III. Rodent models of tumor stem cells and leukemia 
         In the late 1970’s mouse models of ALL consisted of subcutaneous injection of primary 
patient cells or cell lines into nude mice which result in solid tumors that were uncharacteristic of 
the disease. A study in 1978 by Watanabe  et al. documented the ability of ALL patient cells to 
grow in the hematopoietic tissues of a nude mouse 78. This study, however, was done using an 
aneuploid T ALL originally established and maintained as an ascites tumor in nude mice; the 
animals died within 2 to 4 weeks and growth as an ascites does not reflect the normal course of 
the disease 78. In 1989 Dick and colleagues revolutionized the study of ALL by creating an in 
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vivo model of B-lineage ALL that progressed with the same clinco-pathology as patient 
disease79. They demonstrated the ability to engraft patient samples of pre-B-lineage ALL into 
irradiated SCID (Severe Combined Immunodeficiency) mice through intraperitoneal or 
intraveneous injection.  
         SCID mice are homozygous for an autosomal recessive mutation on chromosome 16 
resulting in disruption of the protein kinase DNA activated catalytic polypeptide (Prkdc) gene loci 
preventing the activation of a DNA recombinase enzyme, which in turn leads to impaired 
immunoglobulin and T-cell receptor gene rearrangements and consistent apoptosis of T and B 
cells 80;81. These mice are therefore deficient in both humoral and cellular immunity but retain a 
virtually fully functional innate immune system with normal levels of tissue macrophages, natural 
killer (NK) cells, marginal zone B-cells, serum complement activity and myelopoiesis 80;81 . 
Additionally, despite the immune deficiencies, the haematopoietic microenvironment of SCID, 
including the thymic stroma, remains intact. These properties result in the mice being unable to 
reject allogeneic or xenogeneic organ grafts. Unfortunately, one of the major limitations of SCID 
mice as hosts for xenotransplantation is due to the incomplete penetrance or ‘leakiness’ of the 
SCID mutation 82. Although strain dependent, leakiness results in the spontaneous development 
of partial immune reactivity, with up to 90% of old (>1 year) mice exhibiting high levels of 
immunoglobulin and functional lymphocytic rearrangements which has the potential to interfere 
with graft acceptance in the host 82.   
Currently, the most widely used mouse model of ALL is the NOD/SCID (Non Obese 
Diabetic/ Severe Combined Immunodeficiency) model, which in addition to the immunological 
deficits of the SCID, also exhibits multiple defects in adaptive and innate immunologic function 
including lack of functional lymphoid cells, exhibiting little or no serum immunoglobulin with age, 
lack of  C5 and complement activation,  lack of NK cell activity and a poor macrophage 
secretion of IL-1 83;84. This results in a functionally less mature macrophage population in 
comparison to the parental SCID and therefore has been proven to be the better host, with or 
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without additional immune suppression, for human hematopoietic cells and leukemic blasts than 
SCID mice 83;85;86.  
More recent studies have been done comparing, even further, the engraftment of 
NOD/SCID mice to their NOD/scid/b2 null (lack of MHC class I expression and decreased NK-
cell function)  and NOD/scid/IL-2Rcnull (IL-2Rg-chain deficiency impairs the signaling through 
multiple cytokine receptors blocking NK development and results in additional defects in innate 
immunity) counterparts. Engraftment of malignant cells (primary and cell line ALL, AML and 
CML) was measured using clinico-pathological criteria, PCR, flow cytometry and 
immunohistochemistry. Interestingly, the NOD/scid/IL-2Rcnull had the greatest engraftment in 
both cell lines and patient samples (31/39 and 15/22) followed by the NOD/scid/b2 null (19/38 
and 9/28) and finally the NOD/SCID (13/38 and 7/25) 87.  
In addition to the murine models of leukemia, a 2005 paper by Bernard et al.  
demonstrated the ability to chemically induce leukemia in a rat model 88. This paper was the first 
time a chemically induced model of leukemia was used, and although it isn’t a widely used 
model, they did prove that through administration of N-butylnitrosourea (BNU), an alkylating 
agent for 24 weeks that the rats would develop B lineage ALL that could be serially transplanted 
into healthy rats. Murine models of leukemia are currently not only being used to study the 
dissemination of disease but are also being utilized as models of drug efficacy in pre-clinical 
studies. In this context, the microenvironment warrants careful consideration as a novel 
therapeutic target.   
IV. Therapeutic strategies for leukemia.   
 Acquired resistance of tumor cells to treatment can develop over time as a result of 
sequential genetic changes that ultimately culminate in complex therapy-resistant phenotypes. 
De novo resistance occurs typically in two ways, through both physical interactions (VLA-
4/VCAM-1) and soluble factor interaction (CXCL12, VEGF, TGF-B) of the tumor cells and their 
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surrounding microenvironment. This allows for protection of the tumor cells during 
chemotherapy and has been found to be especially prominent in the leukemia stem cell pool.  
 Studies have shown that not only can leukemia cells respond to the microenvironment 
as a protective force during treatment, but additionally the microenvironment supports selection 
of  those cells inherently resistant to treatment. A study from Mishra et al. demonstrated that 
exogenous SDF-1 (CXCL12) in the absence of bone marrow stromal cells, or bone marrow 
stromal cell co-culture, resulted in selection of  Imatinib-resistant Bcr/Abl P190 lymphoblasts 
with less dependence on Bcr/Abl tyrosine kinase activity89. This selection of resistant cells and 
protection has also been shown by Mudry et al. and others, who showed that physical 
interaction between VCAM-1 on the stromal cell and VLA-4 on the leukemic cell alone is enough 
to confer protection during chemotherapy44;90;91. Although some treatments such as AMD3100 
(inhibitor of the CXCR4 receptor for the CXCL12 ligand) allow for inhibition of tumor cell 
interaction with the microenvironment, it also inhibits the required physical interactions that 
normal hematopoietic cells need for the microenvironment to promote their survival 92;93.  
 Other mechanisms that underlie leukemic cell survival during chemotherapy include 
alterations in leukemic cell surface molecule expression or activity. The Weissman lab has 
recently shown that leukemic cells express high levels of CD47, an immunoglobulin-like protein 
that is known to interact with integrins and thrombospondin-1, to function as an anti-phagocytic 
signal53.  CD47 is typically found on normal hematopoietic cells to ensure that autologous cells 
are not inappropriately phagocytosed. Therefore CD47 may serve as a useful therapeutic target 
if inappropriately up-regulated at high levels on tumor targets on which it could be more readily 
interrupted than on the normal hematopoietic cells.  
 In order to identify more efficacious therapeutic targets an in depth understanding of the 
biology of specific subclasses of leukemia, in our studies, or specific tumor types in general 
other categories of malignancies is required to allow therapeutic strategies that target from 
multiple angles. For example, autophagy is usually thought of as an alternative death 
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mechanism distinct from apoptosis or necrosis. It is defined as is a degradative process in 
eukaryotic cells that results in the breakdown of intracellular material within lysosomes under 
homeostatic conditions or in response to stress signals, allowing cells to adapt to environmental 
and/or developmental signals. It is a genetically controlled process, which progresses through 
definite steps, leading to the engulfment of long-lived proteins and whole organelles into multi-
membraned vacuoles, called autophagosomes, that fuse with lysosomes for final destruction 
and recycling94. However, autophagy is also a process by which cells can adapt their 
metabolism to starvation caused by a decrease in metabolite concentrations or extracellular 
nutrients, a typical consequence of loss of growth factor signaling, allowing cells to evade 
programmed cell death95. Bellodi et al. showed that Imatinib treatment rapidly activates an 
autophagic process, which follows the induction of ER stress and relies on intracellular Ca2+. 
More importantly, inhibition of autophagy by pharmacological inhibitors potentiates Imatinib-
induced cell death in CML cell lines and primary CML cells, including those carrying partially IM-
resistant BCR/ABL mutants94. This study suggests that induction of autophagy provides a 
survival mechanism to IM-treated BCR/ABL-expressing cells, including the stem cell population, 
and that inhibition of autophagy may improve the therapeutic efficacy of Imatinib. These results 
were also seen by the Adachi lab with the Abl kinase inhibitor INNO-406 (NS-187), which is a 
specific dual Bcr-Abl/Lyn kinase inhibitor96.  
 Currently, dual kinase inhibitors, proteasome inhibitors, histone deactylase inhibitors 
(HDACI) and aurora kinase inhibitors are becoming therapeutic options for leukemia 12;22;23. Abl 
kinase inhibitors such as Imatinib (Imatinib Mesylate, Gleevec) are currently being used to treat 
Ph+ ALL and CML. Do to the high level of mutations of the Abl kinase domain and resistance to 
therapy, new more effective single abl kinase inhibitors, as well as dual inhibitors  and the use of 
multiple types of inhibitors together are currently being investigated 97. 
 Dasatinib (BMS-354825, Sprycel) is a dual Src family kinase, Abl kinase inhibitor that 
also targets PDGFR, kit and Ephrin receptor kinases. It has been through phase I and II clinical 
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trials and has been shown to be approximately 300-fold more effective than Imatinib, potentially 
due to its ability to bind both the active and inactive conformation of Bcr/Abl 98. Dasatinib is 
unable to inhibit the T315I mutation but is capable of suppressing many of the Imatinib resistant 
mutations. Bosutinib (SKI-606) is an inhibitor of both Src and Abl kinases but does not have the 
off-target PDGFR and Kit effects of Imatinib or Dasatinib 99. It has been shown to be well 
tolerated in Phase I trials, can bind to both the active and inactive conformation of Abl,  but is 
not effective against all Bcr/Abl mutations. Nilotinib (Tasigna, AMN107) is an Abl kinase (and 
other, not Src) inhibitor that has been shown to an efficacy 20 fold higher than Imatinib and 
more readily crosses the blood brain barrier 100.  
Proteasome inhibitors act to disrupt the degradation of ubiquitinated proteins with small 
molecule inhibitors against one or more catalytic β-subunit 101. They induce cell cycle arrest and 
function to induce apoptosis by inhibition of NF-KB and by endoplasmic reticulum stress and 
subsequent generation of reactive oxygen species. Additionally, they stabilize pro-apoptotic 
proteins such as p53, Bax, Bik, and Bim while reducing levels of anti-apoptotic proteins such as 
Bcl-2 and have been shown to be more effective against leukemic cells than normal cells 102. 
Bortezomib is currently in Phase 1 and 2 clinical trials for CML and other hematologic 
malignancies.  
 Histone deacetylases (HDAC) remove the acetyl groups from the lysine residues leading 
to the formation of a condensed and transcriptionally silenced chromatin 103. Reversible 
modification of the terminal tails of core histones constitutes the major epigenetic mechanism for 
remodeling higher order chromatin structure and controlling gene expression. HDAC inhibitors 
(HDACI) block this action and can result in hyperacetylation of histones, therefore affecting 
gene expression 104;105. However, there are significant gaps regard specifically how HDI cause 
apoptosis of leukemic cells. HDAC inhibitors that are undergoing extensive clinical evaluation 
include the pan-HDAC inhibitors, such as vorinostat and panobinostat, and more selective 
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inhibitors, such as R306465, romidepsin and MS-275 and are starting to be analyzed for their 
use in ALL.  
 The aurora kinases are a family of serine/threonine kinases involved in cellular 
processes including progression through mitosis via regulation of spindle formation, 
chromosome segregation and cytokenesis 106. They are commonly over-expressed in leukemia 
and several aurora kinase inhibitors are currently in clinical trials such as VX680, MLN8054, 
AZD1152,R766, R763, PHA-739358. VX-680 (MK-0457) is a pan-aurora kinase inhibitor that 
has shown in vitro activity against wt and Bcr/ABl mutants including T3151 as well as against 
Imatinib and Dasatinib resistant clones. In a recent phase I/II study it was shown to be active in 
patients with the refractory T3151 phenotype.   
All of the agents discussed will only realize their full utility when the influence of the 
marrow microenvironment on the leukemic target is understood well enough to delineate its 
effect on critical regulatory proteins in the survival or proliferative pathways that are targeted by 
the unique classes of drugs and inhibitors. While some of these proteins are generated by 
unique chromosomal translocations, others are best described as anti-apoptotic, with additional 
factors associated with maintenance of a stem cell phenotype that is coincident with 
chemoresistance.  Examples of each are described in the following section in the context, 
predominantly, of Ph+ ALL. 
V. Bcr/Abl, Beta-catenin, HIF-2alpha, VE-cadherin, and Oct-4 in normal cells and leukemic 
cell biology  
 
In addition to the cytogenic changes seen in ALL (Bcr/Abl, TEL-AML, MLL etc.) 
alterations in protein expression as well as activity have been shown to influence both the tumor 
stem cell phenotype as well as survival during treatment. The proteins that will be discussed in 
this section are relevant to the aggressive nature of Ph+ Acute Lymphoblastic Leukemia or the 
stem cell phenotype and consist of Bcr/Abl, Beta-catenin, VE-cadherin, HIF-2 alpha and OCT-4.  
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 The Bcr/Abl fusion protein (also known as the Philadelphia Chromosome, Ph+) occurs 
due to a reciprocal translocation of the long arms (q) of chromosomes 9 and 22. This 
translocation results in a fusion protein that has 2 forms, 190 and 210, named so due to their 
molecular weight. The proteins have the same regions of Abl but differ in their regions of 
BCR107. The hallmark of this disease is that the Bcr/Abl translocation results in constitutive, high 
levels of Abl kinase activity (regardless of 190 or 210) resulting in abnormal and promiscuous 
signaling cascades 108-110. There is literature to suggest that the different fusion proteins (190 vs 
210) have both conserved (P-CrkL, Src family members, Ras, PI3K, Erk, CyclinD2 111-114)  and 
specific downstream targets (Rho, Rac and CDC42 115) but more studies are needed to confirm 
and elaborate on these findings. In addition to turning on a multitude of signaling cascades, 
studies have shown that Bcr/Abl can also turn off regulatory phosphatases such as Protein 
phosphatase-2A (PP2A)116. The PP2A activator FTY720 is currently in clinical trials and murine 
in vivo data suggests that it is effective against Imatinib and Dasatinib resistant Ph+ ALL and 
CML stem cells carrying the T1351 mutation without negative consequence to the normal 
CD34+ and CD34+/CD19+ bone marrow cells117-119. 
 The Bcr/Abl fusion gene and subsequent fusion protein is commonly seen in Chronic 
Myelogenous Leukemia (CML, 210) and in Acute Lymphoblastic Leukemia (mostly 190 but 
some 210) and in ALL is associated with poor prognosis, aggressive disease, and relapse. The 
frequency of the Bcr/Abl translocation is almost 100% in CML and lack of this fusion protein is 
actually a poor prognostic indicator for CML. In ALL the fusion protein occurs in approximately 
3-5% of pediatric and 25-50% of adult ALL cases.  Imatinib (Imatinib Mesylate, Gleevec) is an 
Abl kinase inhibitor used clinically to treat Ph+ ALL and CML. It acts by  binding to ATP pocket 
and inhibits the activity of the Abl kinase 120. Unfortunately, mutations in the Abl kinase pocket 
(M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) 121 result in resistance to this 
treatment and therefore combined therapies such as  Dasatinib and Nilotinib (Src/Abl inhibitor 
and more potent Abl inhibitor, respectively) along with proteasome inhibitors, HDAC inhibitors 
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and aurora kinase inhibitors, are currently in clinical trials in attempts to improve outcome and 
survival.  While elevated Abl kinase activity has been associated with diverse impacts on tumor 
cells including altered cytoskeletal dynamics and proliferation in addition to altered cell survival, 
other types of proteins impact on tumor phenotype through predominantly regulation of anti-
apoptotic pathways specifically, with one that is relevant to the work being currently described 
being beta-catenin.            
Beta-catenin is a protein that is classically known for being a transcription factor that 
influences, predominantly, the expression of survival proteins and can be regulated  via 
ubiquitination and proteasomal degradation122;123. It is from a family of proteins that contain 6 
armadillo repeat domains which are specialized for protein binding. Beta-catenin has been 
shown to bind to cadherins (VE-cadherin etc.) as well as be regulated by phosphorylation for 
stabilization (tyrosine) or targeted for degradation (serine/threonine) in the proteasome 124-130. 
When beta-catenin is phosphorylated at tyrosine 86 and 654 it can translocate to the nucleus to 
act as a transcription factor for proteins such as c-myc, cyclin D1, and survivin 131. It has been 
shown to not only be important in the survival of Ph+ leukemia, as well as other cancer, but has 
also been shown to physically interact with, and be stabilized by,  the Bcr/Abl fusion protein due 
to phosphorylation at Y86 and Y654 residues126.  A recent publication by the Li lab has shown 
that Beta-catenin is essential for the survival of leukemia stem cells and that it, not resistance to 
Bcr/Abl, was responsible for leukemic stem cell survival during treatment .  Additionally, Beta-
catenin has been shown in both normal cells, such as endothelial cells,  as well as cells that 
have undergone EMT (epithelial to mesenchymal transition) to be able to bind to the 
cytoplasmic tail of cadherins as well as other proteins. This binding results in stabilization of 
beta-catenin and allows it to act as a scaffold for other proteins to bind which initiate signaling 
cascades that promote both metatstasis and survival .  
132
123;129;133
VE-cadherin (Vascular Endothelial cadherin, aka CD144 and Cadherin 5) is one of the 
cadherins to which beta-catenin can bind and is a protein that our laboratory has shown to be 
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important in Ph+ ALL. VE-cadherin is calcium-dependent and interacts homotypically with itself 
through the N-terminal five extracellular cadherin repeats to form adherens junctions between 
endothelial cells, regulate vascular permeability and leukocyte extravasation 134;135. VE-cadherin 
also contains a transmembrane region and a highly conserved cytoplasmic tail to which proteins 
such as beta-catenin, plakoglobin, p120 can bind 134;135. These proteins are important to the 
regulation of VE-cadherin and their phosphorylation status can alter the stability of VE-cadherin 
on the surface of endothelial cells.  
The main mechanism of regulation for VE-cadherin, in endothelial cells in which it has 
been most thoroughly studied,  is clathrin coated endocytosis, via p120,  and recycling of VE-
cadherin back to the membrane surface 136. More recent potential mechanisms of VE-cadherin 
regulation suggest that in response to VEGF, a  Src dependent phosphorylation of the guanine 
exchange factor Vav2 occurs, leading to the activation of the GTPase Rac and subsequent 
phosphorylation of serine 665 of VE-cadherin 137;138. This phosphorylation results in the 
recruitment of -arrestin2, thereby promoting internalization of VE-cadherin. Additionally, studies 
have shown that the tyrosine phosphorylation status of VE-cadherin at y731, and potentially 
658, can be altered by a process that required Src and the proline-rich tyrosine kinase 2 (Pyk-
2), and that the phosphorlyation status could further be altered by the VE-cadherin specific 
receptor type protein tyrosine phosphatase VE-PTP  in normal endothelial cells 139-141.  
An elegant study from the Cheresh lab, using CHO cells lacking endogenous cadherins,  
showed that tyrosine phosphorylation of VE-cadherin at 731 or 658 was sufficient to prevent the 
binding of p120- and β-catenin, respectively, to the cytoplasmic tail of VE-cadherin142. 
Phosphorylation at either site led to the inhibition of cell barrier function and mutants of 731 or 
658 that were not able to be phosphorylated resulted in enhanced cell migration and an invasive 
phenotype142. Interestingly, VE-cadherin has been shown to be unexpectedly expressed in a 
variety of cancers such as melanoma, ewings sarcoma, breast cancer, prostate cancer and our 
laboratory has shown the expression, and functional significance, of VE-cadherin in Ph+ Acute 
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Lymphoblastic leukemia 41;143-145. Studies in both endothelial cells, as well as cancer cells, have 
been varied on the mechanisms by which VE-cadherin surface expression is regulated. Recent 
studies have focused on the potential for VE-cadherin regulation at the level of transcription 
potentially by the hypoxia sensitive transcription factor HIF-2 alpha (Hypoxia inducible factor 2 
alpha) 146 which, in our model of ALL was shown to be modulated by Abl kinase activity as well 
as bone marrow microenvironment signals.  
 HIF-2 is a transcription factor composed of a constitutively expressed  subunit (HIFβ, 
also known as aryl receptor nuclear translocator, ARNT) and an oxygen-regulated α subunit 
(HIFα) 147. Both subunits are basic-helix-loop-helix (bHLH) transcription factors and contain a 
Pax/Aryl hydrocarbon receptor/Sim (PAS) domain. HIFβ is not regulated by oxygen and 
interacts with several bHLH factors other than HIFα148;149 . Although there are 3 isoforms of the 
alpha subunit (1, 2/EPAS, and 3) only 1 and 2 are commonly studied.150  
The regulation of the HIF proteins occurs through both the C terminal oxygen dependent 
domain (ODD) and the N terminal transactivation domain. During high levels of oxygen, or 
normoxia,  an ODD specific proline residue (p531) within the LXXLAP cores are hydroxylated 
and this posttranslational modification is an absolute requirement for its degradation150;151.  
When  hydroxylation occurs this proline residue is recognized by the protein pVHL, the 
substrate recognition component of an E3 ubiquitin ligase complex that targets HIF for 
proteosomal degradation152-154. During hypoxia the alpha subunits are stabilized and HIF can 
translocate to the nucleus where they heterodimerize with ARNT and bind to the HRE (hypoxia 
responsive elements) within the HIF target genes 155;155.  Regulation of transcription via the N-
terminal transactivation domain (NTAD) occurs via hydroxylation of an asparagine residue 
within the NTAD that inhibits its interaction with the transcriptional co-activator p300. 
Interestingly, the enzymes that catalyze both of  these reactions are from the family of  2-
oxoglutarate-dependent dioxygenase (2-ODD) which require molecular oxygen as a co-
substrate for their catalytic reactions 156.  The interaction between HIF and p300/CBP is also 
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regulated in an oxygen-dependent manner by factor inhibiting HIF-1 (FIH-1).  FIH hydroxylates 
asparagine residues located within the HIF-a C-terminal transactivation domain (CTAD) and 
prevents p300/CBP binding 155. Thus, full activation of HIF transcriptional activity requires both 
HIFa stabilization and CTAD activation. 
 HIF-2 shares approximately 48% amino acid homology with HIF-1 but HIF-2 alpha, 
unlike HIF-1, is less ubiquitously expressed and is thought to be limited to cells in the CNS, 
lung, heart and endothelium149. Expression of HIF-2 alpha is found in hypoxic environments 
such as the bone marrow and within tumors and has been shown to have distinct targets 156 157, 
compared to HIF-1, such as OCT-4, VE-cadherin, c-myc, flk-1, tie2, VEGF, CXCR4, TWIST and 
has been shown  to regulate VE-cadherin in normoxia 146;158-162.  In more recent literature HIF-2 
alpha’s mechanism of regulation in normoxia has become of interest to many groups based on 
studies showing that it can be expressed during normoxia and has been found at high levels in 
many tumor models such as colorectal, lung, melanoma, bladder and neuroblastoma 67 163-166. 
Murine knockout models of HIF-2 alpha lead to midgestation lethality (E9-E13.5) and defective 
vascular remodeling during embryonic development. Additionally, HIF-2 alpha knockout mice 
died from irregularities in cardiac hypertrophy, hepatic steatosis, retinopathy, lung maturation, 
hypocellular bone marrow and mitochondrial dysfunctions 167;168 compared to neural tube 
defects, lack of cephalic vascularization and cardiovascular malformations in the HIF-1 mice 
suggesting further the distinct target genes of these proteins 169-171. Additionally, HIF-2 alpha has 
been shown to be critical for normal hematopoiesis and our interest in the potential stem-cell-
like characteristics of Ph+ cells compelled us to look at Oct-4, which is a transcriptional target of 
HIF-2 alpha shown to be crucial in the maintenance of pluripotentcy 158;172.  
 OCT-4 (Octamer-4) is a transcription factor of the POU class 5 Homeobox 1 family 
(POU5F1) that is critically involved in stem cell renewal and pluripotentcy 173;174. It was originally 
investigated in the context of embryonic stem cells where it was found to maintain them in an 
undifferentiated state and since then has become associated with tumors and is a regulator of 
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the tumor “stem cell” phenotype 173. In embryonic stem cells a delicate balance of Oct-4 is 
needed as, too much can lead to differentiation into primitive endoderm and mesoderm 175. In 
contrast, repression of Oct-4 results in failure to form the inner mass and induces loss of 
pluripotency and dedifferentiation to trophectoderm 176. OCT-4 has been shown to be a single 
factor that is capable of reprogramming differentiated cells back into a stem-cell state and is 
thought to be responsible for treatment resistance in some tumor stem cell models 177.  Many of 
these critical proteins described up to this point were uniquely found to be co-expressed in the 
Ph+ ALL cells that were utilized in our some of our studies, elaborated on below.  
 
VI. Unique phenotype of leukemia cells utilized in our model and rationale for our studies 
Seminal work from the Hendrix lab showed the unexpected expression VE-cadherin on 
aggressive melanoma cells and additional labs have shown the expression of VE-cadherin on 
other cancers such as breast and Ewing Sarcoma41;143-145. This prompted our lab to investigate 
VE-cadherin expression, as well as stem cell marker expression, in our ALL cells that were 
Bcr/Abl+, or Ph+, and Ph- cells. In the manuscripts listed below we show the expression of both 
VE-cadherin and PECAM-1 on the surface of BCR/ABL positive cells. Additionally, we show that 
these cells have a stem-like phenotype, expressing HIF-2 alpha as well as markers of 
pluripotentcy such as OCT-4, SSEA-1, TRA-1-80 etc in addition to normal B lineage markers 
such as CD19.  The publications also show that VE-cadherin expression can be regulated by 
BMSC, potentially through Abl kinase activity, HIF-2, and beta-catenin and that knockdown or 
inhibition of VE-cadherin can sensitize cells to treatment even in the presence of BMSC. The 
relevance of these proteins (Bcr/Abl, Beta-catenin, VE-cadherin, HIF-2 alpha and Oct-4) in 
normal and leukemic cells were previously discussed.  
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 Although leukemic stem cells (LSCs) demonstrate a symbiotic relationship with bone marrow 
microenvironmental niches, the mechanism by which the marrow microenvironment contributes to 
self-renewal and proliferation of LSCs remains elusive. In the present study, we identified a unique 
subpopulation of Ph+ ALL cells co-expressing markers of endothelial cells (including VE-cadherin, 
PECAM-1 and Flk-1) and committed B-lineage progenitors. Following long-term co-culture with bone 
marrow stromal cells, tumor cells formed hematopoietic colonies and cords, expressed early stem cell 
markers, and demonstrated endothelial sprouting. Gene expression profiles of LSCs were altered in 
the presence of stromal cell contact. Stromal cell contact promoted leukemic cell VE-cadherin 
expression, stabilized β-catenin and upregulated Bcr-abl fusion gene expression. Our study indicates 
that these specific tumor cells are uniquely positioned to respond to microenvironment-derived self-
renewing and proliferative cues. Ph+/VE-cadherin+ tumor subpopulation circumvents the requirement 
of exogenous Wnt signaling for self-renewal through stromal cell support of leukemic cell VE-cadherin 
expression and upregulated Bcr-abl tyrosine kinase activity. These data suggest that strategies 
targeting signals in the marrow microenvironment that amplify Bcr-abl/VE-cadherin/β-catenin axis 






 The bone marrow microenvironment plays an important role in maintaining the quiescence 
and plasticity of hematopoietic stem cells (HSCs). The stem cell properties are controlled by ligand-
receptor signaling and cell-cell adhesion molecules within microenvironmental niches. These 
anatomical sites predominantly consist of spindle-shaped, N-cadherin positive endosteal osteoblasts 
at the bone surface and VE-cadherin positive sinusoidal endothelium at the thin-walled blood vessels 
(sinusoids). 1,2 The molecular mechanisms underlying interactions between stem cells and their niche 
are better understood in the context of Drosophila germ stem cells and mouse bone marrow than in 
humans. In Drosophila ovary, the molecular hinge that anchors germ stem cells to cap cells (niche 
stromal cells) is E-cadherin and β-catenin.3 In the mouse model of HSC microenvironment,  N-
cadherin is expressed in both quiescent HSCs and osteoblasts, and an increase in the number of N-
cadherin+ osteoblasts is correlated with an increase in N-cadherin+ HSCs.1,4 
 While the impact of bone marrow niches on normal hematopoietic stem/progenitor cells has 
been extensively investigated, less is known about how the same microenvironment influences 
leukemic stem cells (LSCs). Although LSCs demonstrate a symbiotic relationship with the specialized 
bone marrow microenvironment,5 the role of bone marrow fibroblastic stromal cells in supporting self-
renewal of acute lymphoblastic leukemia (ALL) LSCs remains largely unclear. Recent studies 
indicated that the canonical Wnt/β-catenin signaling pathway plays a pivotal role in B-lineage 
hematopoietic stem/progenitor cell development.6 In addition to the destruction and transcription 
complexes involved in Wnt signaling pathway, β-catenin also exists in the cadherin-catenin-actin cell-
cell adhesion complex.7 VE-cadherin (vascular-endothelial cadherin) is one of the classic Ca2+-
dependent, homophilic adhesion molecules primarily expressed in endothelial cell adherens 
junctions. The intracellular domain of VE-cadherin physically interacts with p120 catenin, β-catenin, α-
catenin and the actin cytoskeleton. Tyrosine phosphorylation of the C-terminus of β-catenin at 
Tyr142, or the VE-cadherin intracellular domain at Tyr 658/731 by Src family kinases, alters the 
binding affinity of β-catenin to VE-cadherin.8,9  
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 Interplay between β-catenin and cadherin family proteins may modulate the stem cell 
properties of normal HSCs. Whether this interaction influences LSC maintenance and progression, 
and how this interaction contributes to sustained leukemic cell self-renewal warrant further 
investigation. We present data showing that a putative LSC subset of ALL utilizes Bcr-abl/VE-
cadherin/β-catenin axis to bypass the requirement of externally stimulated Wnt/β-catenin. While 
dependence on microenvironment cues for self-renewal is lost, the ability of leukemic cells to respond 
to stromal signals is maintained. Stromal cells regulate self-renewal and proliferation of this Ph+/VE-
cadherin+ LSC-like subpopulation by upregulation of VE-cadherin and Bcr-abl expression. 
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Materials and methods: 
Cells and reagents  
 Ph+ ALL cell line Sup-B15 (p185 Bcr-abl+) was obtained from ATCC. Nalm27 (p210 Bcr-
abl+). Nalm20 and Nalm29 ALL cell lines were kindly provided by the Fujisaki Cancer Center. Control 
cell lines JM1, RS4;11, REH, Jurkat, HL60, K562 were also from ATCC. Ph+ OP-1 was a gift from Dr. 
Dario Campana (St. Judes Children’s Research Hospital). Maintenance of human bone marrow-
derived stromal cell line PatX and murine stromal cell line S-10 (provided by Dr. Kenneth Dorshkind 
of the University of California) has been previously described in detail.10 To establish long-term co-
culture of stromal and leukemic cells, Sup-B15 and Nalm27 cells were seeded onto 70% confluent 
stromal cells, and maintained by subculture of a portion of Sup-B15 or Nalm27 cells onto new stromal 
cells weekly for more than 12 months. Bcr-abl kinase inhibitors imatinib mesylate (IM) and AG957 
were obtained from Novartis (Basel, Switizerland) and Sigma (St. Louis, MO), respectively. Src 
kinase inhibitor PP2 and proteosome inhibitor MG132 were purchased from Calbiochem (San Diego, 
CA). All recombinant cytokines and growth factors were purchased from R & D systems (Minneapolis, 
MN). 
Plasmid constructs, lentiviral and retroviral vectors  
 Human VE-cadherin (referred to as CDH5/wild type, wt), VE-cadherin lacking the C-terminal 
222-nt β-catenin binding domain (referred as ∆bcat) and VE-cadherin lacking the C-terminal 449-nt 
cytoplasmic domain (referred to as ∆cyto) coding DNA sequences (CDSs) were amplified with high-
fidelity DNA polymerase pfx (Invitrogen, Carlsbad, CA) from a HUVEC cDNA library and 
subsequently ligated into the pENTR-D/TOPO entry vector using the TOPO cloning strategy 
(Invitrogen). The two truncated derivates and the wt VE-cadherin pENTR entry plasmid constructs 
were recombined with the pLenti6.2-Dest/V5 lentiviral vector via LR recombination using the Gateway 
cloning technology (Invitrogen). The pLenti6.2-Dest/V5 empty vector control (referred to as vect) was 
generated via recombination of the destination lentiviral vector with a circularized empty pENTR-
D/TOPO plasmid to replace the attR1-CmR-ccdB-attR2 toxic protein from the pLenti6.2-Dest/V5 
vector.  
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  The murine stem cell retroviral (MSCV) vectors pMigR1-210 and pMigR1-185 carrying the 
Bcr-abl (p210 and p185) full-length fusion gene cDNAs were kindly provided by Dr. Pendergast of 
Duke University. Both plasmid constructs are bicistronic with an internal ribosomal entry site (IRES) 
upstream of the enhanced green fluorescent protein (eGFP) coding sequence. To generate the 
matched empty vector control pMSCV-IRES-eGFP (pMiG), the 7.2-kb EcoRI fragment coding for 
p210 Bcr-abl fusion protein was released and the vector re-ligated with T4 DNA ligase.  
 To construct the β-catenin/Tcf reporter gene system, the synthetic sense and antisense 
strands of the Tcf-binding sites 1 (TBS-1) and Tcf-binding sites 2 (TBS-2) were denatured at 94°C 
and annealed at room temperature.11,12 The ds-TBS-1/2 were 3’ adenine-tailed with Taq DNA 
polymerase at 72°C for 15 minutes followed by in vitro phosphorylation of the 5’-OH ends with T4 
polynucleotide kinase. The resultant double-stranded ds-TBS-1/2 were inserted into pGEM/Tesay 
vector (Promega, Madison, WI) via T/A cloning. The TBS-1/2 inserts flanked by Xho I and Hind III 
sites were excised from the T/A vector and the released TBS-1/2 oligonucleotides were ligated into 
the Xho I-Hind III site of the multiple cloning site in phRL-null Renilla luciferase vector (Promega). To 
construct the Tcf optimal promoter (TOP)/ minimal thymidine kinase (mTK) chermic promoter 
upstream of the Renilla luciferase coding sequence, a 531-bp Bgl II-Pvu II cohesive-blunt fragment of 
the thymidine kinase promoter region was deleted from the phRL-TK vector (Promega) and replaced 
with the Bgl II-Sma I cohesive-blunt fragment containing the TBS-1/2 fragments released from the 
phRL-TBS-1/2.  
 To construct the Bcr-abl promoter reporter, the pMigR1-210 was first digested with BamH I. 
The resulting BamH I 5’-overhangs were fill-in blunted with Klenow. A 640-bp EcoR I-BamH I 
fragment (pp210S) and an approximately 1.5-kb BamH I-EcoR I fragment (pp210L), spanning the 
putative Bcr-abl promoter region and part of the first exon,13 was further released from the linearized 
pMigR1-210 and inserted directionally (for pp210S) and in reverse direction (for pp210L) into the 
EcoR I-Sma I site of the phRL-null Renilla luciferase vector.  
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 All the synthetic oligonucleotides for long and accurate-PCR (LA-PCR) amplification of 
relevant gene CDSs, or for construction of TOP-mTK chimeric promoters, are indicated in Table 1 
(Data supplement). At the 5’-end of each forward primer, a CACC 5’-overhang was added to the 
primer to ensure directional ligation into pENTR-D/TOPO vector and to constitute the Kozak 
consensus sequence (CACCATGC/G) for efficient translational initiation. At the 3’-end of each 
reverse primer, the TGA/TAG stop codons were site-directedly mutated into AGA to allow 
downstream V5 epitope expression. For the Tcf binding sites 1 and 2, the Xho I and Hind III 
restriction sites are underlined, respectively.  
Production of lentiviral and retroviral stocks  
 To generate replication-incompetent lentiviral particles carrying the CDH5-wt, ∆bcat, ∆cyto 
and vect, the pLenti6.2-Dest/V5 vectors containing the gene CDSs described were co-transfected 
with pLP1 (gag/pol), pLP2 (rev) and pLP3 (VSV-G, Vesicular Stomatitis Virus-G pseudotype) 
plasmids (Invitrogen) into 293FT packaging cells (Invitrogen). To generate the replication-
incompetent murine stem cell retroviruses expressing the p210/p185 Bcr-abl fusion protein, the 
pMigR1-210, pMigR1-185 or pMiG empty vector constructs were transfected into the RetroPack PT67 
packing cells (BD-Clontech), in which the gag/pol, rev and the pseudotyped VSV-G envelope coding 
sequences have been stably integrated into the PT67 genome. For detailed protocols of collection, 
titration and cell infection, see data supplement.  
Dual-luciferase Reporter (DLR) assay  
 To evaluate transactivation of the β-catenin/Tcf signaling and Bcr-abl transcription activity 
initiated by long-term stromal cell co-culture or enforced expression of VE-cadherin in Sup-B15 cells, 
cells were transiently co-transfected in triplicate with pGL4.13-CMV/Luc2 (Promega) firefly luciferase 
expression vector (as an internal transfection efficiency control) and the Renilla luciferase TOP1/2-
mTK or Bcr-abl pp210S/pp210L promoter reporter constructs. For collection, cell lysis and 




Knockdown of VE-cadherin expression by RNAi  
 SmartPool short interfering RNAs (siRNAs) corresponding to coding sequences of VE-
cadherin was obtained from Dharmacon (Lafayette, CO). Transient siRNA transfection of Sup-B15 
cells was completed as previously described with use of scrambled siRNA sequence controls.10 
Endothelial differentiation 
 Evaluation of endothelial cell differentiation (i.e. sprouting) of Sup-B15 and Nalm27 cells was 
completed as recommended by the manufacturer (Stemcell technologies, Toronto, Canada). Briefly, 
LTCC Ds-Red labeled Sup-B15 or eGFP labeled Nalm27 were collected and incubated in the 
EndoCult liquid medium supplemented with EndoCult supplements on coverslips. 48 hours following 
induction of differentiation, cells were fixed in formaldehyde and analyzed by confocal microscopy. 
Microarray analysis  
 Wnt, Notch, HSC and CSM (cell surface marker) pathway-focused microarray analyses of 
mRNA transcripts in Sup-B15 LTMC/LTCC were performed according to the manufacturer’s 
instructions (SuperArray, Frederick, MD). For a brief protocol, see data supplement.  
In vitro poly-ubiquitination of β-catenin 
 In vitro poly-ubiquitination was performed as described previously.14 Briefly, β-catenin was 
immunoprecipitated either from 293FT expressing eGFP-210 or eGFP alone, or from Ph+ Sup-B15 or 
Ph- REH leukemic cells. The ubiquitin-protein conjugation reaction was performed at 37°C waterbath 
for 3.5 hours in a volume of 20 μL containing 50 mM HEPES, pH 7.5, 2mM DTT, 5mM MgCl2, 5mM 
ATP, Fraction A (including human E1 and E2 enzymes), Fraction B (containing human E3 enzyme), 
10 g of recombinant ubiquitin (BostonBiochem, Boston, MA) and immunoprecipitated β-catenin in 
the presence of 2M ubiquitin C-terminal hydrolase (UCH) inhibitor ubiquitin aldehyde (Ub-ald).  The 





Confocal microscopy, immunoprecipitation, immunoblotting and flow cytometry 
All the antigen-antibody based evaluations were completed as described previously. 10,15  Antibodies 
are described in detail in data supplement. 
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Results: 
Identification and characterization of a leukemic stem-cell like population that expresses both 
endothelial and hematopoietic progenitor cell surface markers. 
 Both p185 (Sup-B15) and p210 (Nalm27) Bcr-abl positive ALL cells exhibit either as floating 
aggregates or adherent patches, distinct from Ph- leukemic cells during in vitro culture. Screening a 
panel of adhesion molecules including VCAM-1, PECAM-1, ICAM-1 and the cadherin family of 
proteins (data not shown) in Ph+ ALL cells revealed that Bcr-abl positive cells uniquely express VE-
cadherin. Leukemic cell VE-cadherin was calcium-sensitive and predominantly localized on the cell 
surface (Fig 1A). Pretreatment of cells with the calcium chelator EGTA diminished the VE-cadherin 
fluorescent signal on leukemic cells, whereas addition of Ca2+ enhanced the calcium-mediated 
fluorescent signals (Fig 1A). Expression of VE-cadherin is absent on Ph-negative ALL cells, while all 
the Ph+ ALL cell lines tested, including  K562 Ph+ CML (blast crisis), express VE-cadherin (Fig 1B). 
RT-PCR confirmed VE-cadherin expression in Ph+ leukemic cells, but not in Ph- leukemic cells, at 
the mRNA level (data not shown). Immunophenotypic characterization of the Ph+/VE-cadherin+ 
subset of ALL cells indicated that hematopoietic stem/progenitor cell surface markers CD34, CD38 
and c-kit, mature B-cell lymphoid markers CD19, CD45, and the endothelial antigens Flk-1, PECAM-1 
and VE-cadherin are co-expressed on Sup-B15 cell surface (Fig 1C). Approximately 12% of Sup-B15 
cells also expressed the early endothelial marker CD133 (Fig 1C). Thus, Ph+/VE-cadherin+ identifies 
a unique subpopulation of ALL cells distinctive from Ph-negative ALL cell population. 
Ph+/VE-cadherin+ leukemic cells form hematopoietic colonies/cords on bone marrow niche 
stromal cells and differentiate into endothelial cells in vitro.  
 Long-term co-culture (LTCC) of Sup-B15 or Nalm27 leukemic cells on either S10 or PatX 
stromal cells supported the formation of hematopoietic colonies (“hemospheres”, Fig 2A), resembling 
neurospheres generated by neural stem cells or mamospheres formed by breast cancer stem 
cells.16,17 Hemospheres formed on stromal cells morphologically resembled both type I (compact 
colony, Fig 2A upper right) and type II (colony with a dense center surrounded by migrating cells, Fig 
2A lower right) but not type III (diffuse colonies of mobile differentiating cells) as characterized 
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previously.18,19 However, unlike cancer stem cell colonies derived from solid tumors, formation of 
hemospheres from Ph+/VE-cadherin+ leukemic cells are stromal-cell dependent, with hemospheres 
only initiated in physical association with a monolayer of VCAM-1-positive stromal cells. Of all the ALL 
cell lines tested, only the Ph+ subset was capable of hemosphere formation, whereas Ph- ALL cell 
lines did not form hemospheres during LTCC for up to 6 months (data not shown). Moreover, 
hemospheres are resistant to EDTA-free trypsin digestion during regular subculture, while leukemic 
cell aggregates in long-term medium culture (LTMC) can be disrupted by mechanic vibration.  
 Formation of flame-like, finger-shaped hematopoietic cords from Ph+/VE-cadherin+ LTCC on 
both human and murine stromal cells follows formation and growth of hemospheres (Fig 2B, 
supplementary video clips 1-6). Hematopoietic cords were characterized by a bamboo shoot-like 
structure comprised of distinct cellular constituents localized to the peripheral or central regions (Fig 
2B).  In a typical hematopoietic cord, the inner column is comprised of CD133+VE-cadherin+ cells 
with the periphery of the cord constituted by more differentiated CD133-VE-cadherin+ leukemic cells 
(Fig 2B, supplementary video clip 3&4). To further examine the stem-cell potential of the leukemic 
cells that comprised the hemospheres and hematopoietic cords, we stained the hemosphere and 
hematopoietic cord cells with early stem cell (ESC) markers (Fig 2C & 2D). Confocal microscopy 
revealed distinct expression and distribution patterns of ESC markers. Oct-4 was uniquely expressed 
in the peripheral region of the hemospheres (Fig 2D), while SSEA-1, SSEA-3, SSEA-4, Tra-1-61 and 
Tra-1-80 positive cells were limited to the central region (Fig 2C). Migratory leukemic cells 
surrounding the hemospheres were negative for ESC marker staining (Fig 2C & 2D).  
 When LTCC Ph+/VE-cadherin+ cells were incubated in EndoCult, we observed endothelial 
sprouting of Ph+VE-cadherin+ Sup-B15 or Nalm 27 cells (Fig 2E). Many Ph+VE-cadherin+ LTCC 
cells differentiated from round, floating cells to spindle-shaped, adherent cells within 2 days (Fig 2E). 
Thus, deprivation of stromal cell support in the presence of endothelial-trophic growth factors leads to 
a rapid endothelial switch of Ph+/VE-cadherin+ cells following long-term stromal cell contact.  
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LTCC with bone marrow stromal cells promotes self-renewal activity of Ph+/VE-cadherin+ 
leukemic cells independent of the Wnt/β-catenin signaling pathway. 
 To investigate the signaling pathway(s) potentially involved in the stem-cell like phenotypes of 
Ph+/VE-cadherin+ ALL cells following LTCC with stromal cells, pathway-focused microarrays were 
completed to compare the gene expression profiles in LTMC and LTCC Sup-B15. Sup-B15 genes 
involved in the Wnt/β-catenin signaling pathway respond to S10 or PatX stromal cell signals 
differentially (Fig 3 & Table 2, data supplement). Tcf/β-catenin target genes, including Cyclin D1 
(CCND1), Cyclin D3 (CCND3) and c-Myc (MYC), were increased by 2-2.5 fold, 2-2.5 fold and 3-3.5 
fold following LTCC, respectively. The β-catenin transcriptional co-activator Bcl-9 (BCL9) was 
upregulated 1.5-2 fold while its transcriptional co-repressor Tcf (TCF7) and the Wnt inhibitory factor 1 
(WIF1) were down-regulated 2 and 1.5 fold, respectively. However, expression of the intracellular 
signaling mediator β-catenin (CTNNB1) and β-catenin binding protein 1 (CTNNB1P1) remained 
unchanged. Further, the leukemic cell autocrine Wnts, including Wnt1, Wnt2 and Wnt3A, were down-
regulated by 2-2.3 fold in LTCC Sup-B15 as compared to those of LTMC Sup-B15, which were 
coincident with down-regulation of the Wnt co-receptor Frizzled (FZD3, 1.5-fold) and the secretory 
Wnt precursor-processing protein (PORCN, 2-fold). Thus, Wnt signaling cascades downstream of 
ligand/receptor occupancy were aberrantly intercepted and reinforced while the extracellular 
component of the signaling pathway was attenuated or disabled in Ph+/VE-cadherin+ ALL cells 
during LTCC. 
Stromal cells up-regulate VE-cadherin expression and stabilize β-catenin in Ph+/VE-cadherin+ 
cells.  
 The convergence of β-catenin in cadherin-catenin mediated cell-cell adhesion and 
morphogenesis, and as an intracellular mediator of the canonical Wnt signaling pathway, prompted 
us to hypothesize that VE-cadherin expression may contribute to self-renewal and proliferation of 
Ph+/VE-cadherin+ cells. Following LTCC of Sup-B15 with both murine and human marrow stromal 
cells, VE-cadherin expression was upregulated, coincident with elevated Src expression and β-
catenin accumulation (Fig 4A). Screening a panel of stromal cell soluble growth factors and cytokines 
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showed that TGF-β1, bFGF and VEGF stimulated VE-cadherin expression on Sup-B15 cells by 2.0, 
1.5 and 1.8 fold, respectively (Fig 4B). To determine whether upregulated VE-cadherin contributes to 
stabilizing β-catenin in Ph+/VE-cadherin+ ALL cells, reciprocal co-immunoprecipitaton revealed that 
the amount of β-catenin complexed with VE-cadherin in tumor cells derived from either S10 or PatX 
LTCC were 2-3.5 fold higher than those from LTMC alone (Fig 4C).  Because microarray data 
indicated that β-catenin expression is not influenced by stromal cell contact (Fig 3), we hypothesized 
that upregulated VE-cadherin plays a major role in sequestering and stabilizing β-catenin in Ph+/VE-
cadherin+ cells. T 
 To investigate this possibility, lentiviral transduction of Sup-B15 and 293FT cells with vectors 
carrying the wild type and two mutant forms of VE-cadherin, ∆bcat and ∆cyto, were established (Fig 
4D). Expression of the wt VE-cadherin, but not VE-cadherin lacking either the cytoplasmic or β-
catenin binding domains, led to approximately 4 fold more β-catenin accumulation in both 293FT 
(Figure 4D, upper) and Sup-B15 (Fig 4D, lower) cells. Thus, stabilization of β-catenin in the presence 
of VE-cadherin may be a common molecular event in non-endothelial cells. To further investigate the 
relationship between VE-cadherin and β-catenin in Ph+/VE-cadherin+ leukemic cells, VE-cadherin 
siRNA or scrambled control dsRNA was transiently transfected into Sup-B15 cells. Knockdown of VE-
cadherin expression in Sup-B15 cells resulted in diminished β-catenin in a time- (Fig 4E, upper) and 
concentration-dependent manner (Fig 4E, lower). Therefore, bone marrow niche stromal cells may 
modulate Ph+/VE-cadherin+ leukemic cell self-renewal activity, at least in part, by influencing VE-
cadherin expression and subsequent β-catenin stabilization.  
β-catenin is constitutively activated in leukemic stem-like cells that over-express VE-cadherin 
during LTCC. 
 To examine the β-catenin/Tcf transcriptional activity, Sup-B15 LTMC or LTCC cells were 
transiently co-transfected with phRL-TOP1 or phRL-TOP2 (Renilla luciferase) with an internal control 
plasmid, pGL4.13-CMV-Luc2 (firefly luciferase). Stromal cell contact resulted in a 5 to 13 fold 
increase in relative luciferase activity in LTCC (Fig 5A). Moreover, enforced expression of the wt, but 
not ∆bcat and ∆cyto VE-cadherin, significantly promoted β-catenin/Tcf transcriptional activity in Sup-
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B15 cells (Fig 5B). In contrast, depletion of VE-cadherin expression by siRNA resulted in an 
unexpected, transient elevation of β-catenin activity during the first 8 hours after transfection, followed 
by a persistent declining in relative luciferase activities in a time- (Fig 5C, upper) and siRNA 
concentration-dependent manner (Fig 5C, lower). One interpretation of this interesting phenomenon 
is that the initial reduction of the docking protein VE-cadherin releases -catenin capable of driving 
luciferase reporter expression due to the release of excessive, free -catenin that cannot be efficiently 
targeted for proteosome mediated degradation. However, long-term reduction of VE-cadherin may 
diminish its capability to protect -catenin from targeted ubiquitination and degradation that is typically 
achieved through physical interaction. Stromal cell signals also altered the intracellular distribution of 
β-catenin in Ph+/VE-cadherin+ cells. Translocation of β-catenin from the cytoplasm to the nucleus in 
Sup-B15 cells was sporadically observed in actively dividing cells in LTMC (Fig 5D), however, long-
term co-culture of Sup-B15 cells consistently promoted nuclear translocation of β-catenin in most of 
the leukemic cells on hematopoietic cords (Fig 5D).  
Bcr-abl fusion protein is essential for maintaining the VE-cadherin/β-catenin axis in the 
leukemic stem-like cells.  
 In 293FT cells transduced with various forms of VE-cadherin expressing lentiviral vectors, 
forced wild type VE-cadherin stabilized β-catenin as compared to vector control, ∆bcat or ∆cyto VE-
cadherin (Fig 4D, upper). However, the β-catenin/Tcf transcriptional activity did not dramatically 
change following transduction of vect, ∆bcat, ∆cyto or even wt VE-cadherin in 293FT cells (data not 
shown). Therefore, VE-cadherin expression alone is likely necessary, but not sufficient, to maintain 
enhanced β-catenin activity in VE-cadherin+ leukemic cells. We hypothesized that Bcr-abl fusion 
protein, with constitutive tyrosine kinase activity, may synergize with VE-cadherin expression to 
contribute to the unique phenomenon of leukemic cell self-renewal and proliferation. To test this, we 
examined alteration of Bcr-abl protein expression in LTMC and LTCC leukemic cells and observed 
that stromal cell contact upregulated both Abl and Bcr-abl protein expression by 1.5-2 fold (Fig 6A, 
upper). To confirm the observation at the transcriptional level, the Bcr-abl fusion gene promoter 
region was cloned into the phRL-null luciferase reporter vector. The relative luciferase activity was 
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upregulated 2- to 4-fold in Sup-B15 LTCC with S10 or PatX as assayed by the pp210S, but not the 
pp210L reporter (Fig 6A, lower).  To further investigate the role of the Bcr-abl fusion protein, Sup-B15 
cells were infected with retroviruses carrying either the p185 or p210 Bcr-abl full-length cDNA. 
Retroviral transduction of both p185 and p210 Bcr-abl resulted in forced expression of p185 or p210 
protein in Sup-B15 cells (Fig 6B, upper). In Sup-B15 cells over-expressing the p185-eGFP or p210-
eGFP proteins, upregulation of VE-cadherin was also detected as above the parental baseline (Fig 
6B, lower). Consistent with upregulated VE-cadherin expression, β-catenin/Tcf activity was also 
increased 7- to 14 fold in p185-eGFP and p210-eGFP expressing cells, as compared to eGFP 
expression alone (Fig 6C). In contrast, inhibition of Bcr-abl activity with the tyrosine kinase inhibitors 
imatinib mesylate (IM) or AG957 down-regulated VE-cadherin expression in a concentration-
dependent fashion in Sup-B15 cells, coincident with β-catenin cleavage (Fig 6D). In contrast, 
treatment of Ph+/VE-cadherin+ leukemic cells with the proteosome inhibitor MG132 diminished 
imatinib-induced cleavage of β-catenin in both Sup-B15 and Nalm27 cells (Fig 6E). 
Tyrosine phosphorylation of β-catenin mediated by Bcr-abl kinase diminishes its 
ubiquitination-proteosome dependent degradation.  
 To dissect the signaling pathway by which constitutive Bcr-abl kinase activity maintains higher 
VE-cadherin/β-catenin in Ph+/VE-cadherin+ ALL cells, Ph-/VE-cadherin- 293FT cells were co-
transduced with lentiviruses encoding VE-cadherin and retroviruses encoding p210 Bcr-abl fusion 
protein. VE-cadherin/p210 dual transduction resulted in the most pronounced stabilization of β-
catenin in 293FT cells as compared to VE-cadherin transduction alone (Fig 7A). Immuoprecipitation 
of β-catenin from the same samples indicated that β-catenin and Src co-existed in the same 
immunocomplexes and β-catenin was tyrosine-phosphorylated following transduction with p210 Bcr-
abl kinase (Fig 7B). This was consistent with the most pronounced β-catenin transcriptional activity 
being detected in p210 and VE-cadherin co-transduced cells (Fig 7C). Inhibition of Src activity with 
PP2, or Bcr-abl with imatinib, was correlated with modest reduction of β-catenin recognized by a 
monoclonal antibody specific for its active form. The combinatory inhibition of Src and Bcr-abl kinase 
activity was associated with a further reduction in -catenin (Fig 7D). VE-cadherin was 
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immunoprecipitated from the same panel. While expression of Bcr-abl protein resulted in a number of 
tyrosine phosphorylated proteins, VE-cadherin appeared not to be affected by this constitutively 
active kinase (Fig 7E). To investigate whether tyrosine phosphorylated β-catenin is more stable or 
resistant to the ubiquitin-proteosome mediated protein degradation pathway, β-catenin that was 
immunoprecipitated from Ph+/- leukemia or 293FT expressing eGFP-p210/eGFP was subjected to an 
in vitro ubiquitination and degradation assay. In the presence of endogenous (Ph+) or exogenously 
expressed Bcr-abl (eGFP-Bcr-abl), β-catenin had less mono-, poly-ubiquitination and degraded 
fractions. This effect was demonstrated by comparison of Ph+ Sup-B15 or 293FT/eGFP-p210 to Ph- 
REH or 293FT/eGFP cells (Figure 7F). 
 Thus, consistent with the recent reports that Bcr-abl fusion protein promotes Src activation 
and that Bcr-abl mediates tyrosine phosphorylation and subsequent stabilization of β-catenin in Ph+ 
ALL cells, 20,21 our data indicated that upregulated Bcr-abl fusion protein contributes to constitutively 
active β-catenin activity by promoting VE-cadherin expression (physical stabilization) and 
subsequently converting VE-cadherin-stabilized β-catenin to the active form through Src-mediated 
tyrosine phosphorylation (functional stabilization). These data also suggest that tyrosine 
phosphorylation and serine/threonine phosphorylation may differentially influence the fate of β-catenin 




 As compared to the LSC model of AML, the origin of ALL LSCs is less well characterized. 
Recent studies indicated that primitive HSCs were the target for ALL LSC transformation.22-24 In 
contrast, Castor and colleagues demonstrated that different genetic alterations may target different 
stages of hematopoiesis in ALL.25 The p210 Bcr-abl targeted primitive HSCs, whereas p185 and TEL-
AML1 can transform CD34+CD19+ B-cell progenitors,25 raising the question whether LSCs for Ph+ 
ALL may also derive from committed B-cell progenitors.  
 Our data support the hypothesis that LSCs of B-cell Ph+ ALL can originate from committed 
progenitor cells. In the current study, we identified a CD34+CD38+CD19+ Ph+-ALL subpopulation 
with leukemic stem-cell like properties (Fig 1 & Fig 2). Formation of hematopoietic colonies 
(hemospheres) and cords, induction of endothelial sprouting and reactivation of early stem cell genes 
in this CD34+CD38+CD19+ subset during LTCC are consistent with a leukemic stem cell phenotype 
(Fig 2).  Expression of a panel of endothelial cell surface markers, including VE-cadherin, does not 
necessarily imply hemangioblast origin. Rather it may represent one of the biological consequences 
of Bcr-abl expression in this unique setting (Fig 6). In agreement with this possibility, a recent report  
showed that Bcr-abl fusion transcripts can be detected in endothelial cells derived from transplanted 
bone marrow cells from a CML patient.26 This in vivo observation, together with our in vitro induction 
of endothelial differentiation of Ph+/VE-cadherin+ ALL cells (Fig 2), supports the conclusion that Bcr-
abl alone may promote VE-cadherin expression (Fig 6) and contribute to vascular endothelium 
potential.26 Intriguingly, normal myeloid progenitors can also differentiate into endothelial cells,27 
further supporting the notion that determination of endothelial fate is not restricted to the 
hemangioblast or HSC stage, but rather reflects the close developmental relationship between the 
hematopoietic and vascular systems.  
 VE-cadherin expression in non-endothelial cells has been identified and characterized in two 
additional cell types to date. Increased VE-cadherin expression on cytotrophoblast stem cells was 
required for normal placentation and successful endovascular invasion.28 In addition, VE-cadherin 
was expressed in highly aggressive melanoma, and contributed to vascular mimicry.29 Notable are 
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the observations that gestational trophoblastic neoplasia and aggressive melanoma are highly 
metastatic with frequent central nervous system involvement.30,31 It is also widely recognized that, as 
compared to acute non-lymphoblastic leukemia, non-Hodgkin’s lymphoma or Hodgkin’s lymphoma, 
ALL is clinically manifested with a much higher frequency of CNS involvement. Because non-
endothelial cells with VE-cadherin expression identified so far share a common clinical feature, CNS 
involvement, it is tempting to speculate that VE-cadherin expression plays an important role in 
mediating invasion of Ph+/VE-cadherin+ ALL cells into the CNS.  
 Identification of the importance of the Bcr-abl/VE-cadherin/β-catenin axis, and lack of reliance 
upon Wnt initiated signals, indicates that this subset of tumor cells can circumvent the requirement of 
exogenous Wnts for sustained self-renewal activity (Fig 4 & Fig 5). This self-renewal autonomy is 
sustained by stabilized β-catenin in the presence of VE-cadherin expression (Fig 4) coincident with 
high Bcr-Abl kinase activity. Thus, these Ph+/VE-cadherin+ cells can bypass the de novo signaling 
cascade initialized by Wnt ligands for self-renewal and proliferation. Therefore, our data characterize 
a novel model in which the molecular basis underlying the self-renewal autonomy of Ph+ ALL LSCs 
can be further investigated.   
 While Wnt/β-catenin mediated self-renewal is similar in many tumor models, the epigenetic 
and genetic alterations imposed on the tumor by the microenvironment are diverse. Self-renewal 
autonomy conferred by intrinsically active β-catenin reflects one of the differences between normal 
hematopoietic stem cells and leukemic stem cells, since normal stem cells exquisitely rely on self-
renewal signals from supportive niches,32 whereas cancer stem cells can somewhat escape this 
dependency. However, a lack of reliance by tumor cells on niche-derived signals does not indicate a 
loss of ability to respond to these important microenvironmental cues. In our model, bone marrow 
stromal cells modulate the β-catenin mediated self-renewal capacity by up-regulating VE-cadherin 
and Bcr-abl expression (Fig 4 & Fig 6). This observation is consistent with a recent report that 
upregulation of Bcr-abl transcripts, followed by nuclear translocation of β-catenin, plays an important 
role during LSC transformation to CML blast crisis.33 Co-expression of VE-cadherin and Bcr-abl are 
unique to the subset of putative LSCs utilized in this model, with our data suggesting that 
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microenvironmental factors remain influential in augmenting the self-renewal potential of specific 
LSCs. 
 In addition, recent studies indicated that conditional expression of constitutively active β-
catenin in knock-in mice led to the exhaustion of the long-term hematopoietic stem cell pool and loss 
of stem-cell repopulating activity.34,35 This raised the question whether constitutively active β-catenin 
also impairs the plasticity of leukemic stem cells.  Although β-catenin is constitutively active in LTCC 
Ph+VE-cadherin+ cells, in the presence of stromal cells, many early stem cell genes were reactivated 
in Ph+ ALL leukemic cells physically located in hemospheres (Fig 2). These early stem cell markers 
were previously shown to be expressed in primitive embryonic stem cells, and serve as indicators of 
quiescence and pluripotency of embryonic stem cells.36 The observation that tumor cells expressed 
early stem cell markers in a very specific anatomical configuration, with hemosphere structure 
initiation supported by physical attachment to bone marrow stromal cells, was striking. This 
observation suggests that stromal cell dependency distinguishes primitive leukemic stem cells from 
more differentiated progeny leukemic cells. Further, our data also suggest that leukemic cells in long-
term co-culture with stroma are highly heterogeneous, and in vitro LTCC may partially mimic the 
hierarchical differentiation of the hematopoietic stem/progenitor cells in the bone marrow 
microenvironment.  
 The concept of “re-programming” differentiated cells to a stem cell-like phenotype has been 
addressed by several groups, including a recent report that the combination of four transcriptional 
factors, Oct-3/4, Sox2, c-myc and klf4, can reprogram terminally differentiated mouse fibroblasts into 
pluripotent embryonic stem cells.37 Our data suggest that Ph+/VE-cadherin+ ALL cell gene 
expression profiles may be uniquely modified by stromal cells, and support the hypothesis that 
formation of hemospheres with distinct stem cell marker expression may reflect an attempt by bone 
marrow stromal cells to balance the proliferating pool with the primitive, quiescent pool of LSCs. 
Therefore, unlike their normal hematopoietic counterparts,34,35 the LSC subpopulation of Ph+VE-
cadherin+ ALL cells may not be exhausted even if constitutively active β-catenin is driving cell cycle 
entry, due to stromal cell conversion of a pool of LSCs to a quiescent state. Thus, self-renewal 
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autonomy and stromal cell dependence of Ph+VE-cadherin+ ALL cells may be integrated in a way 
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 Figure legends: 
Figure 1. Identification and characterization of a leukemic stem-cell like population that 
expresses both endothelial and hematopoietic progenitor cell surface markers. 
(A) Confocal laser scanning microphotographs (LSMs) of Ph+ ALL Sup-B15 cells stained with anti-
VE-cadherin in the presence of 10 mM EGTA and 5 mM CaCl2. Cell nuclei were counterstained with 
propidium iodide (PI). (B) Cell lysates prepared from Ph-negative acute leukemia cell lines JM1, 
RS4;11, REH, Jurkat, HL60 and Ph+ acute leukemia cell lines K562, Sup-B15, OP-1, Nalm20, 
Nalm27 and Nalm29 were Western blotted with anti-VE-cadherin. The same membranes were 
stripped and re-probed with anti-β-tubulin as a loading control. (C) Immunophenotyping of Ph+/VE-
cadherin+ Sup-B15 cells by flow cytometry. Cells were surface stained to evaluate hematopoietic 
stem/progenitor cell and classic endothelial markers. 
 
Figure 2. Ph+/VE-cadherin+ leukemic cells form hematopoietic colonies/cords on bone 
marrow niche stromal cells and differentiate into endothelial cells in vitro.  
(A) Phase contrast micrographs of Ph+ ALL Sup-B15 (upper panel) and Nalm27 (lower panel) cells 
cultured in medium alone (Long-Term Medium Culture, LTMC) or long-term co-cultured (LTCC) on 
murine stromal cell line S10 (top & bottom right). (B) Confocal LSM microphotographs of 
hematopoietic cords formed on stromal cells. Cells were surface stained with anti-CD34, CD19, VE-
cadherin, and CD133 respectively. Nucleic DNA dyes include Sytox (green), PI (red) and TO-PRO-3 
(blue). Z-stacks were 3-D reconstructed with LSM510 software (Zeiss, version 3.2).  The turning axis 
is the Y axis and turning angle for the displayed static pictures is 45. (C) Confocal micrographs of 
hematopoietic colonies (“hemospheres”) stained with a panel of early stem cell (ESC) markers. 
Stromal monolayer cells underneath hemospheres were counterstained with anti-VCAM-1. Cell nuclei 
were counterstained with DNA dyes PI (red fluorescence) or SYTOX Green (green fluorescence) to 
be compatible with the flurochrome tag of the secondary antibodies of anti-ESC antibody. Merged 
images of 3-channel colors are shown in the final column. (D) 3-dimensional reconstruction of z-
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stacks showing the distribution of transcriptional factor Oct-4 within a hematopoietic cord. Cell nuclei 
were counterstained with PI (red) and localization of Oct-4 was labeled with green fluorescence. The 
turning axis is the Y axis. The tip of the hematopoietic cord was pressed flat by the coverslip. (E) 
DsRed red fluorescent protein labeled Sup-B15 cells (top left) or eGFP labeled Nalm27 cells (bottom 
left) were cultured in standard medium, or in EndoCult endothelial-defined medium (top & bottom 
right). White arrows denote individual endothelial sprouting observed for individual Ph+/VE-cadherin+ 
ALL cells.  
 
Figure 3. LTCC with bone marrow stromal cells promotes self-renewal activity of Ph+/VE-
cadherin+ leukemic cells independent of the Wnt/β-catenin signaling pathway. 
Clustering analysis of gene expression profiles in Sup-B15 cells following LTCC with S10 or PatX 
stromal cells. The hierarchical clusters were created with GEASuite software based on the similarity 
of gene expression. The green color at the farthest left end of the color scale corresponds to the 
minimal value; the red color at the farthest right end of the color scale corresponds to the maximum 
value, Black corresponds to the average value of expression. BAS2C, HSPCB, ACTB and GAPDH 
served as housekeeping gene controls. Analysis of the representative Wnt pathway is shown.  
 
Figure 4. Stromal cells up-regulate VE-cadherin expression and stabilize β-catenin in Ph+/VE-
cadherin+ leukemic cells.  
(A) Western blot analysis of Sup-B15 cells in LTMC (Med) or in LTCC with either S10 (S10) or PatX 
(PatX) stromal cells. The same membrane was probed with anti-VE-cadherin, anti-β-catenin and anti-
Src, respectively. GAPDH was used as the lane loading control. (B) Western blot of cell lysates 
isolated from Sup-B15 cells exposed to recombinant human cytokines, chemokines, or growth factors 
compared to untreated control cells (Cont). (C) Reciprocal co-immunoprecipitation of Sup-B15 cell 
lysates from LTMC (Med) or LTCC (S10 and PatX) with anti-VE-cadherin or anti-β-catenin specific 
antibodies. Membranes were reciprocally probed with anti-β-catenin and anti-VE-cadherin, 
respectively. IgG heavy chains served as the loading control. “Input” denotes sample with antibody 
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alone, lacking cell lysate. (D) Western blot analysis of cell lysates from 293FT (top panel) or Sup-B15 
cells (bottom panel) transduced with lentiviruses carrying the wild type VE-cadherin (WT) or VE-
cadherin lacking either the cytoplasmic domain (∆cyto) or β-catenin binding domain (∆bcat) CDSs 
(Coding DNA Sequences).   “Vect” denotes the empty lentiviral vector encoding the blasticidin 
resistance protein without a CDS insert. (E) Western blot analysis of Sup-B15 cells transiently 
transfected with VE-cadherin siRNA or scrambled (Scr) control siRNA sequence. Time-course (top 
panel) and dose-response (bottom panel) of VE-cadherin siRNA transfected samples were probed 
with anti-VE-cadherin and β-catenin specific antibodies. 
 
Figure 5. β-catenin is constitutively activated in leukemic stem-like cells over-expressing VE-
cadherin during LTCC. 
(A) Dual-luciferase reporter assays (DLR) of Sup-B15 LTMC (Med) or LTCC cells (S10 or PatX) 
transiently co-transfected with phRL-TOP1 or phRL-TOP2 Renilla luciferase reporters with an internal 
control pGL4.13-CMV-Luc2 firefly luciferase reporter. Experimental Renilla luciferase activity was 
normalized to that of control firefly luciferase and is shown as relative luciferase units (RLU). Data 
were presented as mean +/- SD (n=3). (B)  DLR assays of cell lysates from Sup-B15 cells transduced 
with wild type or the two truncated forms of VE-cadherin. Data were presented as mean +/- SD (n=3). 
“*” denotes significant differences as compared to Vect controls (p<0.01) based on the Student’s t 
test. (C) Sup-B15 cells transfected with 100nM VE-cadherin siRNA for 8-72 hours (top panel) or at a 
concentration of 50-200nM for 24 hours (bottom panel). Data are shown as the mean +/- SD (n=3). 
(D) Confocal micrographs of LTMC or LTCC Sup-B15 cells stained with anti- active β-catenin 
antibody. Cell nuclei were counterstained with SYTOX Green. The photograph of LTMC was made 
from cytospin preparation and the photograph of LTCC Sup-B15 cells was taken from a portion of one 




Figure 6. Bcr-abl fusion protein is essential for maintaining the VE-cadherin/β-catenin axis in 
Ph+ ALL.  
(A) Upper panel: Western blot analysis of Bcr-abl expression by Sup-B15 in LTMC (Med) or LTCC 
(S10 or PatX). Lower panel: DLR assays of LTMC (Med) and LTCC (S10 and PatX) Sup-B15 cells 
transiently co-transfected with the Bcr-abl promoter reporters phRL-pp210L or phRL-pp210S with an 
internal control pGL4.13-CMV-Luc2 firefly luciferase reporter. Data were shown as mean +/- SD 
(n=3). “*” denotes statistically significant differences as compared to values from cells in media alone 
(p<0.01) based on Student t test. (B) Western blot analysis of Bcr-abl expression by Sup-B15 cells 
transduced with retroviruses containing p185-eGFP or p210-eGFP forms of Bcr-abl, or the empty 
vector control (MSCV-IRES-eGFP, MiG) alone (top western blot).  Dual-color flow cytometric analysis 
of VE-cadherin expression in Sup-B15 cells over-expressing the exogenous Bcr-abl fusion proteins or 
empty retroviral control vector (bottom flow cytometry). Baseline VE-cadherin was set to “zero” for 
comparison of the net increases following retroviral transduction. (C) DLR assay of Sup-B15 cells 
infected with p185-eGFP, p210-eGFP or MiG vector control retroviruses. Data are shown as mean +/- 
SD (n=3). “*” denotes significant differences as compared to MSCV empty vector controls (p<0.01) 
based on Student t test.  (D) Western blot analysis of cell lysates from Sup-B15 cells treated with the 
Bcr-abl kinase inhibitors Imatinib Mesylate or AG957 at various concentrations. (E) Western blot of 
Sup-B15 or Nalm27 leukemic cells treated with 20 M Imatinib Mesylate, 10 M proteosome inhibitor 
MG132, or a combination of both inhibitors for 16 hours.  
 
Figure 7. Tyrosine phosphorylation of β-catenin mediated by Bcr-abl kinase diminishes 
 β-catenin  ubiquitination-proteosome-dependent degradation.  
(A) Western blot analysis of cell lysates from 293FT cells co-transduced with lentiviral vector (Lenti-
Vect), lentiviruses carrying WT VE-cadherin (Lenti-VE-cad), retroviral vector (Retro-MiG) or 
retroviruses encoding p210-eGFP (Retro-MiG-p210). β-catenin was densitometrically normalized to 
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GAPDH with the control value set at 1.0 and all other values shown relative to the control. (B)  
Immunoprecipitation of β-catenin was done using the above cell lysates and Western blots were 
probed with anti-P-Tyr (Phospho-Tyr102), anti-β-catenin, anti-phospho-Src and anti-Src antibodies. 
IgG heavy chain served as the loading control. (C) DLR assays from the above 293FT cells 
transiently co-transfected with the phRL-TOP1 and phRL-TOP2 reporters and an internal pGL4.13-
CMV-Luc2 firefly luciferase reporter. Data are shown as mean +/- SD (n=3). “*” denotes significant 
differences as compared to vector controls (p<0.01) based on Student’s t test. (D) Western blot 
analysis of β-catenin stabilization from 293FT cells co-expressing VE-cadherin/eGFP-p210 or VE-
cadherin/eGFP treated with 10 M Src kinase inhibitor PP2, 10 M Bcr-abl inhibitor Imatinib Mesylate 
or both inhibitors for 16 hours. β-catenin was densitometrically normalized to VE-cadherin with the 
untreated control value of expressing MiG vector alone set to 1.0. All other ratios are normalized to 
this control value. (E) VE-cadherin was immunoprecipitated from 293FT cells co-expressing VE-
cadherin/eGFP-p210 or VE-cadherin/eGFP. The immunoprecipitates and cell lysates were loaded in 
parallel and probed with anti-phospho-Tyrosine (4G10) and VE-cadherin, c-Abl and eGFP antibodies. 
(F) β-catenin immunoprecipitated either from 293FT expressing eGFP-210 or eGFP alone, or from 
Ph+ Sup-B15 or Ph- REH leukemic cells was in vitro labeled with recombinant ubiquitin and subjected 
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Abstract: 
The mechanisms by which the bone marrow microenvironment regulates tumor cell survival are 
diverse. This study describes the novel observation that in addition to Philadelphia chromosome 
positive (Ph+) acute lymphoblastic leukemia (ALL) cell lines, primary patient cells also express Hypoxia 
Inducible Factor-2  (HIF-2) and Vascular Endothelial Cadherin (VE-cadherin), which are regulated by 
Abl kinase. Tumor expression of the classical endothelial protein, VE-cadherin, has been associated 
with aggressive phenotype and poor prognosis in other models, but has not been investigated in 
hematopoietic malignancies. Targeted knockdown of VE-cadherin rendered Ph+ ALL cells more 
susceptible to chemotherapy, even in the presence of bone marrow stromal cell (BMSC) derived 
survival cues. Pre-treatment of Ph+ ALL cells with ADH100191, a VE-cadherin antagonist, resulted in 
increased apoptosis during in vitro chemotherapy exposure. Consistent with a role for VE-cadherin in 
modulation of leukemia cell viability, lentiviral-mediated expression of VE-cadherin in Ph- ALL cells 
resulted in increased resistance to treatment-induced apoptosis. These observations suggest a novel 




 Acute lymphoblastic leukemia (ALL) patients are classified as “high risk” based on the presence 
of tumor cells harboring the 9;22 translocation (Philadelphia chromosome; Ph+). This translocation 
results in constitutively active Abl kinase, characteristic of cells resistant to standard chemotherapeutic 
regimens {1, 2, 3, 4, 5}. Although advances in treatment have increased the 5 year event free survival 
and cure rate, patients with Ph+ ALL continue to have a high incidence of bone marrow and central 
nervous system (CNS) relapse relative to Ph- ALL {6, 7}.  While first line treatment with Imatinib 
Mesylate (Gleevec, IM), in combination with conventional treatments, was initially thought to be 
successful in Ph+ ALL, it has been demonstrated that specific mutations in the Abl kinase catalytic 
domain render this drug ineffective {8, 9}.  In addition to mutations inherent to the tumor cell, the role of 
the microenvironment in modulating drug resistance has proven to be an important factor in the efficacy 
of treatment in many tumors, including primary and relapsed ALL {10}. Previous reports indicate the 
importance of the microenvironment in protection of tumor cell viability during disease initiation and 
progression, and during treatment {11, 12, 13, 14, 15, 16, 17, 18, 19}.  
 We recently identified a unique population of Ph+ ALL cells that express Vascular Endothelial 
Cadherin (VE-cadherin) on their surface and respond to bone marrow stromal cells (BMSC) through 
stimulation of several anti-apoptotic pathways {20}. VE-cadherin expression is often discussed in the 
context of vasculogenic mimicry, a process by which tumor cells gain characteristics normally restricted 
to endothelial cells, allowing tumors to better utilize microenvironment cues contributing to increased 
survival {21}. VE-cadherin expression has also been shown to be an indicator of poor prognosis in 
melanoma and Ewings sarcoma {21, 22}.  
  The Hypoxia Inducible Factor (HIF) family of proteins are transcriptional regulators of  pro-
angiogenic and survival proteins that have been shown to be important in tumor cell progression and 
aggressiveness {23}.  HIF-2 can be regulated by Erk and Akt-induced phosphorylation cascades that 
either directly phosphorylate HIF-2 or are involved in its trans-activation {24, 25, 26}.  Relevant to our 
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model, HIF-2 has been shown to regulate the transcription of VE-cadherin in other systems {27}. 
Because HIF-2 can be active under normoxic conditions it is distinct from the more extensively 
studied, and more rigorously hypoxia-driven, HIF-1. HIF-2 regulates transcriptional targets through 
binding to distinct promoters, as well as promoters overlapping with HIF-1, and the ability of HIF-2 to 
respond to signals outside hypoxia driven regulation positions it to have both constitutive and hypoxia-
induced functions in Ph+ ALL {28}. HIF-2 is up-regulated in some primary tumors including bladder, 
renal and high grade neuroblastomas and is associated with poor prognosis {23, 26, 29, 30, 31}.  
Therefore, the regulation of HIF-2 and VE-cadherin expression by bone marrow stromal cells (BMSC), 
and their role in hematopoietic tumor cell response to treatment, was investigated in the current study. 
 We demonstrate that, consistent with Ph+ ALL cell lines, primary Ph+ patient derived 
leukapheresis samples also express surface VE-cadherin.  Primary ALL (Ph+ and Ph-) bone marrow 
core sections were positive for VE-cadherin expression by IHC. Exposure of Ph+/VE-cadherin+ ALL to 
IM resulted in diminished HIF-2 and VE-cadherin.  Abl kinase activity, as well as expression of VE-
cadherin and -catenin, are maintained by BMSC contact during in vitro exposure to chemotherapy with 
lentiviral-mediated surface expression of VE-cadherin increasing chemoresistance. Disruption of VE-
cadherin by siRNA or the antagonist ADH100191 (ADH) led to increased sensitivity of Ph+ ALL cells to 
chemotherapy, even in the presence of an adherent microenvironment, BMSC. Collectively, these 
observations suggest that BMSC may provide cues that converge on hematopoietic tumor cell VE-
cadherin as one of the factors that modulate response to therapy.   
162
Materials and methods: 
Cells and reagents  
 Ph+ SUP-B15, and Ph- REH, leukemic cell lines were obtained from the ATCC (CRL-1929 and 
CRL-8286, Manassas, VA) and have been verified by both RT-PCR and fluorescent in situ hybridization 
(FISH) for analysis of Bcr/Abl, and other, translocations.  Primary de-identified Ph+ (IM resistant) and 
Ph- ALL leukophoresis and bone marrow core biopsies were evaluated by fluorescent in situ 
hybridization (FISH) for analysis of Bcr/Abl translocations.  Maintenance and derivation of human 
BMSC has been previously described {11}. To establish long-term co-culture (LTCC) of BMSC and 
leukemic cells, SUP-B15 cells were seeded onto 70% confluent BMSC, and SUP-B15 were sub-
cultured onto new BMSC weekly for more than 12 months. Long term media cultures (LTMC) include 
SUP-B15 cells cultured in media alone and were used in short term (24-120 hour) co-culture 
experiments with adherent BMSC. The Bcr/Abl kinase inhibitor Imatinib Mesylate (IM) (LGM 
pharmaceuticals, Boca Raton, FL) was reconstituted in DMSO and used at 10µM. Daunorubicin 
hydrochloride (DNR) (Sigma, St. Louis, MO) was diluted in Iscove’s DMEM (CellGRO/Mediatech, Inc. 
Herndon,VA) immediately prior to use at 0.01-0.1mg/ml. The peptide antagonist of VE-cadherin, 
ADH100191, (ADH, Adherex Technologies Inc., Durham, NC) was used at a concentration of 1mg/ml.  
Knockdown of VE-cadherin and HIF-2 expression by RNAi  
 SmartPool siRNA for VE-cadherin (CDH5) or HIF-2 (EPAS-1) was obtained from Dharmacon 
(Lafayette, CO) and Qiagen (Valencia, CA), respectively. Transient transfection of SUP-B15 cells, with 
sequence specific siRNA or scrambled control, was completed using oligofectamine (Invitrogen, 
Carlsbad, CA), 200nM siRNA and 1.5x106 cells per reaction as previously described {20}.  Cells were 
then treated with DNR, and collected at 72 hours for evaluation of viability. Confirmation of knockdown 
was completed by flow cytometric analysis (FACS).  
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Confocal microscopy, flow cytometry and cell viability 
 Anti-human antibodies specific for HIF-2 (flow cytometry), VE-cadherin (flow cytometry) and 
phosphorylated -catenin (confocal microscopy) were purchased from Novus (Littleton,CO clone 
ep190b), R&D systems (Minneapolis, MN clone 123433) and Cell Signaling (Beverly, MA), respectively. 
In addition, a polyclonal antibody to VE-cadherin utilized for confocal microscopy was purchased from 
AXXORA LLC (San Diego, CA).  Intracellular staining (for HIF-2 and phosphorylated -catenin) were 
completed by fixing the cells in 10% formaldehyde for 30 minutes, followed by a 30 minute ethanol 
permeabolization and a BSA block. For all staining, primary antibodies were used at 1µg per sample 
and all experiments included matched isotype controls. Following incubation in secondary antibody 
(Alexa fluor 488 or 555), cells were analyzed using a FACScalibur flow cytometer (BD, Franklin Lakes, 
NJ) with 10,000 events collected.  Remaining cells were observed by confocal microscopy. Confocal 
images were acquired on a Zeiss LSM510 confocal system attached to an AxioImager Z1 microscope 
using  40x and 63x/1.3 oil objective and the 405, 488, 543 and 633 nm lasers. DAPI was used as a 
nuclear stain. The images were acquired and processed using the Zeiss LSM510 software version 3.21 
(Carl Zeiss, Thornwood, NY) {20}. To assess viability, cells were enumerated via trypan blue exclusion, 
or stained with Annexin V FITC (R&D systems, Minneapolis, MN) and analyzed by flow cytometry 
(FACS). Flow cytometric data were analyzed using Win Midi software.  
Immunohistochemistry 
 Bone marrow core biopsy samples were formalin-fixed, lightly decalcified and paraffin-
embedded with samples representative of Ph+ and Ph- patients at either primary or relapse stage of 
disease as indicated. Five micron sections were hand stained using ducal breast carcinoma as control 
tissue. In brief, the histologic sections were deparaffinized and antigen retrieval was performed by 
heating in a tris based buffer for 30 minutes. The primary antibody (mouse monoclonal anti-human VE-
cadherin, clone BV6; Millipore Billerica, MA) was applied at a dilution of 1:10 for 24 hours; negative 
controls used a 1:10 diluted mouse IgG2 matched isotype (BD Biosciences, San Jose CA). The slides 
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were then incubated for 12 minutes with a conjugated secondary antibody and counterstained with 
hematoxylin. The slides were then analyzed using routine light microscopy and all images shown are 
400x.  
Reverse Transcriptase (RT-PCR) 
 Total RNA was isolated from leukemic cells using the Micro-to-Midi Total RNA Isolation kit 
(Invitrogen). Primers for HIF-2 (EPAS1, PPH02551B), VE-cadherin (CDH5, PPH00668E) and actin, 
as a housekeeping gene control, were purchased from Superarray (Fredrick, MD). PCR conditions 
were in the linear range of amplification. Images were cropped to show only data relevant to this paper. 
However, all comparison data were run on the same gel.   
Constitutive expression of VE-cadherin 
 Cloning of human VE-cadherin (CDH5) into pLenti6.2-DEST/V5 (Invitrogen), and generation of 
the pLenti6.2-DEST/V5 empty vector control and lentiviral particles has been described {20}. To 
generate lentiviral particles the pLenti6.2-Dest/V5 vectors were transfected into 293FT packaging cells 
and viral particles were collected, filtered, and concentrated as described by Burns et. al. {32}. Lentiviral 
stocks were titered with HT1080 (ATCC CCL-121) using the blasticidin-resistance colony assay.  To 
generate REH cell lines stably expressing empty vector (REHvect), or VE-cadherin (REHCDH5), cells were 
infected with lentiviral supernatants with an MOI of 1.  Clones stably expressing the genes of interest 
were selected by blasticidin (3µg/mL) and expression was confirmed by quantitative real time RT-PCR, 
flow cytometry and western blot. 
Western Blot analysis 
 Anti-GAPDH (1:10,000) and anti-VE-cadherin (1:200) antibodies were purchased from 
Research Diagnostics Inc., (Flanders, NJ). Anti--catenin (1:200) and anti-phosphorylated CrkL 
(1:1000) antibodies were purchased from Santa Cruz (Santa Cruz, CA) and Cell Signaling Technology, 
Inc. (Danvers, MA), respectively. Leukemic cells were lysed in complete cell lysis buffer, protein 
concentrations were determined and westerns were performed as described by Wang et al {20}. Signal 
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was visualized with enhanced chemiluminescence reagents (Amersham, Pharmacia Biotech, 
Piscataway, NJ).  Images were cropped to show only data relevant to this paper. However, all 
comparison data were run on the same gel.   
Statistics 
          Where appropriate, data were analyzed using the Students–t test or ANOVA with statistical 
significance of p≤.001 denoted by “#”, p≤.01 by “*”, and p≤ .05 by “+”.  Annexin experiments were not 
merged into one data set, but rather representative data from a single experiment are presented that 
are indicative of the consistent trend.  As such, no error bars are shown.  While absolute values 
between experiments may differ based on slightly different tumor cell viabilities at the start of the 
experiment, the magnitude and trend of the response is consistent.  
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Results 
VE-cadherin is expressed in primary, patient derived ALL cells.  
      Several studies have documented the unexpected presence of VE-cadherin in aggressive 
types of tumors {20, 22, 33, 34, 35}.  Wang et al. showed that VE-cadherin was present in a panel of 
Philadelphia chromosome positive (Ph+) cell lines that express a stem cell like phenotype {20}.  To 
further investigate our previous findings, primary patient derived Ph+ and Ph- ALL cells, obtained from 
leukapheresis, were assessed for the presence or absence of VE-cadherin and HIF-2, a known 
regulator of VE-cadherin. Transcripts for VE-cadherin and HIF-2 were detected in the Ph+ patient 
leukapheresis cells while patient cells lacking the Ph translocation had minimal levels of both VE-
cadherin and HIF-2 mRNA (Figure 1A). Consistent with the gene expression profiles, Figure 1B shows 
that VE-cadherin and HIF-2 proteins were expressed on the Ph+ patient cells (black line) but were 
negligible on the Ph- patient cells (gray line).  Additionally, 11/12 patient bone marrow core biopsies 
were positive for VE-cadherin, with four representative samples shown (Figure 1C and Table 1). 
Although IHC does not allow determination of the precise localization of VE-cadherin, the results are 
consistent with intracellular flow cytometry staining of Ph- and Ph+ ALL following paraformaldehyde 
fixation of cell lines in which expression of VE-cadherin was detected intracellularly (unpublished data) 
while only being consistently detected on the surface of Ph+ tumor lines and primary cells.  These data 
demonstrate that the expression patterns and localization of VE-cadherin and HIF-2 in Ph+ primary 
patient cells correlate with representative cell lines and suggest that SUP-B15 cells are a relevant 
model of Ph+ ALL.  
BMSC maintain expression of Ph+ ALL VE-cadherin during treatment. 
 It has been previously reported that VE-cadherin protein levels are decreased by treatment with 
Imatinib Mesylate (IM) without significantly altering cell viability in the absence of additional stress, such 
as chemotherapy {20, 36}. However, the mechanism that underlies this decrease, and the contribution 
of bone marrow stromal cells (BMSC) to blunting this decrease, are unknown. To determine if the 
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decrease in VE-cadherin occurs at the transcriptional level, and if BMSC can offset reduced 
expression, SUP-B15 cells were co-cultured with BMSC in the presence of IM, or DMSO control, for 24 
hours.  The relative abundance of VE-cadherin transcripts were decreased by treatment with IM, but 
co-culture with BMSC blunted the reduction (Figure 2A, left panel). In contrast, the HIF-2 transcript 
was not affected by IM exposure (Figure 2A, right panel).  
 The mechanisms by which HIF-2, an upstream regulator of VE-cadherin, is regulated in Ph+ 
ALL, potentially through Abl kinase activity, has not yet been elucidated. Data from our laboratory 
shows that the activity of Abl kinase can be increased, and maintained during cellular stress, by bone 
marrow stromal cells (BMSC) and can physically interact with VE-cadherin and -catenin {20}. 
Interestingly, Akt and Erk, both established regulators of HIF-2, can be regulated by both Abl kinase 
and the stromal cell niche {12, 37, 38, 39}.  Therefore, we investigated if HIF-2 and VE-cadherin were 
regulated by Abl kinase activity in Ph+ ALL cells. SUP-B15 cells were treated with Imatinib with HIF-2 
and VE-cadherin protein expression analyzed by FACS (Figure 2B). Inhibition of Abl kinase resulted in 
diminished levels of HIF-2 and VE-cadherin protein without significantly altering cell viability when no 
additional stress was applied to the cells, suggesting a link between Abl kinase activity and regulation 
of the levels of VE-cadherin and HIF-2.  The specific mechanism between Abl activity and HIF-2 
remain to be determined in studies that are beyond the scope of this manuscript and may have 
relevance in the setting of physiological levels of Abl kinase as well in tumors that do not harbor the 
Bcr/Abl translocation.  
 We subsequently evaluated the ability of BMSC contact to modulate Imatinib-induced down 
regulation of VE-cadherin at the protein level, and found that consistent with the observation at the 
mRNA level, Imatinib induced a modest down regulation in VE-cadherin protein that was partially offset 
by the presence of BMSC during treatment as demonstrated by flow cytometric analysis and confocal 
microscopy (Figure 2C; top and bottom panels respectively).  Due to the observations that Abl kinase 
activity can be increased by BMSC, and that VE-cadherin expression can be maintained by BMSC 
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during IM treatment, we investigated the ability of BMSC to maintain VE-cadherin, phosphorylated CrkL 
(as an indicator of Abl kinase activity) and -catenin (a pro-survival factor) during chemotherapy. Figure 
2D shows that during treatment with Daunorubicin (DNR) the levels of all 3 proteins are reduced in 
leukemia cells in the absence of BMSC cues. However, BMSC co-culture increases the levels of all 3 
proteins and maintains the increase in the presence of chemotherapy (Figure 2D).  These data suggest 
that HIF-2 and VE-cadherin protein expression is regulated by Abl kinase activity, with BMSC contact 
maintaining the expression of Abl kinase, VE-cadherin and -catenin during treatment.  
The bone marrow microenvironment regulates HIF-2 
      We have shown that leukemic cell Bcr/Abl kinase activity, as well as -catenin and VE-
cadherin, can be maintained by bone marrow stromal cells (BMSC), even in the presence of 
chemotherapy (Figure 2) and we have previously shown a physical interaction between Bcr/Abl, -
catenin, VE-cadherin {20}. The current study, and previous publication, demonstrates that in addition to 
a physical interaction, a signaling cascade may occur between Bcr/Abl and subsequent stabilization of 
HIF-2, VE-cadherin and -catenin (Figure 2D) {20, 40}. However, the modulation of HIF-2 by BMSC 
has not been investigated. Therefore, we determined the influence of BMSC on HIF-2 expression. 
LTMC and LTCC SUP-B15 cells were cultured in media alone or with BMSC. HIF-2 message and 
protein expression were analyzed by RT-PCR and FACS, respectively. Data presented in Figure 3A 
show that in both media alone and during co-culture with BMSC, the message levels of HIF-2 remain 
constant. However, HIF-2 protein is increased by co-culture with BMSC, regardless of whether ALL 
cells were originally from LTMC or LTCC conditions (Figure 3B). Consistent with this observation, VE-
cadherin levels increase with BMSC contact as well {Figure 2C, 20}.  Additionally, when the baseline 
HIF-2 expression in LTMC and LTCC cells was compared, by placing SUP-B15 cells from LTMC or 
LTCC in media for 24 (Figure 3C), or 120 hours (data not shown), the LTCC derived Ph+ ALL cells had 
higher levels of HIF-2. This was intriguing as the LTCC cells also have increased resistance to 
treatment compared to the LTMC cells, and have higher levels of VE-cadherin at baseline {20} (data 
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not shown).  To further substantiate the functional significance of BMSC increasing HIF-2 protein 
levels, Oct-4, a stem cell marker and direct transcriptional target of HIF-2, was evaluated and shown 
to increase in the presence of BMSC (Figure 3D).Taken together, these data suggest that BMSC 
increase HIF-2 protein, as well as targets of HIF-, Oct-4 and VE-cadherin,  in our model. 
Modulation of VE-cadherin reduces chemotherapy-induced apoptosis  
  To further investigate the roles of HIF-2 and VE-cadherin in regulation of apoptosis, SUP-B15 
cells were treated with siRNA specific to HIF-2, VE-cadherin, or scrambled control sequence. After 72 
hours, efficiency of knockdown was determined by FACS (Figure 4A). The labels above the histogram 
represent the specific siRNA utilized for that experiment compared to the scrambled (Scr) control while 
the labels on the X axis correspond to the staining detected for either HIF-2 or VE-cadherin in those 
cells.  HIF-2 has been shown to directly regulate the transcription of VE-cadherin and as expected, 
when HIF-2 was down-regulated, VE-cadherin decreased as well (Figure 4A top panel).  
 Surprisingly, when VE-cadherin was down-regulated, slightly less HIF-2 protein was detected 
(Figure 4A bottom panel). There are potentially intermediate regulators in this pathway, along with the 
possibility that HIF-2 is acting directly as a transcription factor for VE-cadherin gene expression, as 
documented in studies from other laboratories {27}.  Following down-regulation of HIF-2 or VE-
cadherin, SUP-B15 cells were treated with Imatinib Mesylate (IM), Daunorubicin (DNR) or a 
combination of IM/DNR and viability was evaluated. Cells in which either VE-cadherin or HIF-2 were 
down-regulated were more susceptible to chemotherapy-induced death than their controls, and VE-
cadherin down-regulation rendered the cells susceptible, even when co-cultured with BMSC (Figures 
4B and 4C). 
       To confirm the potential role of surface VE-cadherin in modulation of therapeutic response, Ph-
/surface VE-cadherin- REH cells were transduced with a lentiviral vector containing full length VE-
cadherin (REHCDH5) or empty vector control (REHVect). Western blot and FACs analysis confirmed 
expression of VE-cadherin (Figure 5A, data not shown).  REHCDH5 and REHVect expressing cells were 
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challenged with DNR and viability was evaluated. Ph- REH cells expressing surface VE-cadherin show 
a modest, but statistically significant, increase in survival during chemotherapy compared to their VE-
cadherin negative vector control (Figure 5B).   
Disruption of VE-cadherin signaling as a therapeutic target  
 To address the role of VE-cadherin as a potential therapeutic target in Ph+ ALL, ADH100191 
(ADH), a specific peptide inhibitor directed against the surface cell adhesion recognition sequence of 
the VE-cadherin extracellular domain, was utilized.  SUP-B15 cells were pre-treated with 1 mg/ml ADH 
for 6 hours prior to treatment with Daunorubicin (DNR). ADH pretreated Ph+/surface VE-cadherin+ 
leukemic cells were more susceptible to DNR as shown by trypan blue exclusion and Annexin-V-FITC 
staining (Figure 6A). This effect was consistent and was partially sustained in the presence of BMSC 
(Figure 6B). In experiments where all cells shown were treated with chemotherapy, ADH/IM, in 
combination with DNR, increased the sensitivity of the Ph+ cells in media alone with the increased 
sensitivity sustained in the presence of BMSC (Figure 6C). In contrast, Ph-/surface VE-cadherin- REH 
cells pre-treated with ADH100191 (ADH) prior to Daunorubicin (DNR) had no increase in response to 
chemotherapy, demonstrating the specificity of the ADH for surface VE-cadherin positive cells poised to 
respond to a signaling antagonist (Figure 6D).  Due to the specificity of  the VE-cadherin antagonist 
ADH100191 (ADH) for surface VE-cadherin, and the ability of VE-cadherin to be endocytosed from the 
membrane, we evaluated the expression of surface VE-cadherin in the presence of ADH100191 
(Figure 6E).  
 Our laboratory has previously shown physical interaction between Bcr/Abl, VE-cadherin and -
catenin in Ph+ cells, a stabilization of -catenin in cells expressing all 3 proteins, and the ability of 
BMSC to increase their expression and maintain expression during treatment (Figure 2C) {20}. We 
have additionally determined that Ph+ cell lines have higher baseline levels of -catenin compared to 
Ph- cell lines (unpublished data).  Therefore, we sought to determine if the mechanism by which VE-
cadherin signaling influences response to cytotoxic agents was potentially -catenin mediated. 
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Treatment of SUP-B15 cells with ADH100191 (ADH) for 6 hours showed an increase in the amount of 
Ser(33,37)/Thr(41) phosphorylated -catenin, characteristic of that targeted for degradation, compared 
to untreated control cells (Figure 7A). Additionally, after treatment with the VE-cadherin antagonist ADH 
for 24 hours there was a decrease in total -catenin protein detected (Figure 7B).    
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Discussion: 
 In the current study we characterize the impact of VE-cadherin on the sensitivity of Philadelphia 
chromosome positive (Ph+) ALL cells to Daunorubicin (DNR) and Imatinib Mesylate (IM) in vitro.  While 
VE-cadherin surface expression in this unique and difficult to treat, sub-type of ALL, and its expression 
in a panel of patient samples, was somewhat surprising initially, it is not the first description of its 
expression in non-endothelial cells. Previous studies have shown the expression of VE-cadherin in fetal 
liver cells with expression subsequently lost in adult stem cells and not present on the surface of B-
lineage cells {41, 42}.  Recent studies have also demonstrated that VE-cadherin is induced during 
epithelial-to-mesenchymal transition (EMT) in mammary tumor cells {35}, contributes to vascular 
mimicry in highly aggressive melanoma {43, 44} is required for successful endovascular invasion and 
normal placentation in cytotrophoblast stem cells {45}, is involved during trans-endothelial migration of 
metastatic cancer cells and is up-regulated in neighboring vasculature during tumor induced 
angiogenesis {46, 47, 48, 49}, and is a critical regulator of TGF- signaling in endothelial cells {50}.  
Therefore, it is tempting to speculate that the surface expression of VE-cadherin in Ph+ ALL cells would 
position these tumors to better interact with signals from the microenvironment that promote tumor cell 
survival, including TGF-. Interestingly, unpublished data from our laboratory observed that BMSC 
knock down of TGF- diminishes the ability of bone marrow stromal cells (BMSC) to protect B lineage 
leukemic cells from treatment.  
 Implications of VE-cadherin as a mediator of aggressive phenotype underscore our interest in 
understanding its regulation by the microenvironment in which ALL cells thrive. One upstream factor of 
interest, based on its stabilization by microenvironment-derived cues, and its influence on VE-cadherin 
expression, is HIF-2 which can respond to low oxygen levels but also regulates VE-cadherin 
independent of hypoxia {27}. Therefore, HIF-2 supported VE-cadherin expression would allow for 
homotypic tumor interactions as well as interactions with endothelial cells in bone marrow niches or 
other anatomical locations that include VE-cadherin positive cells. The expression of high levels of both 
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HIF-2 and VE-cadherin in primary ALL cells is consistent with the literature describing the role of 
these two proteins in other aggressive tumor models (Figure 1) {23, 26, 33, 34, 35, 46, 51}. Although 
one caveat of staining formalin fixed bone marrow core biopsy samples is the lack of specific cellular 
protein localization determination, it is intriguing to detect expression of VE-cadherin on the majority 
(11/12) of samples and on the surface of Ph+ leukapheresis samples (Figure1). While the interpretation 
of the IHC staining is limited, it supports the assertion that VE-cadherin protein expression is observed 
in primary B lineage ALL, with the potential that it is stabilized and regulated uniquely in the context of 
high Abl kinase activity characteristic of Ph+ ALL. Accumulation of high levels of VE-cadherin may 
result in stabilization of -catenin and transcription of downstream targets as we have previously 
published via binding to the TCF/LEF consensus sequence {20} while also being presented on the cell 
surface where it may respond to inhibition via signaling antagonists such as ADH.   
 Data presented in the current study also show that forced surface expression of VE-cadherin in 
Ph- cells significantly increased their viability during treatment (Figure 5).  In our model, bone marrow 
stromal cells (BMSC) modulated and maintained HIF-2, Oct-4 and VE-cadherin in Ph+ ALL cells 
(Figure 2, 3) {20}.  Our data suggests that the signaling pathway relies on active Abl kinase influencing 
HIF-2, VE-cadherin and subsequently -catenin (Figures 2 and 7) with potential intermediate effector 
proteins still to be determined. Importantly, the targeted inhibition of either HIF-2 or VE-cadherin, 
during chemotherapy exposure in vitro, significantly diminished cell viability even in the presence of 
BMSCs (Figures 4 and 6) suggesting relevance in the context of the marrow microenvironment in which 
leukemic cells are often refractory to therapy, at relapse in particular.  Somewhat speculative in nature, 
but worth consideration, is the possibility that BMSC cues influence tumor resistance to therapy, in part, 
by maintaining proteins associated with a tumor stem cell phenotype that is coincident with resistance.  
 HIF-2 has been documented to increase expression of at least two factors relevant to the stem 
like phenotype of the Ph+ ALL cells in this study; Oct-4 (Oct-3/4, Pou5F1) {52} and VE-cadherin {27} 
under hypoxic and normoxic conditions, respectively. Of note, evaluations of anatomical regions within 
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the marrow that support hematopoietic stem cells were localized predominantly to areas of low oxygen 
perfusion {53}. Recent literature suggests that over expression of HIF family members, and particularly 
HIF-2, promoted differentiation of BMSC to the endothelial lineage {28}.  The hypoxic nature of the 
stem cell niche in the marrow emphasizes the need to consider the influence of hypoxia on the 
expression and activity of factors, including the hypoxia inducible factors (HIF-1 and HIF-2), that can 
regulate genes that sustain tumor cell survival, proliferation, and self-renewal.  
 HIF target specificity has been shown to originate through its N-terminal trans-activation domain 
and distinct target genes have been identified for these two factors, with little functional redundancy 
even though they have the potential to bind comparable DNA motifs {54}. The co-factors that contribute 
to their specificity of binding and gene regulation appear to be cell, tissue, and “circumstance” specific, 
and investigation of the details are underway to better understand these important factors in regulation 
of growth, survival, and differentiation.  Relevant to our model is the unique role of HIF-2 in support of 
VE-cadherin expression, and therefore its potential importance as a transcription factor that may 
regulate therapeutic response. Further investigation will determine if BMSC derived cues impact on 
binding partners of HIF-2 that may influence its effect on ALL cells beyond its role as a transcription 
factor for VE-cadherin.   
 Exciting reports have recently emerged describing the use of diverse agents, including the 
microtubule destabilizing agent CA4P, to selectively disrupt VE-cadherin in endothelial cells {55, 56}.  
CA4P was shown to increase tumor cell apoptosis without negatively affecting smooth muscle cells or 
the normal vasculature, highlighting its promise as a therapeutic agent. Our recent observations 
suggest that, in general, agents designed to disrupt vasculature and tumor angiogenesis, particularly 
those that target VE-cadherin, may have previously unappreciated benefit through their direct effects on 
hematopoietic tumor cells while not damaging  normal cells or the stem cell pool {41, 42}.  Our 
utilization of the VE-cadherin antagonist, ADH100191 (ADH), demonstrates the importance of VE-
cadherin in Ph+ ALL cells, with the VE-cadherin antagonist having no effect on Ph- ALL cells (Figure 
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6D) while decreasing the viability of Ph+ cells during chemotherapy (Figures 6 and 7). The fact that 
hematopoietic tumor cells lacking surface VE-cadherin were spared any effect by ADH100191 
underlies speculation that normal hematopoietic cells might also be unaffected by this agent making it a 
potentially useful chemo-sensitization therapy.  It also suggests that while the majority of both Ph+ and 
Ph- primary cells expressed VE-cadherin protein when a “total” protein IHC approach was utilized, the 
efficacy of VE-cadherin antagonists may be logically limited to those tumors in which the VE-cadherin is 
presented on the cell surface.  The modulation of -catenin in response to inhibition of VE-cadherin in 
our model of lymphoid leukemia (Figure 7) is consistent with a recent report documenting that -catenin 
is essential for survival of Ph+ myeloid leukemic stem cells {57, 58}. Although the changes in viability 
when VE-cadherin signaling is inhibited are quantitatively modest, they remain relevant in the context of 
the significant proliferative potential of a small residual tumor load in the setting of aggressive leukemia 
which may subsequently contribute to relapse of disease. 
 Potentially, signals from the bone marrow microenvironment culminate on targets that are also 
impacted by the hypoxic nature of protective niches. Sustained expression of surface VE-cadherin in 
Ph+ ALL cells, supported by signals inherent to the tumor such as high Abl kinase activity and through 
microenvironment cues that influence transcriptional regulators including HIF-2 and -catenin, provide 
us a model in which we can begin to investigate the complexity of survival signals in the marrow milieu. 
From these models we can optimize novel therapeutic strategies designed to target residual tumor cells 
that are refractory to standard therapy by understanding the critical targets on which survival signals 
converge.  Pathways that we have traditionally considered in the context of a solid tumor cell survival 
and support of vasculogenesis and angiogenesis warrant further consideration in the biology of 
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Figure 1: Patient derived ALL cells express VE-cadherin and HIF-2.  A) RNA was isolated from 
5x106 patient derived cells and RT-PCR was performed for HIF-2, VE-cadherin or actin. B) 1x106 
patient derived Ph+ (black line) and Ph- (gray line) cells were obtained from  leukapheresis and stained 
to detect HIF-2 (intracellular), VE-cadherin (surface) , or matched isotype control and analyzed by 
FACS. C) Ph+ and Ph- primary patient bone marrow core biopsies were stained for VE-cadherin or 
matched isotype control. 11/12 samples were positive for VE-cadherin and 4 representative samples 
are shown. All samples were positive for CD19, CD10, CD22, HLADR and TDT.   
Figure 2: Bone marrow stromal cells  maintain Ph+ ALL expression of VE-cadherin during 
Imatinib treatment.   A) SUP-B15 cells were cultured in media alone or co-cultured with BMSC and 
subsequently treated with 10µM Imatinib Mesylate (IM). RT-PCR was performed for VE-cadherin, HIF-
2 and actin. B) SUP-B15 cells were exposed to DMSO as the control solvent, or to 10uM IM, for 24 
hours. HIF-2 and VE-cadherin proteins were evaluated by FACS.  C) SUP-B15 cells were cultured in 
either media alone, in contact with BMSC, or in contact with BMSC and Imatinib for 24 hours.  Tumor 
cells were subsequently fixed with 4% PFA, permeabilized with 0.5% Triton-X 100 and stained with 
anti-VE-cadherin antibody or a matched isotype control for evaluation by confocal microscopy (images 
shown are 63X with no zoom) or following the standard protocol described in materials and methods for 
flow cytometric analysis.  D) SUP-B15 cells were cultured in media alone, or in the presence of BMSC 
for 24 hours, and subsequently treated with  0.1mg/ml DNR overnight. Cells were collected, lysed and 
western blots were completed to analyze Bcr/abl activity as well as VE-cadherin and -catenin 
expression. GAPDH was used as a loading control.  Loading of gels is as follows: Lane 1 is media 
alone, Lane 2 is DNR treatment, Lane 3 is co-culture with BMSC and Lane 4 is co-culture with BMSC 
and DNR treatment.  
Figure 3: Bone marrow stromal cells modulate HIF-2.  A & B) LTMC and LTCC SUP-B15 cells 
were cultured in media alone or in the presence of BMSC. HIF-2 mRNA and protein were evaluated 
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by RT-PCR and FACS, respectively. C) LTMC and LTCC cells were placed in media for 24 hours and 
their baseline expression of HIF-2 was evaluated by FACS. D) SUP-B15 cells were cultured in media 
alone or in the presence of BMSC  and evaluated for expression of Oct-4.   
Figure 4: Modulation of VE-cadherin results in altered chemosensitivity. A) SUP-B15 cells were 
transiently transfected with scrambled, HIF-2, or VE-cadherin siRNA and conformation of down-
regulation was determined using FACS.  B & C) siRNA transfected cells were subsequently cultured in 
media alone or in the presence of BMSC and exposed to 10uM IM or DMSO and 0.01mg/ml DNR. Cell 
viability was determined by trypan blue exclusion and Annexin-V-FITC.   
Figure 5: Expression of VE-cadherin decreases leukemic cell sensitivity to chemotherapy. A) 
Ph-/surface VE-cadherin- REH cells were transduced with virus containing empty vector control 
(REHVect) or wild type CDH5 (REHCDH5). Western blot was completed to demonstrate expression of VE-
cadherin. B) REHVect and REHCDH5 cells were challenged with 0.6mg/ml DNR for 48 hours and viability 
was evaluated by trypan blue exclusion.  
Figure 6: Disruption of VE-cadherin signaling using the VE-cadherin antagonist ADH increases 
Ph+ ALL sensitivity to apoptosis.  A & B) SUP-B15 were cultured in media alone or co-cultured with 
BMSC for 24 hours. The cells were then pre-treated with 1mg/ml ADH, or media control, for 6 hours 
and subsequently challenged with chemotherapy (0.1mg/ml Daunorubicin (DNR)/24 hours). Viability 
was determined by trypan blue exclusion and Annexin-V-FITC. C) SUP-B15 cells we cultured in media 
alone or in the presence of BMSC for 24 hours, pre-treated with either media/DMSO, IM, ADH or a 
combination of IM & ADH for 6  hours prior to treatment with DNR. Cell viability was then determined by 
trypan blue analysis. Statistical significance is shown comparing both the SUP-B15 on BMSC treated 
with DNR to the IM/DNR, ADH/DNR or IM/ADH/DNR groups as well as the comparison between the 
IM/DNR or ADH/DNR to IM/ADH/DNR. D) Ph- REH cells were pre-treated with 1mg/ml or 2mg/ml ADH 
for 6 hours and subsequently treated with 0.6mg/ml DNR. Viability was determined by Annexin-V-FITC. 
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E. SUP-B15 cells were treated with media alone or with 1mg/ml ADH for 24 hours and surface stained 
for VE-cadherin.  
 Figure 7: Inhibition of VE-cadherin signaling leads to targeted degradation of -catenin.  A) 
SUP-B15 cells were treated with 1mg/ml ADH or media control for 4 hours and subsequently stained 
for phospho--catenin (Ser33/37 and Thr41) or matched isotype control. Cells were analyzed by 
confocal microscopy (images shown are 40X with zoom).  B) SUP- B15 cells were treated with 1mg/ml 
ADH or media control for 24 hours and analyzed by western blot to observe changes in total -catenin. 
Samples shown were run on the same gel, in outer lanes, and therefore the image was cut to show 







Table 1: Patient derived ALL cells express VE-cadherin.  Table is representative of patient history of 



















 The broad goals of the studies presented in this work were two-fold.  They are 
unified by an interest in understanding critical biological events that occur in the bone 
marrow microenvironment.  First, we sought to better understand the direct and indirect 
damage of aggressive chemotherapy on supportive cells in the marrow, with focus on 
osteoblasts.  As critical regulators of steady state hematopoeisis, as well as 
hematopoietic recovery following transplantation, we focused this investigation on the 
functional vulnerability of marrow osteoblasts and the mechanistic underpinnings of 
treatment-induced changes in osteoblasts that would negatively influence their capacity 
to support human stem, and progenitor, cell development.  Based on the capacity of the 
marrow to nurture development of normal hematopoietic cells 1;2, and B lineage cells in 
particular 3-5, we next sought to evaluate interactions between B lineage hematopoietic 
tumors (ALL) and the marrow microenvironment.  This investigation further drew on 
similarities that exist, and the fine line between, normal hematopoiesis and the 
development of hematopoietic malignancies – processes that share common signaling 
pathways and anatomical location 6;7.  Investigations into ALL cell support by the marrow 
microenvironment, and mechanisms by which microenvironment derived cues modulate 
chemosensitivity as well as a “tumor stem cell” phenotype, brought into focus regulatory 
proteins that had not been previously appreciated in this context, including VE-cadherin. 
 To evaluate the effect of ablative chemotherapy on the endosteal niche, a key 
regulatory component of stem cell development in the bone marrow microenvironment, 
human primary derived osteoblasts (HOB) were utilized and treated with a high dose of 
Melphalan and Etoposide (VP-16) which are clinically relevant chemotherapeutic agents 
for high-dose therapy prior to stem cell transplant 8. The translational relevance of this 
study is drawn, in part, from the observation that patients who have received ablative 
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therapy and stem cell transplantation report deficits in hematopoietic recovery up to 15 
years post transplant compared to their normal counterparts 9. This suggests that even 
after transplant there is residual damage to the microenvironment that alters the ability of 
the transplanted cells to normally incorporate and differentiate in the stem cell niche.  
While our mechanistic studies could not recapitulate this time frame, they did offer 
insight into possible reasons that underlie these reported deficits including alterations of 
cytokine and chemokine profiles subsequent to stress.  Obtaining a better understanding 
of therapy induced damage has the potential to identify critical pathways that could be 
modulated during the aggressive pre-transplantation stage of treatment to increase the 
efficiency of hematopoietic recovery, and diminish the risks to patients, during this critical 
stage.  
 Initial studies included chemotherapy treated osteoblasts examined for both 
alterations in gene and protein expression as well as through functional assays. Studies 
from our laboratory and others had previously shown that ablative therapy increased the 
amount of active TGF- (transforming growth factor-) secreted by bone marrow stromal 
cells 10-12. Although results from patient tissues vary, some studies have shown that bone 
marrow stromal cells taken from patients who received ablative therapy had increases in 
active TGF- compared to their normal counterparts 11 . This led us to the hypothesis 
that osteoblasts in the endosteal niche may not only be damaged directly by ablative 
chemotherapy (ie: high dose Melphalan or VP-16) but also indirectly from the high levels 
of TGF- being secreted by the BMSC. Based on this question, we initiated experiments 
to determine if ablative chemotherapy would result in an increase in osteoblast secreted 
active TGF- and alter the ability of osteoblasts to support human embryonic stem cells 
and pro-B cells.  
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 These studies confirmed that dose escalated Melphalan or VP-16, at 
concentrations that mimic those reported in serum of patients prior to bone marrow 
transplantation, resulted in increases in the amount of active TGF- secreted by the 
osteoblasts, as measured by SMAD-3 phosphorylation. Additionally, HOB treated with 
high dose Melphalan, VP-16, or recombinant TGF-  had diminished capacity to support 
pluripotent embryonic stem cell colonies, as measured by expression of the pluripotent 
stem cell protein Oct-4. Osteoblasts treated with chemotherapy or  rTGF- had 
diminshed CXCL12 mRNA and protein as well as reduced pro-B cell chemotaxis and 
adherence to the HOB.  Collectively, these results suggest that ablative therapy alters 
the osteoblasts’ secretion of active TGF-, suggesting that chemotherapy damage may 
result from both direct, and indirect effects, on the osteoblasts through paracrine and 
autocrine  mechanisms. These data correlate with retrospective patient data and 
suggests a role for TGF- in the inability of engraftment and correct differentiation of 
stem cell transplants. 
 The overall conclusions of this study show for the first time that osteoblasts are 
damaged in response to both direct chemotherapy, as well as indirect TGF- secretion 
from damaged BMSC, and that both types of damage diminish the osteoblasts ability to 
support primitive and progenitor cells. This work gives insight into the broad damage 
done by ablative chemotherapy and a potential mechanism for the inhibition of 
engraftment and differentiation of transplanted HSC.  Although this work answers some 
questions regarding damage during pre-transplant ablative therapy, it emphasizes the 
need for further studies to observe: 1) the impact of ablative therapy on MSC to 
determine if damage to the progenitor cells that osteoblasts and BMSC are derived from 
retain the damage caused by chemotherapy in a heritable manner,  2) studies in mouse 
models and subsequently patients to determine if the same damage seen in vitro is 
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occurring in vivo consistent with hematopoietic deficits seen in patients post transplant 
as well as the incidence of minimal residual disease and relapse,  3) the determination of 
other factors that may be playing a role, and if the damage can be reversed, or 
diminished by the use of inhibitors such as the TGF- inhibitors (p144, LY2109761 and 
GC1008) currently in clinical trials, 4) in vitro and in vivo studies focusing on the 
mechanisms by which TGF- alters the engraftment and differentiation of HSC 
transplants and  finally 5) an increase in the number of retrospective studies to better 
understand the potential genetic or epigenetic changes that may be present in patients 
who successfully have their marrow reconstituted after transplant, without delayed 
hematopoietic recovery, compared to those that do not.  Interestingly, the infusion of 
MSC during hematopoietic stem cell transplants is beginning to be explored to treat 
other diseases such as stroke, auditory defects, type 1 diabetes and genetic diseases 
and clinical trials are underway to determine if it may be useful in the setting of ablative 
chemotherapy to help replace the damaged cells as well.  
  Our laboratory is not only interested in the marrow microenvironment as the 
home for normal hematopoieis, or hematopoietic recovery following transplantation, but 
also as a site of sanctuary for hematopoietic tumors.  The similarity between normal pro-
B cells and their malignant counterparts that comprise B lineage leukemia is intriguing, 
but also clinically challenging.  Our investigation of tumor cell interactions with the bone 
marrow were focused on  a sub-type of  ALL that expresses the Bcr/Abl translocation. 
Patients that have this mutation are automatically placed in a high risk of relapse, poor 
prognosis group regardless of any other factor. They are typically resistant to therapy, 
and although it is a subpopulation of patients (3-5% of pediatric ALL and 25-50% of adult 
ALL),  the survival rates for this disease with chemotherapy alone are 20% or less and 
chemotherapy treatment with allogeneic transplant only increases to survival rate to 30-
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50% 13;14. Therefore, it is relevant to study the phenotype of the cells, and our 
observations suggested this class of tumor may have stem cell like properties that could 
be contributing to therapeutic resistance. 
 Our first study was initiated, in part, based on the work of Mary Hendrix. Her 
group determined, in a melanoma model, that particularly aggressive tumor cells 
expressed VE-cadherin and were able to create neovasculature and form networks that 
imitated endothelial cells, a process termed “vasculogenic mimicry” 6;8;15.  Therefore in 
our model of aggressive, Ph+ ALL we chose to look at the phenotype of these cells and 
the expression of stem cell markers.  We determined that the Ph+ cells had a unique 
phenotype of surface VE-cadherin expression that is more readily detected than in their 
Ph- counterparts, as well as PECAM-1. Ph+ cells also generated hemospheres when 
cultured with bone marrow stromal cells, that were reminiscent of mammospheres or 
neurospheres propagated from the stem cell pool of breast and neural cells 16. 
Additionally, these VE-cadherin +, PECAM-1+, PH+ ALL cells had the ability to sprout 
branches like normal endothelial cells when grown in endocult giving endothelial signals.  
 The Ph+ cells and their hemospheres also had a stem-like phenotype and had 
the expression of Oct-4 as well as CD133 (promin-1). We further evaluated the effect of 
BMSC co-culture and soluble factors on this phenotype and determined, between our 
two tumor studies, that VE-cadherin, beta-catenin, HIF-2 alpha, Src, Oct-4 and Bcr/Abl 
kinase activity could all be increased by BMSC contact, and in the presence of 
chemotherapy most of these proteins are maintained by BMSC contact. We investigated 
the relationship between beta-catenin and VE-cadherin and noticed that Ph+ cells had 
higher levels of beta-catenin at baseline than Ph- cells (unpublished data). We then 
determined that beta-catenin physically interacts with and is stabilized by VE-cadherin 
and that both of these proteins are regulated by Bcr/Abl kinase activity. Treatment of 
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Ph+ cells with the Abl kinase inihibitor Imatinib resulted in decreased VE-cadherin and 
beta-catenin protein.  
 This inhibition of survival proteins with modulation of Abl kinase or VE-cadherin 
led us to investigate the potential  therapeutic importance of VE-cadherin. Although 
Imatinib was initially very successful in the treatment of CML and Ph+ ALL, patients who 
relapse tend to have mutations in the Abl kinase domain (E225K, T315I, as well as 
alternative splicing of Bcr/Abl). These mutations leave the patients resistant to Imatinib 
suggesting that proteins downstream of Abl kinase activity may be relevant therapeutic 
targets.  
 To confirm our previous results in cell lines, we obtained primary, patient 
leukapheresis and bone marrow core samples from Ph- and Ph+ patient and examined 
them for the presence of VE-cadherin. The Ph+ leukapheresis samples had VE-cadherin 
on their surface while the Ph- samples did not. The staining of the bone marrow core 
samples was intracellular and all samples had VE-cadherin which correlated with our cell 
line data showing stabilized VE-cadherin on the surface of Ph+ ALL but found 
intracellularly on Ph+ and Ph- ALL. We treated SUP-B15, a Ph+ ALL cell line, with 
Imatinib and determined that VE-cadherin and HIF-2 alpha protein were both decreased 
in the presence of Imatinib but that VE-cadherin could be maintained in the presence of 
BMSC. Baseline protein expression of VE-cadherin, HIF-2 alpha, Oct-4 and beta-catenin 
could all be increased by BMSC contact, and during chemotherapy VE-cadherin and 
beta-catenin protein were maintained (HIF and Oct were not tested.)  
 This led us to the hypothesis that Bcr/Abl was regulating HIF-2 alpha which 
subsequently could act as a transcription factor for VE-cadherin and Oct-4 and lead to 
VE-cadheirn mediated stability of beta-catenin and stem cell phenotype, respectively.  
When HIF-2 alpha or VE-cadherin were inhibited with siRNA, the Ph+ leukemic cells 
were more susceptible to daunorubicin treatment, even in the presence of BMSC. 
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Inhibition of VE-cadherin signaling with ADH100191 (ADH) , a VE-cadherin antagonist 
that binds to the extracellular domain, resulting in diminished viability during treatment as 
well as increased  Ser/Thr phosphorylated beta-catenin targeted for degradation. Our 
data suggest that VE-cadherin is a novel and relevant therapeutic target that regulates 
beta-catenin expression which has been shown to be critical in leukemic (CML) stem cell 
survival during treatment  17. 
 The collective observations of the studies discussed in chapters 2 and 3 
demonstrates  the importance of microenvironmental regulation of tumor cell signals 
during chemotherapy treatment. Not only is it clinically important and particularly 
challenging in the setting of hematopoietic malignancies to attempt to find markers on 
tumor cells that are not on normal cells, but it is also crucial to determine the functional 
relevance and regulation of these aberrantly expressed proteins. The expression of VE-
cadherin in leukemia, as well as breast, prostate and other tumors that commonly 
metastasize to the bone marrow, may not only play a role in tumor resistance to 
chemotherapy but may also underlie a new mechanism by which tumor cells incorporate 
into the vasculature.  
 A recent study by Alvero et al. showed that a stem-cell-like population of ovarian 
cancer cells expressed CD34+, VE-cadherin and were able to form xenograft tumors 
containing blood vessels, lined by human CD34+ cells 18. Additionally, these cells 
mimicked the behavior of normal endothelial cells, could form vessel like structures in 24 
hours and could form vessels with extended branching and maturation after 7 days of 
culture in matrigel 18. Studies from multiple groups have shown an increase in 
microvessel density in patients with different types of leukemia (AML, CLL, ALL etc.) 
suggesting the potential broad therapeutic implications of specific VE-cadherin 
antagonists for cancer therapy 19;20.  
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 Clinical trials are ongoing for drugs that have effects on VE-cadherin such as 
Combrostatin-A-4-Phosphate (CA4P). CA4P results in the depolymerization of 
microtubules resulting in detachment and apoptosis of endothelial cells.  Although CA4P 
seems to selectively target endothelial cells it is not specifically a VE-cadherin 
antagonist. The Rafii lab has shown that CA4P can induce regression of unstable 
nascent tumor neovessels and inhibit leukemic cell proliferation and survival in vitro and 
in vivo in part by VE-cadherin/-catenin/Akt signaling pathway and disruption of 
mitochondrial membrane potential resulting in caspase-dependent cell death, 
respectively 21;22. These studies, as well as the studies performed in our own laboratory, 
emphasize the ability of VE-cadherin inhibition, even in the presence of the protective 
tumor microenvironment, to be a potential novel therapeutic option for aggressive tumors 
that may express cadherin proteins as anti-apoptotic regulators and/or mediators of 
contribution to new vasculature as tumors reach significant size.  These data suggest we 
should consider angiogenesis inhibitors in a novel context, that of hematological 
malignancies.   
 In addition to this work converging “in” the bone marrow, the studies focusing on 
normal leukemic cell survival also identified TGF- as an intriguing factor.   We know 
from the studies shown here, as well as the studies previously published by our lab, that 
both bone marrow stromal cells and osteoblasts secrete high levels of active TGF- after 
treatment with chemotherapy 12. In the normal hematopoieis model the secretion of 
active TGF- is tightly regulated, and high levels inhibit the ability of osteoblasts to 
interact with and support primitive stem cells as well as progenitor pro-B cells. However, 
in the leukemia model TGF- increased the amount of VE-cadherin expression in the 
Ph+ cells coincident with protection of tumor cells from chemotherapy. The Dejana lab 
has shown that in normal endothelial cells VE-cadherin acts as a critical regulator of 
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TGF- signaling, and a study by Labelle et al. demonstrated that VE-cadherin is induced 
during EMT in mammary tumor cells and is aberrantly expressed in invasive human 
breast carcinomas 23;24. VE-cadherin expression in these tumors influences the levels of 
Smad2 phosphorylation and expression of TGF-. These data suggest a link between 
VE-cadherin and TGF- as well as a dual role for VE-cadherin , promotion of tumor 
progression via angiogenesis and enhancement of  tumor cell proliferation through the 
TGF- signaling pathway.  
 These data remind us of the complexity of the marrow microenvironment in both 
its hematopoietic support role and its capacity to serve as a tumor sanctuary.  Further, 
the studies emphasize the vulnerability of the “structural” components of the marrow, 
including osteoblasts, that regulate diverse processes through their expression of 
adhesion molecules, cytokines, chemokines, and ECM driven signals. Many questions 
emerge from a common niche that can house and support both healthy and transformed 
hematopoietic cells and is exposed to aggressive cytotoxic drugs in an attempt to 
eradicate tumor, or conversely, to prepare for transplantation of healthy stem cells.  
Future studies will be required for us to optimally modulate the bone marrow 
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